Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2020-07-13
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
## x
## 5S_rRNA 2.6287595
## 7SK 1.9599554
## A1BG 1.0745665
## A1CF -0.6138023
## A2M -0.3233384
## A3GALT2 1.0054503Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2400 |
| num_genes_in_profile | 16173 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8634 |
| num_profile_genes_not_in_sets | 7539 |
Here is a plot of the input profiles. Note the dynamic ranges. 
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2400 |
| num_genesets_excluded | 1010 |
| num_genesets_included | 1390 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Results table
Top N= 50 gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Regulation of IFNA signaling | 25 | 3.24e-06 | 0.538 | 1.10e-03 |
| Presynaptic nicotinic acetylcholine receptors | 12 | 2.41e-03 | -0.506 | 1.80e-01 |
| TRAF6 mediated IRF7 activation | 28 | 5.74e-06 | 0.495 | 1.33e-03 |
| Synthesis of PIPs at the late endosome membrane | 10 | 1.04e-02 | 0.468 | 4.02e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 7.96e-03 | -0.462 | 3.46e-01 |
| Mitophagy | 20 | 3.75e-04 | -0.459 | 4.74e-02 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 11 | 1.16e-02 | 0.440 | 4.03e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 11 | 1.16e-02 | 0.440 | 4.03e-01 |
| Classical antibody-mediated complement activation | 10 | 1.63e-02 | -0.439 | 4.38e-01 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 13 | 7.02e-03 | -0.432 | 3.46e-01 |
| Nucleotide-like (purinergic) receptors | 12 | 1.00e-02 | 0.429 | 3.97e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 10 | 1.95e-02 | 0.427 | 4.63e-01 |
| PINK1-PRKN Mediated Mitophagy | 14 | 7.09e-03 | -0.416 | 3.46e-01 |
| Glucuronidation | 17 | 5.89e-03 | 0.386 | 3.27e-01 |
| Platelet Adhesion to exposed collagen | 13 | 1.60e-02 | 0.386 | 4.38e-01 |
| Acetylcholine binding and downstream events | 14 | 1.37e-02 | -0.381 | 4.19e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 14 | 1.37e-02 | -0.381 | 4.19e-01 |
| Organic anion transporters | 10 | 4.42e-02 | -0.367 | 6.61e-01 |
| Surfactant metabolism | 21 | 5.00e-03 | -0.354 | 3.02e-01 |
| Organic cation transport | 10 | 5.33e-02 | 0.353 | 6.95e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 5.40e-02 | 0.352 | 6.95e-01 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 4.35e-02 | 0.352 | 6.61e-01 |
| Regulation of TLR by endogenous ligand | 15 | 1.89e-02 | 0.350 | 4.63e-01 |
| Creation of C4 and C2 activators | 17 | 1.25e-02 | -0.350 | 4.19e-01 |
| Synthesis of pyrophosphates in the cytosol | 10 | 5.57e-02 | -0.349 | 7.09e-01 |
| Transport of vitamins, nucleosides, and related molecules | 37 | 2.86e-04 | -0.345 | 4.42e-02 |
| Glutathione synthesis and recycling | 12 | 4.63e-02 | -0.332 | 6.78e-01 |
| Lewis blood group biosynthesis | 12 | 4.76e-02 | 0.330 | 6.82e-01 |
| CRMPs in Sema3A signaling | 15 | 2.77e-02 | 0.328 | 5.50e-01 |
| Regulation of localization of FOXO transcription factors | 12 | 5.35e-02 | -0.322 | 6.95e-01 |
| Degradation of cysteine and homocysteine | 11 | 7.07e-02 | -0.315 | 7.50e-01 |
| Receptor-type tyrosine-protein phosphatases | 19 | 1.76e-02 | 0.315 | 4.62e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 14 | 4.24e-02 | -0.313 | 6.61e-01 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 33 | 1.84e-03 | 0.313 | 1.51e-01 |
| Cleavage of the damaged pyrimidine | 13 | 5.34e-02 | -0.309 | 6.95e-01 |
| Depyrimidination | 13 | 5.34e-02 | -0.309 | 6.95e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 13 | 5.34e-02 | -0.309 | 6.95e-01 |
| Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) | 12 | 6.37e-02 | -0.309 | 7.38e-01 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 9.31e-02 | 0.307 | 7.65e-01 |
| Defective GALNT12 causes colorectal cancer 1 (CRCS1) | 12 | 6.98e-02 | -0.302 | 7.50e-01 |
| O-glycosylation of TSR domain-containing proteins | 34 | 2.46e-03 | 0.300 | 1.80e-01 |
| Initial triggering of complement | 24 | 1.16e-02 | -0.298 | 4.03e-01 |
| DCC mediated attractive signaling | 14 | 5.40e-02 | 0.298 | 6.95e-01 |
| Retrograde neurotrophin signalling | 14 | 5.72e-02 | 0.294 | 7.09e-01 |
| Adherens junctions interactions | 24 | 1.39e-02 | 0.290 | 4.19e-01 |
| RNA Polymerase III Chain Elongation | 13 | 7.02e-02 | -0.290 | 7.50e-01 |
| Activated NTRK2 signals through FRS2 and FRS3 | 10 | 1.13e-01 | -0.289 | 7.76e-01 |
| Olfactory Signaling Pathway | 276 | 7.06e-16 | 0.283 | 9.81e-13 |
| Signaling by FGFR4 in disease | 11 | 1.07e-01 | -0.281 | 7.65e-01 |
| Pyruvate metabolism | 25 | 1.64e-02 | -0.277 | 4.38e-01 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Regulation of IFNA signaling | 25 | 3.24e-06 | 5.38e-01 | 1.10e-03 |
| Presynaptic nicotinic acetylcholine receptors | 12 | 2.41e-03 | -5.06e-01 | 1.80e-01 |
| TRAF6 mediated IRF7 activation | 28 | 5.74e-06 | 4.95e-01 | 1.33e-03 |
| Synthesis of PIPs at the late endosome membrane | 10 | 1.04e-02 | 4.68e-01 | 4.02e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 7.96e-03 | -4.62e-01 | 3.46e-01 |
| Mitophagy | 20 | 3.75e-04 | -4.59e-01 | 4.74e-02 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 11 | 1.16e-02 | 4.40e-01 | 4.03e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 11 | 1.16e-02 | 4.40e-01 | 4.03e-01 |
| Classical antibody-mediated complement activation | 10 | 1.63e-02 | -4.39e-01 | 4.38e-01 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 13 | 7.02e-03 | -4.32e-01 | 3.46e-01 |
| Nucleotide-like (purinergic) receptors | 12 | 1.00e-02 | 4.29e-01 | 3.97e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 10 | 1.95e-02 | 4.27e-01 | 4.63e-01 |
| PINK1-PRKN Mediated Mitophagy | 14 | 7.09e-03 | -4.16e-01 | 3.46e-01 |
| Glucuronidation | 17 | 5.89e-03 | 3.86e-01 | 3.27e-01 |
| Platelet Adhesion to exposed collagen | 13 | 1.60e-02 | 3.86e-01 | 4.38e-01 |
| Acetylcholine binding and downstream events | 14 | 1.37e-02 | -3.81e-01 | 4.19e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 14 | 1.37e-02 | -3.81e-01 | 4.19e-01 |
| Organic anion transporters | 10 | 4.42e-02 | -3.67e-01 | 6.61e-01 |
| Surfactant metabolism | 21 | 5.00e-03 | -3.54e-01 | 3.02e-01 |
| Organic cation transport | 10 | 5.33e-02 | 3.53e-01 | 6.95e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 5.40e-02 | 3.52e-01 | 6.95e-01 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 4.35e-02 | 3.52e-01 | 6.61e-01 |
| Regulation of TLR by endogenous ligand | 15 | 1.89e-02 | 3.50e-01 | 4.63e-01 |
| Creation of C4 and C2 activators | 17 | 1.25e-02 | -3.50e-01 | 4.19e-01 |
| Synthesis of pyrophosphates in the cytosol | 10 | 5.57e-02 | -3.49e-01 | 7.09e-01 |
| Transport of vitamins, nucleosides, and related molecules | 37 | 2.86e-04 | -3.45e-01 | 4.42e-02 |
| Glutathione synthesis and recycling | 12 | 4.63e-02 | -3.32e-01 | 6.78e-01 |
| Lewis blood group biosynthesis | 12 | 4.76e-02 | 3.30e-01 | 6.82e-01 |
| CRMPs in Sema3A signaling | 15 | 2.77e-02 | 3.28e-01 | 5.50e-01 |
| Regulation of localization of FOXO transcription factors | 12 | 5.35e-02 | -3.22e-01 | 6.95e-01 |
| Degradation of cysteine and homocysteine | 11 | 7.07e-02 | -3.15e-01 | 7.50e-01 |
| Receptor-type tyrosine-protein phosphatases | 19 | 1.76e-02 | 3.15e-01 | 4.62e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 14 | 4.24e-02 | -3.13e-01 | 6.61e-01 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 33 | 1.84e-03 | 3.13e-01 | 1.51e-01 |
| Cleavage of the damaged pyrimidine | 13 | 5.34e-02 | -3.09e-01 | 6.95e-01 |
| Depyrimidination | 13 | 5.34e-02 | -3.09e-01 | 6.95e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 13 | 5.34e-02 | -3.09e-01 | 6.95e-01 |
| Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) | 12 | 6.37e-02 | -3.09e-01 | 7.38e-01 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 9.31e-02 | 3.07e-01 | 7.65e-01 |
| Defective GALNT12 causes colorectal cancer 1 (CRCS1) | 12 | 6.98e-02 | -3.02e-01 | 7.50e-01 |
| O-glycosylation of TSR domain-containing proteins | 34 | 2.46e-03 | 3.00e-01 | 1.80e-01 |
| Initial triggering of complement | 24 | 1.16e-02 | -2.98e-01 | 4.03e-01 |
| DCC mediated attractive signaling | 14 | 5.40e-02 | 2.98e-01 | 6.95e-01 |
| Retrograde neurotrophin signalling | 14 | 5.72e-02 | 2.94e-01 | 7.09e-01 |
| Adherens junctions interactions | 24 | 1.39e-02 | 2.90e-01 | 4.19e-01 |
| RNA Polymerase III Chain Elongation | 13 | 7.02e-02 | -2.90e-01 | 7.50e-01 |
| Activated NTRK2 signals through FRS2 and FRS3 | 10 | 1.13e-01 | -2.89e-01 | 7.76e-01 |
| Olfactory Signaling Pathway | 276 | 7.06e-16 | 2.83e-01 | 9.81e-13 |
| Signaling by FGFR4 in disease | 11 | 1.07e-01 | -2.81e-01 | 7.65e-01 |
| Pyruvate metabolism | 25 | 1.64e-02 | -2.77e-01 | 4.38e-01 |
| ERBB2 Regulates Cell Motility | 14 | 7.55e-02 | 2.74e-01 | 7.50e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 13 | 9.15e-02 | -2.70e-01 | 7.65e-01 |
| Dissolution of Fibrin Clot | 13 | 9.16e-02 | 2.70e-01 | 7.65e-01 |
| mRNA decay by 3' to 5' exoribonuclease | 11 | 1.21e-01 | -2.70e-01 | 7.76e-01 |
| Signal transduction by L1 | 19 | 4.33e-02 | -2.68e-01 | 6.61e-01 |
| G1/S-Specific Transcription | 26 | 1.82e-02 | 2.68e-01 | 4.63e-01 |
| Dermatan sulfate biosynthesis | 11 | 1.27e-01 | 2.66e-01 | 7.96e-01 |
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | 11 | 1.27e-01 | -2.66e-01 | 7.96e-01 |
| Tandem pore domain potassium channels | 11 | 1.29e-01 | -2.64e-01 | 8.05e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 11 | 1.30e-01 | 2.64e-01 | 8.06e-01 |
| RUNX3 regulates NOTCH signaling | 13 | 9.97e-02 | 2.64e-01 | 7.65e-01 |
| RNA Polymerase III Transcription Initiation | 28 | 1.58e-02 | -2.64e-01 | 4.38e-01 |
| WNT ligand biogenesis and trafficking | 24 | 2.68e-02 | -2.61e-01 | 5.48e-01 |
| Insulin receptor recycling | 23 | 3.06e-02 | -2.60e-01 | 5.92e-01 |
| Creatine metabolism | 10 | 1.57e-01 | -2.58e-01 | 8.22e-01 |
| Purine ribonucleoside monophosphate biosynthesis | 11 | 1.38e-01 | -2.58e-01 | 8.14e-01 |
| Other semaphorin interactions | 18 | 5.83e-02 | 2.58e-01 | 7.17e-01 |
| Aspartate and asparagine metabolism | 11 | 1.39e-01 | 2.57e-01 | 8.14e-01 |
| ERBB2 Activates PTK6 Signaling | 13 | 1.11e-01 | 2.55e-01 | 7.76e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 23 | 3.50e-02 | -2.54e-01 | 6.35e-01 |
| Beta defensins | 22 | 3.96e-02 | -2.54e-01 | 6.35e-01 |
| Synthesis of PIPs at the early endosome membrane | 15 | 8.94e-02 | 2.53e-01 | 7.65e-01 |
| ROS and RNS production in phagocytes | 33 | 1.27e-02 | -2.51e-01 | 4.19e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 13 | 1.18e-01 | -2.50e-01 | 7.76e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 19 | 5.94e-02 | -2.50e-01 | 7.25e-01 |
| Interleukin-7 signaling | 17 | 7.47e-02 | 2.50e-01 | 7.50e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 1.06e-01 | 2.49e-01 | 7.65e-01 |
| Glucagon-type ligand receptors | 28 | 2.38e-02 | -2.47e-01 | 5.11e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 10 | 1.80e-01 | 2.45e-01 | 8.32e-01 |
| Apoptotic factor-mediated response | 12 | 1.42e-01 | -2.45e-01 | 8.19e-01 |
| Glyoxylate metabolism and glycine degradation | 28 | 2.65e-02 | -2.42e-01 | 5.48e-01 |
| Base-Excision Repair, AP Site Formation | 15 | 1.06e-01 | -2.41e-01 | 7.65e-01 |
| FOXO-mediated transcription of cell death genes | 14 | 1.20e-01 | 2.40e-01 | 7.76e-01 |
| Metabolism of amine-derived hormones | 16 | 9.71e-02 | -2.40e-01 | 7.65e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 14 | 1.21e-01 | 2.39e-01 | 7.76e-01 |
| Formation of the Early Elongation Complex | 25 | 3.85e-02 | -2.39e-01 | 6.35e-01 |
| Formation of the HIV-1 Early Elongation Complex | 25 | 3.85e-02 | -2.39e-01 | 6.35e-01 |
| CD209 (DC-SIGN) signaling | 19 | 7.24e-02 | 2.38e-01 | 7.50e-01 |
| Cell-cell junction organization | 54 | 2.98e-03 | 2.34e-01 | 2.02e-01 |
| Interferon alpha/beta signaling | 54 | 3.05e-03 | 2.33e-01 | 2.02e-01 |
| IRE1alpha activates chaperones | 44 | 7.64e-03 | -2.32e-01 | 3.46e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 62 | 1.65e-03 | 2.31e-01 | 1.43e-01 |
| Postmitotic nuclear pore complex (NPC) reformation | 20 | 7.38e-02 | -2.31e-01 | 7.50e-01 |
| Nicotinamide salvaging | 15 | 1.22e-01 | -2.31e-01 | 7.78e-01 |
| Aflatoxin activation and detoxification | 16 | 1.11e-01 | -2.30e-01 | 7.76e-01 |
| GP1b-IX-V activation signalling | 10 | 2.08e-01 | 2.30e-01 | 8.56e-01 |
| Nucleobase biosynthesis | 13 | 1.53e-01 | -2.29e-01 | 8.22e-01 |
| Regulation of IFNG signaling | 13 | 1.53e-01 | 2.29e-01 | 8.22e-01 |
| Glycogen storage diseases | 11 | 1.89e-01 | -2.29e-01 | 8.55e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 1.55e-01 | 2.28e-01 | 8.22e-01 |
| Defective EXT2 causes exostoses 2 | 13 | 1.55e-01 | 2.28e-01 | 8.22e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 20 | 7.76e-02 | -2.28e-01 | 7.50e-01 |
| Blood group systems biosynthesis | 15 | 1.27e-01 | 2.28e-01 | 7.96e-01 |
| PI3K events in ERBB4 signaling | 10 | 2.13e-01 | 2.28e-01 | 8.56e-01 |
| Eicosanoid ligand-binding receptors | 13 | 1.56e-01 | 2.27e-01 | 8.22e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 20 | 8.01e-02 | 2.26e-01 | 7.50e-01 |
| p75NTR signals via NF-kB | 11 | 2.01e-01 | 2.23e-01 | 8.56e-01 |
| Dectin-2 family | 20 | 8.55e-02 | -2.22e-01 | 7.62e-01 |
| VxPx cargo-targeting to cilium | 19 | 9.40e-02 | 2.22e-01 | 7.65e-01 |
| DARPP-32 events | 21 | 7.89e-02 | 2.21e-01 | 7.50e-01 |
| G beta:gamma signalling through PI3Kgamma | 19 | 9.47e-02 | -2.21e-01 | 7.65e-01 |
| Netrin-1 signaling | 49 | 7.73e-03 | 2.20e-01 | 3.46e-01 |
| AKT phosphorylates targets in the cytosol | 13 | 1.78e-01 | -2.16e-01 | 8.29e-01 |
| Antimicrobial peptides | 55 | 6.22e-03 | -2.13e-01 | 3.33e-01 |
| rRNA modification in the nucleus and cytosol | 47 | 1.14e-02 | -2.13e-01 | 4.03e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 2.02e-01 | -2.13e-01 | 8.56e-01 |
| Serotonin receptors | 10 | 2.55e-01 | 2.08e-01 | 8.56e-01 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 2.35e-01 | -2.07e-01 | 8.56e-01 |
| FCGR activation | 16 | 1.56e-01 | -2.05e-01 | 8.22e-01 |
| Defensins | 24 | 8.26e-02 | -2.05e-01 | 7.56e-01 |
| Plasma lipoprotein remodeling | 28 | 6.11e-02 | -2.05e-01 | 7.32e-01 |
| Metalloprotease DUBs | 17 | 1.45e-01 | 2.04e-01 | 8.22e-01 |
| Glucocorticoid biosynthesis | 10 | 2.63e-01 | 2.04e-01 | 8.56e-01 |
| Fertilization | 22 | 9.74e-02 | -2.04e-01 | 7.65e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 13 | 2.03e-01 | -2.04e-01 | 8.56e-01 |
| Insulin processing | 22 | 9.85e-02 | 2.03e-01 | 7.65e-01 |
| Interaction between L1 and Ankyrins | 28 | 6.27e-02 | 2.03e-01 | 7.32e-01 |
| XBP1(S) activates chaperone genes | 42 | 2.32e-02 | -2.03e-01 | 5.11e-01 |
| HS-GAG biosynthesis | 26 | 7.73e-02 | 2.00e-01 | 7.50e-01 |
| Voltage gated Potassium channels | 40 | 2.87e-02 | 2.00e-01 | 5.61e-01 |
| Termination of O-glycan biosynthesis | 18 | 1.44e-01 | -1.99e-01 | 8.22e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 18 | 1.45e-01 | 1.98e-01 | 8.22e-01 |
| Glutathione conjugation | 30 | 6.20e-02 | -1.97e-01 | 7.32e-01 |
| NF-kB is activated and signals survival | 10 | 2.83e-01 | 1.96e-01 | 8.56e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 11 | 2.61e-01 | 1.96e-01 | 8.56e-01 |
| Role of phospholipids in phagocytosis | 27 | 7.90e-02 | -1.95e-01 | 7.50e-01 |
| Mitotic Telophase/Cytokinesis | 10 | 2.85e-01 | 1.95e-01 | 8.56e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 10 | 2.86e-01 | 1.95e-01 | 8.56e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 19 | 1.42e-01 | 1.95e-01 | 8.19e-01 |
| Signaling by NOTCH2 | 23 | 1.07e-01 | 1.94e-01 | 7.66e-01 |
| Phase 4 - resting membrane potential | 18 | 1.56e-01 | -1.93e-01 | 8.22e-01 |
| Nicotinate metabolism | 25 | 9.48e-02 | -1.93e-01 | 7.65e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 70 | 5.26e-03 | -1.93e-01 | 3.05e-01 |
| Selective autophagy | 50 | 1.88e-02 | -1.92e-01 | 4.63e-01 |
| TNFs bind their physiological receptors | 24 | 1.05e-01 | -1.91e-01 | 7.65e-01 |
| Diseases of carbohydrate metabolism | 27 | 8.66e-02 | -1.91e-01 | 7.62e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 11 | 2.74e-01 | 1.90e-01 | 8.56e-01 |
| Factors involved in megakaryocyte development and platelet production | 120 | 3.27e-04 | 1.90e-01 | 4.54e-02 |
| Apoptotic cleavage of cell adhesion proteins | 10 | 2.98e-01 | 1.90e-01 | 8.56e-01 |
| RAF activation | 32 | 6.56e-02 | -1.88e-01 | 7.42e-01 |
| Regulation of TP53 Activity through Methylation | 13 | 2.40e-01 | 1.88e-01 | 8.56e-01 |
| Formation of Incision Complex in GG-NER | 33 | 6.23e-02 | -1.88e-01 | 7.32e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 44 | 3.19e-02 | -1.87e-01 | 6.08e-01 |
| Interconversion of nucleotide di- and triphosphates | 25 | 1.06e-01 | -1.87e-01 | 7.65e-01 |
| Tight junction interactions | 28 | 8.77e-02 | 1.87e-01 | 7.62e-01 |
| G alpha (s) signalling events | 405 | 1.43e-10 | 1.86e-01 | 9.91e-08 |
| RHO GTPases activate KTN1 | 10 | 3.09e-01 | 1.86e-01 | 8.57e-01 |
| Pregnenolone biosynthesis | 10 | 3.10e-01 | -1.86e-01 | 8.57e-01 |
| Non-integrin membrane-ECM interactions | 38 | 4.82e-02 | -1.85e-01 | 6.84e-01 |
| Phospholipase C-mediated cascade; FGFR3 | 13 | 2.48e-01 | 1.85e-01 | 8.56e-01 |
| Signaling by FGFR3 fusions in cancer | 10 | 3.12e-01 | -1.85e-01 | 8.60e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 2.70e-01 | -1.84e-01 | 8.56e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 19 | 1.67e-01 | -1.83e-01 | 8.26e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 14 | 2.36e-01 | 1.83e-01 | 8.56e-01 |
| Keratan sulfate degradation | 10 | 3.17e-01 | 1.83e-01 | 8.68e-01 |
| Early Phase of HIV Life Cycle | 10 | 3.20e-01 | 1.82e-01 | 8.68e-01 |
| Carnitine metabolism | 11 | 2.97e-01 | -1.82e-01 | 8.56e-01 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 33 | 7.18e-02 | 1.81e-01 | 7.50e-01 |
| FGFR3 ligand binding and activation | 13 | 2.62e-01 | 1.80e-01 | 8.56e-01 |
| FGFR3c ligand binding and activation | 13 | 2.62e-01 | 1.80e-01 | 8.56e-01 |
| Transferrin endocytosis and recycling | 28 | 9.99e-02 | -1.80e-01 | 7.65e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 14 | 2.44e-01 | 1.80e-01 | 8.56e-01 |
| G beta:gamma signalling through BTK | 13 | 2.65e-01 | -1.79e-01 | 8.56e-01 |
| Signaling by BMP | 26 | 1.15e-01 | 1.78e-01 | 7.76e-01 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 16 | 2.17e-01 | -1.78e-01 | 8.56e-01 |
| Oncogene Induced Senescence | 29 | 9.76e-02 | 1.78e-01 | 7.65e-01 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 13 | 2.70e-01 | 1.77e-01 | 8.56e-01 |
| Complex I biogenesis | 39 | 5.61e-02 | -1.77e-01 | 7.09e-01 |
| FGFR3 mutant receptor activation | 12 | 2.90e-01 | 1.76e-01 | 8.56e-01 |
| Signaling by activated point mutants of FGFR3 | 12 | 2.90e-01 | 1.76e-01 | 8.56e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 34 | 7.54e-02 | 1.76e-01 | 7.50e-01 |
| Cholesterol biosynthesis | 20 | 1.73e-01 | -1.76e-01 | 8.26e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 13 | 2.73e-01 | 1.76e-01 | 8.56e-01 |
| FRS-mediated FGFR4 signaling | 20 | 1.75e-01 | -1.75e-01 | 8.26e-01 |
| Condensation of Prophase Chromosomes | 10 | 3.42e-01 | 1.74e-01 | 8.68e-01 |
| Selenocysteine synthesis | 47 | 3.98e-02 | -1.73e-01 | 6.35e-01 |
| Organic cation/anion/zwitterion transport | 14 | 2.64e-01 | 1.72e-01 | 8.56e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 11 | 3.25e-01 | 1.72e-01 | 8.68e-01 |
| PI3K events in ERBB2 signaling | 16 | 2.36e-01 | 1.71e-01 | 8.56e-01 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 30 | 1.04e-01 | -1.71e-01 | 7.65e-01 |
| HIV Transcription Elongation | 30 | 1.04e-01 | -1.71e-01 | 7.65e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 30 | 1.04e-01 | -1.71e-01 | 7.65e-01 |
| Diseases associated with N-glycosylation of proteins | 16 | 2.37e-01 | 1.71e-01 | 8.56e-01 |
| HDMs demethylate histones | 19 | 1.98e-01 | 1.71e-01 | 8.56e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 31 | 1.00e-01 | -1.71e-01 | 7.65e-01 |
| ER Quality Control Compartment (ERQC) | 13 | 2.88e-01 | 1.70e-01 | 8.56e-01 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 1.26e-01 | -1.70e-01 | 7.96e-01 |
| FGFRL1 modulation of FGFR1 signaling | 13 | 2.89e-01 | 1.70e-01 | 8.56e-01 |
| Cell surface interactions at the vascular wall | 128 | 9.38e-04 | -1.69e-01 | 9.31e-02 |
| RHO GTPases activate CIT | 18 | 2.15e-01 | -1.69e-01 | 8.56e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 48 | 4.39e-02 | -1.68e-01 | 6.61e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 11 | 3.35e-01 | -1.68e-01 | 8.68e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 18 | 2.19e-01 | 1.67e-01 | 8.56e-01 |
| Activation of Ca-permeable Kainate Receptor | 10 | 3.60e-01 | 1.67e-01 | 8.83e-01 |
| Ionotropic activity of kainate receptors | 10 | 3.60e-01 | 1.67e-01 | 8.83e-01 |
| Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | 11 | 3.38e-01 | -1.67e-01 | 8.68e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 27 | 1.34e-01 | 1.67e-01 | 8.12e-01 |
| Heme biosynthesis | 12 | 3.18e-01 | -1.67e-01 | 8.68e-01 |
| Mitochondrial tRNA aminoacylation | 15 | 2.66e-01 | -1.66e-01 | 8.56e-01 |
| FGFR2 ligand binding and activation | 19 | 2.14e-01 | 1.65e-01 | 8.56e-01 |
| Activation of SMO | 14 | 2.88e-01 | 1.64e-01 | 8.56e-01 |
| Peptide hormone biosynthesis | 10 | 3.70e-01 | -1.64e-01 | 8.89e-01 |
| Selenoamino acid metabolism | 61 | 2.75e-02 | -1.63e-01 | 5.50e-01 |
| Acyl chain remodelling of PC | 23 | 1.76e-01 | -1.63e-01 | 8.26e-01 |
| Sulfur amino acid metabolism | 22 | 1.88e-01 | -1.62e-01 | 8.54e-01 |
| Cell junction organization | 76 | 1.46e-02 | 1.62e-01 | 4.32e-01 |
| Glycogen breakdown (glycogenolysis) | 14 | 2.97e-01 | 1.61e-01 | 8.56e-01 |
| Mitochondrial protein import | 50 | 4.93e-02 | -1.61e-01 | 6.89e-01 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 3.36e-01 | -1.60e-01 | 8.68e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 3.36e-01 | -1.60e-01 | 8.68e-01 |
| MET activates PTK2 signaling | 18 | 2.40e-01 | -1.60e-01 | 8.56e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 24 | 1.75e-01 | 1.60e-01 | 8.26e-01 |
| FGFR2c ligand binding and activation | 13 | 3.20e-01 | 1.59e-01 | 8.68e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 18 | 2.45e-01 | -1.58e-01 | 8.56e-01 |
| Formation of RNA Pol II elongation complex | 42 | 7.62e-02 | -1.58e-01 | 7.50e-01 |
| RNA Polymerase II Transcription Elongation | 42 | 7.62e-02 | -1.58e-01 | 7.50e-01 |
| Pentose phosphate pathway | 14 | 3.07e-01 | -1.58e-01 | 8.57e-01 |
| Loss of Nlp from mitotic centrosomes | 59 | 3.67e-02 | 1.57e-01 | 6.35e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 59 | 3.67e-02 | 1.57e-01 | 6.35e-01 |
| RHO GTPases activate IQGAPs | 11 | 3.67e-01 | 1.57e-01 | 8.89e-01 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 11 | 3.67e-01 | 1.57e-01 | 8.89e-01 |
| IKK complex recruitment mediated by RIP1 | 17 | 2.63e-01 | 1.57e-01 | 8.56e-01 |
| Regulation of ornithine decarboxylase (ODC) | 43 | 7.64e-02 | -1.56e-01 | 7.50e-01 |
| G0 and Early G1 | 25 | 1.76e-01 | 1.56e-01 | 8.26e-01 |
| E2F mediated regulation of DNA replication | 19 | 2.39e-01 | 1.56e-01 | 8.56e-01 |
| Dual Incision in GG-NER | 34 | 1.16e-01 | -1.56e-01 | 7.76e-01 |
| Complement cascade | 52 | 5.30e-02 | -1.55e-01 | 6.95e-01 |
| Inflammasomes | 18 | 2.55e-01 | 1.55e-01 | 8.56e-01 |
| Cytochrome P450 - arranged by substrate type | 56 | 4.49e-02 | 1.55e-01 | 6.63e-01 |
| Purine salvage | 11 | 3.75e-01 | -1.54e-01 | 8.91e-01 |
| Transcriptional regulation of pluripotent stem cells | 27 | 1.66e-01 | 1.54e-01 | 8.26e-01 |
| Mitochondrial calcium ion transport | 17 | 2.72e-01 | -1.54e-01 | 8.56e-01 |
| Keratinization | 115 | 4.45e-03 | 1.54e-01 | 2.81e-01 |
| NGF-stimulated transcription | 39 | 9.79e-02 | 1.53e-01 | 7.65e-01 |
| RHO GTPases activate PKNs | 32 | 1.36e-01 | -1.52e-01 | 8.13e-01 |
| PCP/CE pathway | 77 | 2.11e-02 | -1.52e-01 | 4.80e-01 |
| Viral mRNA Translation | 44 | 8.09e-02 | -1.52e-01 | 7.50e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 33 | 1.31e-01 | -1.52e-01 | 8.06e-01 |
| RNA Polymerase III Transcription | 33 | 1.31e-01 | -1.52e-01 | 8.06e-01 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 42 | 8.88e-02 | -1.52e-01 | 7.65e-01 |
| Metabolism of polyamines | 50 | 6.42e-02 | -1.51e-01 | 7.38e-01 |
| SHC-mediated cascade:FGFR4 | 19 | 2.54e-01 | -1.51e-01 | 8.56e-01 |
| PERK regulates gene expression | 25 | 1.92e-01 | 1.51e-01 | 8.56e-01 |
| Cytosolic sulfonation of small molecules | 21 | 2.32e-01 | 1.51e-01 | 8.56e-01 |
| Laminin interactions | 23 | 2.12e-01 | -1.50e-01 | 8.56e-01 |
| Serotonin Neurotransmitter Release Cycle | 14 | 3.31e-01 | 1.50e-01 | 8.68e-01 |
| Signaling by NOTCH3 | 41 | 9.74e-02 | 1.50e-01 | 7.65e-01 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 39 | 1.07e-01 | -1.49e-01 | 7.65e-01 |
| Pausing and recovery of Tat-mediated HIV elongation | 20 | 2.50e-01 | -1.49e-01 | 8.56e-01 |
| Tat-mediated HIV elongation arrest and recovery | 20 | 2.50e-01 | -1.49e-01 | 8.56e-01 |
| HIV elongation arrest and recovery | 21 | 2.38e-01 | -1.49e-01 | 8.56e-01 |
| Pausing and recovery of HIV elongation | 21 | 2.38e-01 | -1.49e-01 | 8.56e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 47 | 7.80e-02 | -1.49e-01 | 7.50e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 13 | 3.55e-01 | 1.48e-01 | 8.83e-01 |
| Semaphorin interactions | 60 | 4.71e-02 | 1.48e-01 | 6.82e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 24 | 2.09e-01 | -1.48e-01 | 8.56e-01 |
| tRNA modification in the nucleus and cytosol | 32 | 1.49e-01 | -1.47e-01 | 8.22e-01 |
| Class B/2 (Secretin family receptors) | 83 | 2.06e-02 | -1.47e-01 | 4.76e-01 |
| Sema3A PAK dependent Axon repulsion | 15 | 3.25e-01 | 1.47e-01 | 8.68e-01 |
| N-Glycan antennae elongation | 14 | 3.42e-01 | 1.47e-01 | 8.68e-01 |
| Removal of the Flap Intermediate from the C-strand | 12 | 3.79e-01 | -1.47e-01 | 8.92e-01 |
| Regulation of PTEN mRNA translation | 14 | 3.43e-01 | 1.46e-01 | 8.68e-01 |
| Activation of gene expression by SREBF (SREBP) | 39 | 1.14e-01 | -1.46e-01 | 7.76e-01 |
| AURKA Activation by TPX2 | 61 | 4.96e-02 | 1.45e-01 | 6.89e-01 |
| Assembly of active LPL and LIPC lipase complexes | 18 | 2.87e-01 | -1.45e-01 | 8.56e-01 |
| RUNX2 regulates bone development | 30 | 1.69e-01 | 1.45e-01 | 8.26e-01 |
| Vif-mediated degradation of APOBEC3G | 40 | 1.13e-01 | -1.45e-01 | 7.76e-01 |
| Sodium/Calcium exchangers | 10 | 4.30e-01 | 1.44e-01 | 9.01e-01 |
| Incretin synthesis, secretion, and inactivation | 21 | 2.54e-01 | 1.44e-01 | 8.56e-01 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 3.69e-01 | -1.44e-01 | 8.89e-01 |
| Degradation of AXIN | 43 | 1.03e-01 | -1.44e-01 | 7.65e-01 |
| Interleukin receptor SHC signaling | 24 | 2.24e-01 | -1.43e-01 | 8.56e-01 |
| Purine catabolism | 17 | 3.07e-01 | -1.43e-01 | 8.57e-01 |
| WNT5A-dependent internalization of FZD4 | 14 | 3.54e-01 | -1.43e-01 | 8.83e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 | 49 | 8.32e-02 | -1.43e-01 | 7.56e-01 |
| Negative regulation of NOTCH4 signaling | 43 | 1.05e-01 | -1.43e-01 | 7.65e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 19 | 2.82e-01 | 1.43e-01 | 8.56e-01 |
| Glycosphingolipid metabolism | 36 | 1.39e-01 | -1.43e-01 | 8.14e-01 |
| RAS processing | 17 | 3.09e-01 | -1.42e-01 | 8.57e-01 |
| The citric acid (TCA) cycle and respiratory electron transport | 115 | 8.65e-03 | -1.42e-01 | 3.64e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 51 | 8.07e-02 | -1.41e-01 | 7.50e-01 |
| Signaling by FGFR | 73 | 3.75e-02 | 1.41e-01 | 6.35e-01 |
| Collagen chain trimerization | 42 | 1.16e-01 | 1.40e-01 | 7.76e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 15 | 3.49e-01 | 1.40e-01 | 8.77e-01 |
| Apoptotic cleavage of cellular proteins | 35 | 1.54e-01 | 1.39e-01 | 8.22e-01 |
| Class I peroxisomal membrane protein import | 16 | 3.36e-01 | 1.39e-01 | 8.68e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 12 | 4.05e-01 | 1.39e-01 | 9.01e-01 |
| activated TAK1 mediates p38 MAPK activation | 17 | 3.22e-01 | -1.39e-01 | 8.68e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 24 | 2.40e-01 | 1.39e-01 | 8.56e-01 |
| Sphingolipid metabolism | 74 | 3.96e-02 | -1.38e-01 | 6.35e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 21 | 2.74e-01 | -1.38e-01 | 8.56e-01 |
| Defective B3GAT3 causes JDSSDHD | 19 | 3.02e-01 | 1.37e-01 | 8.56e-01 |
| Transcriptional activation of mitochondrial biogenesis | 49 | 9.89e-02 | -1.36e-01 | 7.65e-01 |
| Peptide chain elongation | 44 | 1.19e-01 | -1.36e-01 | 7.76e-01 |
| Formation of a pool of free 40S subunits | 53 | 8.72e-02 | -1.36e-01 | 7.62e-01 |
| VEGFR2 mediated vascular permeability | 26 | 2.32e-01 | 1.36e-01 | 8.56e-01 |
| Signaling by NTRK3 (TRKC) | 17 | 3.34e-01 | -1.35e-01 | 8.68e-01 |
| Ethanol oxidation | 11 | 4.38e-01 | 1.35e-01 | 9.01e-01 |
| rRNA processing in the nucleus and cytosol | 124 | 9.68e-03 | -1.35e-01 | 3.96e-01 |
| Signaling by KIT in disease | 20 | 2.97e-01 | 1.35e-01 | 8.56e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 2.97e-01 | 1.35e-01 | 8.56e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 4.20e-01 | 1.35e-01 | 9.01e-01 |
| FGFR1c ligand binding and activation | 11 | 4.40e-01 | 1.34e-01 | 9.01e-01 |
| Signaling by activated point mutants of FGFR1 | 11 | 4.40e-01 | 1.34e-01 | 9.01e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 50 | 1.01e-01 | -1.34e-01 | 7.65e-01 |
| Regulation of necroptotic cell death | 13 | 4.02e-01 | 1.34e-01 | 9.01e-01 |
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | 10 | 4.63e-01 | -1.34e-01 | 9.01e-01 |
| Iron uptake and transport | 49 | 1.05e-01 | -1.34e-01 | 7.65e-01 |
| Peroxisomal lipid metabolism | 26 | 2.37e-01 | -1.34e-01 | 8.56e-01 |
| Sphingolipid de novo biosynthesis | 38 | 1.53e-01 | -1.34e-01 | 8.22e-01 |
| TNFR2 non-canonical NF-kB pathway | 80 | 3.86e-02 | -1.34e-01 | 6.35e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE | 20 | 3.00e-01 | -1.34e-01 | 8.56e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 20 | 3.00e-01 | -1.34e-01 | 8.56e-01 |
| Degradation of DVL | 46 | 1.17e-01 | -1.34e-01 | 7.76e-01 |
| RHO GTPases Activate NADPH Oxidases | 23 | 2.70e-01 | -1.33e-01 | 8.56e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 20 | 3.05e-01 | 1.33e-01 | 8.57e-01 |
| Transport of organic anions | 11 | 4.47e-01 | 1.32e-01 | 9.01e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 10 | 4.69e-01 | -1.32e-01 | 9.01e-01 |
| Adenylate cyclase activating pathway | 10 | 4.69e-01 | -1.32e-01 | 9.01e-01 |
| Post-chaperonin tubulin folding pathway | 22 | 2.86e-01 | -1.31e-01 | 8.56e-01 |
| Metabolism of nucleotides | 86 | 3.56e-02 | -1.31e-01 | 6.35e-01 |
| p38MAPK events | 13 | 4.13e-01 | -1.31e-01 | 9.01e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 3.67e-01 | 1.30e-01 | 8.89e-01 |
| Peroxisomal protein import | 54 | 9.86e-02 | -1.30e-01 | 7.65e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 44 | 1.36e-01 | -1.30e-01 | 8.13e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 38 | 1.66e-01 | 1.30e-01 | 8.26e-01 |
| Cell-Cell communication | 109 | 1.92e-02 | 1.30e-01 | 4.63e-01 |
| Heme degradation | 15 | 3.84e-01 | -1.30e-01 | 8.92e-01 |
| G beta:gamma signalling through PLC beta | 15 | 3.85e-01 | -1.29e-01 | 8.92e-01 |
| Calnexin/calreticulin cycle | 16 | 3.71e-01 | 1.29e-01 | 8.90e-01 |
| ABC transporters in lipid homeostasis | 14 | 4.03e-01 | 1.29e-01 | 9.01e-01 |
| Signaling by FGFR1 | 45 | 1.37e-01 | 1.28e-01 | 8.13e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 14 | 4.07e-01 | -1.28e-01 | 9.01e-01 |
| Lysine catabolism | 12 | 4.43e-01 | -1.28e-01 | 9.01e-01 |
| Processing of Capped Intronless Pre-mRNA | 19 | 3.35e-01 | 1.28e-01 | 8.68e-01 |
| Recruitment of NuMA to mitotic centrosomes | 68 | 6.86e-02 | 1.28e-01 | 7.50e-01 |
| Signaling by Retinoic Acid | 39 | 1.69e-01 | -1.27e-01 | 8.26e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 43 | 1.49e-01 | -1.27e-01 | 8.22e-01 |
| Signaling by PDGF | 52 | 1.13e-01 | 1.27e-01 | 7.76e-01 |
| Pre-NOTCH Processing in Golgi | 14 | 4.11e-01 | 1.27e-01 | 9.01e-01 |
| Resolution of D-Loop Structures | 29 | 2.38e-01 | 1.27e-01 | 8.56e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 14 | 4.12e-01 | 1.27e-01 | 9.01e-01 |
| GAB1 signalosome | 17 | 3.67e-01 | 1.26e-01 | 8.89e-01 |
| Negative regulation of FGFR3 signaling | 26 | 2.65e-01 | 1.26e-01 | 8.56e-01 |
| Gamma-carboxylation of protein precursors | 10 | 4.89e-01 | -1.26e-01 | 9.11e-01 |
| Other interleukin signaling | 20 | 3.29e-01 | 1.26e-01 | 8.68e-01 |
| RIPK1-mediated regulated necrosis | 15 | 3.99e-01 | 1.26e-01 | 8.98e-01 |
| Regulated Necrosis | 15 | 3.99e-01 | 1.26e-01 | 8.98e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 18 | 3.57e-01 | 1.25e-01 | 8.83e-01 |
| Cellular hexose transport | 20 | 3.33e-01 | -1.25e-01 | 8.68e-01 |
| Chylomicron remodeling | 10 | 4.94e-01 | -1.25e-01 | 9.11e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 11 | 4.75e-01 | -1.24e-01 | 9.01e-01 |
| alpha-linolenic acid (ALA) metabolism | 11 | 4.75e-01 | -1.24e-01 | 9.01e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 22 | 3.13e-01 | 1.24e-01 | 8.61e-01 |
| Ub-specific processing proteases | 155 | 7.70e-03 | -1.24e-01 | 3.46e-01 |
| Metabolism of porphyrins | 25 | 2.84e-01 | -1.24e-01 | 8.56e-01 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 2.07e-01 | 1.23e-01 | 8.56e-01 |
| Tryptophan catabolism | 12 | 4.60e-01 | 1.23e-01 | 9.01e-01 |
| rRNA processing | 131 | 1.51e-02 | -1.23e-01 | 4.37e-01 |
| Digestion and absorption | 25 | 2.87e-01 | 1.23e-01 | 8.56e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 72 | 7.23e-02 | 1.23e-01 | 7.50e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 24 | 2.99e-01 | -1.22e-01 | 8.56e-01 |
| Integrin signaling | 27 | 2.71e-01 | -1.22e-01 | 8.56e-01 |
| EPHB-mediated forward signaling | 32 | 2.32e-01 | 1.22e-01 | 8.56e-01 |
| Respiratory electron transport | 67 | 8.41e-02 | -1.22e-01 | 7.59e-01 |
| Spry regulation of FGF signaling | 13 | 4.46e-01 | 1.22e-01 | 9.01e-01 |
| Triglyceride biosynthesis | 12 | 4.64e-01 | -1.22e-01 | 9.01e-01 |
| PCNA-Dependent Long Patch Base Excision Repair | 17 | 3.84e-01 | -1.22e-01 | 8.92e-01 |
| Uptake and function of anthrax toxins | 11 | 4.84e-01 | 1.22e-01 | 9.08e-01 |
| Cell recruitment (pro-inflammatory response) | 21 | 3.35e-01 | 1.22e-01 | 8.68e-01 |
| Purinergic signaling in leishmaniasis infection | 21 | 3.35e-01 | 1.22e-01 | 8.68e-01 |
| Lagging Strand Synthesis | 17 | 3.86e-01 | -1.22e-01 | 8.92e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 117 | 2.33e-02 | -1.22e-01 | 5.11e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 55 | 1.21e-01 | -1.21e-01 | 7.76e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 30 | 2.53e-01 | 1.21e-01 | 8.56e-01 |
| Acyl chain remodelling of PE | 21 | 3.39e-01 | -1.21e-01 | 8.68e-01 |
| Retrograde transport at the Trans-Golgi-Network | 40 | 1.88e-01 | 1.20e-01 | 8.54e-01 |
| FGFR2 alternative splicing | 19 | 3.68e-01 | 1.19e-01 | 8.89e-01 |
| Activation of RAC1 | 12 | 4.75e-01 | 1.19e-01 | 9.01e-01 |
| GABA synthesis, release, reuptake and degradation | 17 | 3.95e-01 | -1.19e-01 | 8.98e-01 |
| Metabolism of amino acids and derivatives | 285 | 5.69e-04 | -1.19e-01 | 6.59e-02 |
| CD28 dependent PI3K/Akt signaling | 20 | 3.58e-01 | 1.19e-01 | 8.83e-01 |
| Eukaryotic Translation Termination | 47 | 1.61e-01 | -1.18e-01 | 8.26e-01 |
| Plasma lipoprotein assembly | 15 | 4.28e-01 | -1.18e-01 | 9.01e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 22 | 3.37e-01 | -1.18e-01 | 8.68e-01 |
| Collagen biosynthesis and modifying enzymes | 61 | 1.11e-01 | 1.18e-01 | 7.76e-01 |
| MET promotes cell motility | 29 | 2.72e-01 | -1.18e-01 | 8.56e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 28 | 2.82e-01 | 1.17e-01 | 8.56e-01 |
| PKMTs methylate histone lysines | 35 | 2.29e-01 | 1.17e-01 | 8.56e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 75 | 7.96e-02 | 1.17e-01 | 7.50e-01 |
| Signaling by EGFR | 46 | 1.71e-01 | 1.17e-01 | 8.26e-01 |
| RNA Polymerase II Transcription Termination | 49 | 1.58e-01 | 1.17e-01 | 8.22e-01 |
| Aggrephagy | 18 | 3.93e-01 | 1.16e-01 | 8.98e-01 |
| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | 42 | 1.92e-01 | -1.16e-01 | 8.56e-01 |
| Nuclear signaling by ERBB4 | 29 | 2.79e-01 | 1.16e-01 | 8.56e-01 |
| Phospholipase C-mediated cascade; FGFR2 | 18 | 3.95e-01 | 1.16e-01 | 8.98e-01 |
| Hyaluronan metabolism | 15 | 4.41e-01 | -1.15e-01 | 9.01e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 48 | 1.69e-01 | 1.15e-01 | 8.26e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 48 | 1.69e-01 | 1.15e-01 | 8.26e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 48 | 1.69e-01 | 1.15e-01 | 8.26e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 48 | 1.69e-01 | 1.15e-01 | 8.26e-01 |
| Signaling by NOTCH1 in Cancer | 48 | 1.69e-01 | 1.15e-01 | 8.26e-01 |
| HS-GAG degradation | 19 | 3.88e-01 | 1.14e-01 | 8.93e-01 |
| Signaling by TGFB family members | 87 | 6.53e-02 | 1.14e-01 | 7.42e-01 |
| Vpr-mediated nuclear import of PICs | 24 | 3.33e-01 | 1.14e-01 | 8.68e-01 |
| Regulation of Complement cascade | 42 | 2.02e-01 | -1.14e-01 | 8.56e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 22 | 3.57e-01 | 1.14e-01 | 8.83e-01 |
| Phospholipase C-mediated cascade: FGFR1 | 16 | 4.32e-01 | 1.13e-01 | 9.01e-01 |
| BBSome-mediated cargo-targeting to cilium | 19 | 3.92e-01 | -1.13e-01 | 8.98e-01 |
| Establishment of Sister Chromatid Cohesion | 10 | 5.35e-01 | 1.13e-01 | 9.28e-01 |
| Phase 0 - rapid depolarisation | 39 | 2.23e-01 | 1.13e-01 | 8.56e-01 |
| Deadenylation of mRNA | 20 | 3.82e-01 | 1.13e-01 | 8.92e-01 |
| EGFR downregulation | 28 | 3.02e-01 | 1.13e-01 | 8.56e-01 |
| Metabolic disorders of biological oxidation enzymes | 32 | 2.71e-01 | 1.12e-01 | 8.56e-01 |
| Gene Silencing by RNA | 56 | 1.46e-01 | 1.12e-01 | 8.22e-01 |
| Striated Muscle Contraction | 33 | 2.65e-01 | -1.12e-01 | 8.56e-01 |
| Biosynthesis of DHA-derived SPMs | 16 | 4.37e-01 | 1.12e-01 | 9.01e-01 |
| Kinesins | 40 | 2.21e-01 | 1.12e-01 | 8.56e-01 |
| Asymmetric localization of PCP proteins | 53 | 1.60e-01 | -1.12e-01 | 8.26e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 56 | 1.49e-01 | 1.12e-01 | 8.22e-01 |
| Reproduction | 74 | 9.76e-02 | -1.11e-01 | 7.65e-01 |
| Signaling by Activin | 12 | 5.05e-01 | 1.11e-01 | 9.16e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 15 | 4.58e-01 | -1.11e-01 | 9.01e-01 |
| Translesion Synthesis by POLH | 12 | 5.07e-01 | -1.11e-01 | 9.19e-01 |
| Glucagon signaling in metabolic regulation | 28 | 3.12e-01 | -1.10e-01 | 8.60e-01 |
| TBC/RABGAPs | 37 | 2.45e-01 | -1.10e-01 | 8.56e-01 |
| Regulation of KIT signaling | 16 | 4.45e-01 | 1.10e-01 | 9.01e-01 |
| Base Excision Repair | 37 | 2.46e-01 | -1.10e-01 | 8.56e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 20 | 3.95e-01 | -1.10e-01 | 8.98e-01 |
| Degradation of GLI2 by the proteasome | 47 | 1.94e-01 | -1.10e-01 | 8.56e-01 |
| SRP-dependent cotranslational protein targeting to membrane | 62 | 1.36e-01 | -1.09e-01 | 8.13e-01 |
| Signaling by SCF-KIT | 43 | 2.15e-01 | 1.09e-01 | 8.56e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 34 | 2.70e-01 | -1.09e-01 | 8.56e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 10 | 5.49e-01 | 1.09e-01 | 9.33e-01 |
| NRAGE signals death through JNK | 58 | 1.51e-01 | 1.09e-01 | 8.22e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 49 | 1.88e-01 | -1.09e-01 | 8.54e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 23 | 3.67e-01 | 1.09e-01 | 8.89e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 16 | 4.53e-01 | 1.08e-01 | 9.01e-01 |
| CASP8 activity is inhibited | 11 | 5.34e-01 | 1.08e-01 | 9.28e-01 |
| Dimerization of procaspase-8 | 11 | 5.34e-01 | 1.08e-01 | 9.28e-01 |
| Regulation by c-FLIP | 11 | 5.34e-01 | 1.08e-01 | 9.28e-01 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 57 | 1.58e-01 | -1.08e-01 | 8.22e-01 |
| Cyclin E associated events during G1/S transition | 70 | 1.18e-01 | -1.08e-01 | 7.76e-01 |
| Protein-protein interactions at synapses | 84 | 8.78e-02 | 1.08e-01 | 7.62e-01 |
| Vpu mediated degradation of CD4 | 41 | 2.34e-01 | -1.07e-01 | 8.56e-01 |
| Inhibition of DNA recombination at telomere | 13 | 5.03e-01 | -1.07e-01 | 9.16e-01 |
| Signaling by NOTCH1 | 63 | 1.42e-01 | 1.07e-01 | 8.19e-01 |
| Diseases of glycosylation | 124 | 4.02e-02 | 1.07e-01 | 6.35e-01 |
| Branched-chain amino acid catabolism | 20 | 4.08e-01 | -1.07e-01 | 9.01e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription | 41 | 2.37e-01 | 1.07e-01 | 8.56e-01 |
| Autophagy | 107 | 5.68e-02 | -1.07e-01 | 7.09e-01 |
| Endogenous sterols | 25 | 3.56e-01 | 1.07e-01 | 8.83e-01 |
| Eukaryotic Translation Elongation | 47 | 2.06e-01 | -1.07e-01 | 8.56e-01 |
| Degradation of GLI1 by the proteasome | 48 | 2.02e-01 | -1.07e-01 | 8.56e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 17 | 4.47e-01 | 1.06e-01 | 9.01e-01 |
| Hh mutants abrogate ligand secretion | 45 | 2.18e-01 | -1.06e-01 | 8.56e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 25 | 3.58e-01 | -1.06e-01 | 8.83e-01 |
| Mitochondrial biogenesis | 67 | 1.34e-01 | -1.06e-01 | 8.12e-01 |
| Activated point mutants of FGFR2 | 17 | 4.50e-01 | 1.06e-01 | 9.01e-01 |
| G-protein beta:gamma signalling | 26 | 3.51e-01 | -1.06e-01 | 8.79e-01 |
| Protein localization | 132 | 3.73e-02 | -1.05e-01 | 6.35e-01 |
| NIK-->noncanonical NF-kB signaling | 46 | 2.19e-01 | -1.05e-01 | 8.56e-01 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 18 | 4.42e-01 | 1.05e-01 | 9.01e-01 |
| Centrosome maturation | 69 | 1.34e-01 | 1.04e-01 | 8.12e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 69 | 1.34e-01 | 1.04e-01 | 8.12e-01 |
| Regulation of Apoptosis | 41 | 2.49e-01 | -1.04e-01 | 8.56e-01 |
| G alpha (z) signalling events | 41 | 2.49e-01 | -1.04e-01 | 8.56e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 24 | 3.77e-01 | 1.04e-01 | 8.92e-01 |
| ABC transporter disorders | 60 | 1.65e-01 | -1.04e-01 | 8.26e-01 |
| Notch-HLH transcription pathway | 24 | 3.80e-01 | 1.04e-01 | 8.92e-01 |
| Diseases associated with O-glycosylation of proteins | 55 | 1.87e-01 | 1.03e-01 | 8.54e-01 |
| Mitochondrial translation initiation | 64 | 1.56e-01 | -1.03e-01 | 8.22e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 60 | 1.71e-01 | -1.02e-01 | 8.26e-01 |
| Post-translational protein phosphorylation | 98 | 8.10e-02 | 1.02e-01 | 7.50e-01 |
| ADP signalling through P2Y purinoceptor 1 | 20 | 4.31e-01 | -1.02e-01 | 9.01e-01 |
| mRNA decay by 5' to 3' exoribonuclease | 13 | 5.25e-01 | 1.02e-01 | 9.28e-01 |
| FGFR1 ligand binding and activation | 15 | 4.95e-01 | 1.02e-01 | 9.11e-01 |
| Degradation of the extracellular matrix | 100 | 7.93e-02 | -1.02e-01 | 7.50e-01 |
| The NLRP3 inflammasome | 13 | 5.26e-01 | 1.02e-01 | 9.28e-01 |
| Dual incision in TC-NER | 51 | 2.10e-01 | -1.02e-01 | 8.56e-01 |
| FCERI mediated NF-kB activation | 66 | 1.55e-01 | -1.01e-01 | 8.22e-01 |
| Acyl chain remodelling of PG | 15 | 4.97e-01 | -1.01e-01 | 9.11e-01 |
| FOXO-mediated transcription of cell cycle genes | 15 | 4.98e-01 | 1.01e-01 | 9.11e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 24 | 3.91e-01 | 1.01e-01 | 8.98e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 40 | 2.69e-01 | -1.01e-01 | 8.56e-01 |
| p53-Independent DNA Damage Response | 40 | 2.69e-01 | -1.01e-01 | 8.56e-01 |
| p53-Independent G1/S DNA damage checkpoint | 40 | 2.69e-01 | -1.01e-01 | 8.56e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 72 | 1.39e-01 | -1.01e-01 | 8.14e-01 |
| p75 NTR receptor-mediated signalling | 83 | 1.13e-01 | 1.01e-01 | 7.76e-01 |
| Phosphorylation of CD3 and TCR zeta chains | 15 | 5.00e-01 | 1.01e-01 | 9.13e-01 |
| RNA Polymerase I Transcription Termination | 22 | 4.14e-01 | -1.01e-01 | 9.01e-01 |
| Nuclear Envelope (NE) Reassembly | 62 | 1.71e-01 | -1.01e-01 | 8.26e-01 |
| Stabilization of p53 | 44 | 2.49e-01 | -1.00e-01 | 8.56e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 41 | 2.67e-01 | -1.00e-01 | 8.56e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 41 | 2.68e-01 | -1.00e-01 | 8.56e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 62 | 1.75e-01 | -9.97e-02 | 8.26e-01 |
| Regulation of PTEN stability and activity | 54 | 2.05e-01 | -9.96e-02 | 8.56e-01 |
| Signaling by FGFR2 | 61 | 1.79e-01 | 9.95e-02 | 8.31e-01 |
| Acyl chain remodelling of PS | 18 | 4.67e-01 | -9.92e-02 | 9.01e-01 |
| GPCR downstream signalling | 911 | 4.83e-07 | 9.91e-02 | 2.24e-04 |
| G-protein mediated events | 49 | 2.31e-01 | 9.90e-02 | 8.56e-01 |
| Negative regulation of MAPK pathway | 40 | 2.80e-01 | -9.88e-02 | 8.56e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 42 | 2.69e-01 | -9.86e-02 | 8.56e-01 |
| Signaling by RAS mutants | 42 | 2.69e-01 | -9.86e-02 | 8.56e-01 |
| Signaling by moderate kinase activity BRAF mutants | 42 | 2.69e-01 | -9.86e-02 | 8.56e-01 |
| Signaling downstream of RAS mutants | 42 | 2.69e-01 | -9.86e-02 | 8.56e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 50 | 2.30e-01 | -9.81e-02 | 8.56e-01 |
| Downstream signaling of activated FGFR4 | 25 | 3.96e-01 | -9.81e-02 | 8.98e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 50 | 2.33e-01 | -9.76e-02 | 8.56e-01 |
| Dopamine Neurotransmitter Release Cycle | 19 | 4.62e-01 | 9.75e-02 | 9.01e-01 |
| Passive transport by Aquaporins | 12 | 5.59e-01 | -9.75e-02 | 9.38e-01 |
| Phosphorylation of the APC/C | 17 | 4.87e-01 | -9.74e-02 | 9.09e-01 |
| Prostacyclin signalling through prostacyclin receptor | 14 | 5.29e-01 | -9.72e-02 | 9.28e-01 |
| Vitamin B5 (pantothenate) metabolism | 13 | 5.44e-01 | 9.72e-02 | 9.33e-01 |
| Cap-dependent Translation Initiation | 65 | 1.76e-01 | -9.72e-02 | 8.26e-01 |
| Eukaryotic Translation Initiation | 65 | 1.76e-01 | -9.72e-02 | 8.26e-01 |
| Meiotic synapsis | 30 | 3.58e-01 | -9.71e-02 | 8.83e-01 |
| Regulation of gene expression by Hypoxia-inducible Factor | 11 | 5.77e-01 | 9.70e-02 | 9.46e-01 |
| Recycling pathway of L1 | 27 | 3.83e-01 | 9.69e-02 | 8.92e-01 |
| Pre-NOTCH Transcription and Translation | 33 | 3.36e-01 | 9.68e-02 | 8.68e-01 |
| Signaling by NOTCH4 | 66 | 1.74e-01 | -9.68e-02 | 8.26e-01 |
| Triglyceride catabolism | 21 | 4.43e-01 | 9.68e-02 | 9.01e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 60 | 1.95e-01 | -9.68e-02 | 8.56e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 17 | 4.91e-01 | 9.66e-02 | 9.11e-01 |
| Beta-catenin phosphorylation cascade | 16 | 5.04e-01 | 9.65e-02 | 9.16e-01 |
| Peptide hormone metabolism | 77 | 1.44e-01 | 9.62e-02 | 8.22e-01 |
| Interleukin-12 family signaling | 48 | 2.49e-01 | -9.62e-02 | 8.56e-01 |
| RNA Polymerase I Transcription | 40 | 2.94e-01 | -9.59e-02 | 8.56e-01 |
| Negative regulation of FGFR2 signaling | 31 | 3.57e-01 | 9.57e-02 | 8.83e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 111 | 8.20e-02 | 9.57e-02 | 7.54e-01 |
| PRC2 methylates histones and DNA | 12 | 5.67e-01 | -9.54e-02 | 9.43e-01 |
| RORA activates gene expression | 17 | 4.96e-01 | -9.53e-02 | 9.11e-01 |
| Erythropoietin activates RAS | 13 | 5.52e-01 | -9.52e-02 | 9.33e-01 |
| Cargo concentration in the ER | 25 | 4.11e-01 | -9.49e-02 | 9.01e-01 |
| Leading Strand Synthesis | 13 | 5.54e-01 | -9.48e-02 | 9.33e-01 |
| Polymerase switching | 13 | 5.54e-01 | -9.48e-02 | 9.33e-01 |
| Signaling by high-kinase activity BRAF mutants | 34 | 3.41e-01 | -9.45e-02 | 8.68e-01 |
| Nucleotide salvage | 19 | 4.76e-01 | -9.44e-02 | 9.01e-01 |
| Signaling by ERBB2 in Cancer | 25 | 4.14e-01 | 9.44e-02 | 9.01e-01 |
| Phase 2 - plateau phase | 21 | 4.54e-01 | 9.44e-02 | 9.01e-01 |
| Digestion | 20 | 4.66e-01 | 9.43e-02 | 9.01e-01 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 59 | 2.11e-01 | -9.43e-02 | 8.56e-01 |
| Signaling by Hippo | 19 | 4.77e-01 | 9.42e-02 | 9.01e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 67 | 1.83e-01 | 9.41e-02 | 8.42e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 30 | 3.73e-01 | -9.40e-02 | 8.90e-01 |
| tRNA Aminoacylation | 20 | 4.67e-01 | -9.39e-02 | 9.01e-01 |
| Transcriptional Regulation by MECP2 | 53 | 2.38e-01 | 9.37e-02 | 8.56e-01 |
| Signaling by ERBB4 | 51 | 2.48e-01 | 9.36e-02 | 8.56e-01 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 73 | 1.68e-01 | -9.34e-02 | 8.26e-01 |
| Aquaporin-mediated transport | 45 | 2.79e-01 | -9.33e-02 | 8.56e-01 |
| Anchoring of the basal body to the plasma membrane | 81 | 1.48e-01 | 9.30e-02 | 8.22e-01 |
| Negative regulation of FGFR1 signaling | 29 | 3.87e-01 | 9.29e-02 | 8.93e-01 |
| Regulation of RUNX3 expression and activity | 43 | 2.93e-01 | -9.26e-02 | 8.56e-01 |
| MET activates RAS signaling | 11 | 5.96e-01 | -9.23e-02 | 9.54e-01 |
| PLC beta mediated events | 48 | 2.70e-01 | 9.21e-02 | 8.56e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 5.55e-01 | 9.12e-02 | 9.33e-01 |
| PECAM1 interactions | 11 | 6.00e-01 | 9.12e-02 | 9.54e-01 |
| Negative regulation of MET activity | 18 | 5.04e-01 | 9.11e-02 | 9.16e-01 |
| Beta-catenin independent WNT signaling | 125 | 7.99e-02 | -9.08e-02 | 7.50e-01 |
| Inositol phosphate metabolism | 44 | 2.98e-01 | -9.07e-02 | 8.56e-01 |
| Formation of TC-NER Pre-Incision Complex | 39 | 3.27e-01 | -9.06e-02 | 8.68e-01 |
| Calcitonin-like ligand receptors | 10 | 6.20e-01 | 9.05e-02 | 9.54e-01 |
| tRNA processing in the nucleus | 47 | 2.84e-01 | 9.04e-02 | 8.56e-01 |
| GLI3 is processed to GLI3R by the proteasome | 47 | 2.84e-01 | -9.04e-02 | 8.56e-01 |
| Glycerophospholipid biosynthesis | 104 | 1.12e-01 | -9.04e-02 | 7.76e-01 |
| Signaling by Receptor Tyrosine Kinases | 454 | 1.07e-03 | 8.99e-02 | 9.94e-02 |
| NOTCH3 Intracellular Domain Regulates Transcription | 23 | 4.56e-01 | 8.98e-02 | 9.01e-01 |
| Meiotic recombination | 24 | 4.47e-01 | -8.97e-02 | 9.01e-01 |
| Activation of NF-kappaB in B cells | 56 | 2.47e-01 | -8.95e-02 | 8.56e-01 |
| Intraflagellar transport | 38 | 3.40e-01 | -8.95e-02 | 8.68e-01 |
| Sema4D in semaphorin signaling | 22 | 4.68e-01 | -8.93e-02 | 9.01e-01 |
| Late endosomal microautophagy | 26 | 4.32e-01 | -8.90e-02 | 9.01e-01 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 48 | 2.86e-01 | -8.90e-02 | 8.56e-01 |
| Diseases associated with glycosaminoglycan metabolism | 38 | 3.46e-01 | 8.85e-02 | 8.72e-01 |
| CS/DS degradation | 14 | 5.68e-01 | 8.82e-02 | 9.43e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 69 | 2.05e-01 | -8.82e-02 | 8.56e-01 |
| Signalling to ERKs | 34 | 3.74e-01 | -8.81e-02 | 8.90e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 23 | 4.65e-01 | 8.81e-02 | 9.01e-01 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 23 | 4.65e-01 | 8.81e-02 | 9.01e-01 |
| Amino acid transport across the plasma membrane | 31 | 3.98e-01 | -8.77e-02 | 8.98e-01 |
| Signaling by ERBB2 KD Mutants | 24 | 4.59e-01 | 8.74e-02 | 9.01e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 17 | 5.33e-01 | -8.73e-02 | 9.28e-01 |
| Trafficking of GluR2-containing AMPA receptors | 15 | 5.60e-01 | 8.69e-02 | 9.39e-01 |
| Nuclear Receptor transcription pathway | 52 | 2.80e-01 | -8.67e-02 | 8.56e-01 |
| Mismatch Repair | 13 | 5.88e-01 | 8.67e-02 | 9.52e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 63 | 2.34e-01 | -8.67e-02 | 8.56e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 63 | 2.34e-01 | -8.67e-02 | 8.56e-01 |
| Gap junction assembly | 16 | 5.49e-01 | -8.66e-02 | 9.33e-01 |
| Myogenesis | 27 | 4.36e-01 | 8.66e-02 | 9.01e-01 |
| p53-Dependent G1 DNA Damage Response | 53 | 2.77e-01 | -8.64e-02 | 8.56e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 53 | 2.77e-01 | -8.64e-02 | 8.56e-01 |
| CD28 co-stimulation | 31 | 4.05e-01 | 8.64e-02 | 9.01e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex | 27 | 4.38e-01 | -8.62e-02 | 9.01e-01 |
| Mitochondrial translation elongation | 64 | 2.34e-01 | -8.60e-02 | 8.56e-01 |
| Nephrin family interactions | 21 | 4.95e-01 | 8.60e-02 | 9.11e-01 |
| ERKs are inactivated | 13 | 5.93e-01 | -8.56e-02 | 9.54e-01 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 12 | 6.08e-01 | -8.54e-02 | 9.54e-01 |
| Xenobiotics | 23 | 4.79e-01 | 8.53e-02 | 9.03e-01 |
| Response of Mtb to phagocytosis | 20 | 5.09e-01 | -8.52e-02 | 9.19e-01 |
| CDT1 association with the CDC6:ORC:origin complex | 46 | 3.19e-01 | -8.49e-02 | 8.68e-01 |
| Interleukin-27 signaling | 11 | 6.28e-01 | -8.44e-02 | 9.57e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 23 | 4.86e-01 | -8.39e-02 | 9.09e-01 |
| Regulation of TP53 Activity through Acetylation | 27 | 4.52e-01 | -8.37e-02 | 9.01e-01 |
| ADP signalling through P2Y purinoceptor 12 | 17 | 5.51e-01 | -8.36e-02 | 9.33e-01 |
| mRNA 3'-end processing | 42 | 3.49e-01 | 8.35e-02 | 8.77e-01 |
| Signaling by FGFR3 | 36 | 3.87e-01 | 8.33e-02 | 8.93e-01 |
| Cellular response to hypoxia | 59 | 2.70e-01 | -8.32e-02 | 8.56e-01 |
| Interleukin-6 family signaling | 23 | 4.91e-01 | -8.30e-02 | 9.11e-01 |
| Prolactin receptor signaling | 15 | 5.80e-01 | -8.25e-02 | 9.46e-01 |
| Orc1 removal from chromatin | 57 | 2.83e-01 | -8.23e-02 | 8.56e-01 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 31 | 4.30e-01 | -8.20e-02 | 9.01e-01 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 6.54e-01 | -8.19e-02 | 9.57e-01 |
| Regulation of PTEN gene transcription | 55 | 2.94e-01 | 8.19e-02 | 8.56e-01 |
| MAP2K and MAPK activation | 36 | 3.95e-01 | -8.19e-02 | 8.98e-01 |
| Adenylate cyclase inhibitory pathway | 14 | 5.96e-01 | -8.19e-02 | 9.54e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 30 | 4.38e-01 | 8.19e-02 | 9.01e-01 |
| Macroautophagy | 94 | 1.71e-01 | -8.17e-02 | 8.26e-01 |
| mRNA Capping | 21 | 5.17e-01 | -8.17e-02 | 9.20e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 30 | 4.39e-01 | -8.17e-02 | 9.01e-01 |
| Bicarbonate transporters | 10 | 6.55e-01 | 8.16e-02 | 9.57e-01 |
| Translesion synthesis by POLK | 13 | 6.11e-01 | -8.15e-02 | 9.54e-01 |
| Signaling by GPCR | 967 | 2.08e-05 | 8.15e-02 | 3.62e-03 |
| Signaling by TGF-beta Receptor Complex | 60 | 2.77e-01 | 8.13e-02 | 8.56e-01 |
| Metabolism of Angiotensinogen to Angiotensins | 16 | 5.74e-01 | 8.11e-02 | 9.46e-01 |
| Deubiquitination | 221 | 3.88e-02 | -8.08e-02 | 6.35e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 14 | 6.01e-01 | 8.08e-02 | 9.54e-01 |
| Glutamate and glutamine metabolism | 13 | 6.15e-01 | -8.07e-02 | 9.54e-01 |
| Apoptotic execution phase | 42 | 3.67e-01 | 8.04e-02 | 8.89e-01 |
| Scavenging by Class A Receptors | 17 | 5.67e-01 | 8.02e-02 | 9.43e-01 |
| Influenza Infection | 90 | 1.89e-01 | -8.02e-02 | 8.55e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 12 | 6.31e-01 | 8.01e-02 | 9.57e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 19 | 5.46e-01 | -8.01e-02 | 9.33e-01 |
| PI-3K cascade:FGFR4 | 19 | 5.46e-01 | -7.99e-02 | 9.33e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 21 | 5.27e-01 | 7.97e-02 | 9.28e-01 |
| Unfolded Protein Response (UPR) | 78 | 2.24e-01 | -7.96e-02 | 8.56e-01 |
| Suppression of phagosomal maturation | 10 | 6.63e-01 | -7.96e-02 | 9.57e-01 |
| Polymerase switching on the C-strand of the telomere | 21 | 5.28e-01 | -7.95e-02 | 9.28e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 60 | 2.89e-01 | -7.93e-02 | 8.56e-01 |
| RET signaling | 37 | 4.05e-01 | -7.91e-02 | 9.01e-01 |
| Reduction of cytosolic Ca++ levels | 12 | 6.36e-01 | 7.90e-02 | 9.57e-01 |
| IL-6-type cytokine receptor ligand interactions | 16 | 5.85e-01 | -7.89e-02 | 9.50e-01 |
| G2/M DNA damage checkpoint | 52 | 3.25e-01 | -7.89e-02 | 8.68e-01 |
| Listeria monocytogenes entry into host cells | 17 | 5.75e-01 | 7.86e-02 | 9.46e-01 |
| Synthesis of PC | 25 | 4.96e-01 | -7.86e-02 | 9.11e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 28 | 4.73e-01 | 7.84e-02 | 9.01e-01 |
| Trafficking of AMPA receptors | 28 | 4.73e-01 | 7.84e-02 | 9.01e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 14 | 6.13e-01 | 7.82e-02 | 9.54e-01 |
| Influenza Viral RNA Transcription and Replication | 76 | 2.40e-01 | -7.80e-02 | 8.56e-01 |
| RNA Polymerase III Transcription Termination | 18 | 5.67e-01 | -7.80e-02 | 9.43e-01 |
| FGFR1 mutant receptor activation | 30 | 4.61e-01 | 7.79e-02 | 9.01e-01 |
| Acyl chain remodelling of PI | 14 | 6.15e-01 | -7.77e-02 | 9.54e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 73 | 2.53e-01 | 7.75e-02 | 8.56e-01 |
| SCF-beta-TrCP mediated degradation of Emi1 | 44 | 3.76e-01 | -7.72e-02 | 8.91e-01 |
| LDL clearance | 19 | 5.60e-01 | 7.72e-02 | 9.39e-01 |
| Translation | 185 | 7.09e-02 | -7.71e-02 | 7.50e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 14 | 6.22e-01 | -7.61e-02 | 9.54e-01 |
| CYP2E1 reactions | 11 | 6.62e-01 | -7.60e-02 | 9.57e-01 |
| PI-3K cascade:FGFR3 | 18 | 5.77e-01 | 7.60e-02 | 9.46e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 74 | 2.59e-01 | 7.60e-02 | 8.56e-01 |
| MTOR signalling | 35 | 4.37e-01 | -7.60e-02 | 9.01e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 6.38e-01 | 7.54e-02 | 9.57e-01 |
| Removal of the Flap Intermediate | 11 | 6.65e-01 | -7.54e-02 | 9.57e-01 |
| Nuclear Events (kinase and transcription factor activation) | 61 | 3.09e-01 | 7.53e-02 | 8.57e-01 |
| Translation initiation complex formation | 30 | 4.76e-01 | -7.53e-02 | 9.01e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 32 | 4.61e-01 | 7.53e-02 | 9.01e-01 |
| Signaling by VEGF | 97 | 2.01e-01 | 7.52e-02 | 8.56e-01 |
| Neurexins and neuroligins | 54 | 3.39e-01 | 7.52e-02 | 8.68e-01 |
| TRP channels | 24 | 5.25e-01 | -7.50e-02 | 9.28e-01 |
| Ribosomal scanning and start codon recognition | 31 | 4.70e-01 | -7.49e-02 | 9.01e-01 |
| RNA Polymerase I Promoter Clearance | 39 | 4.21e-01 | -7.45e-02 | 9.01e-01 |
| Growth hormone receptor signaling | 21 | 5.55e-01 | 7.44e-02 | 9.33e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 63 | 3.08e-01 | -7.43e-02 | 8.57e-01 |
| Termination of translesion DNA synthesis | 24 | 5.31e-01 | -7.40e-02 | 9.28e-01 |
| MAPK6/MAPK4 signaling | 75 | 2.69e-01 | -7.38e-02 | 8.56e-01 |
| Regulation of beta-cell development | 35 | 4.50e-01 | 7.37e-02 | 9.01e-01 |
| CD28 dependent Vav1 pathway | 12 | 6.59e-01 | 7.36e-02 | 9.57e-01 |
| Signaling by EGFR in Cancer | 22 | 5.50e-01 | 7.36e-02 | 9.33e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 67 | 2.98e-01 | -7.36e-02 | 8.56e-01 |
| Estrogen-dependent gene expression | 83 | 2.50e-01 | 7.31e-02 | 8.56e-01 |
| Signaling by Interleukins | 391 | 1.37e-02 | -7.28e-02 | 4.19e-01 |
| O-linked glycosylation | 91 | 2.30e-01 | 7.28e-02 | 8.56e-01 |
| mRNA Splicing - Minor Pathway | 37 | 4.44e-01 | -7.28e-02 | 9.01e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 36 | 4.53e-01 | 7.23e-02 | 9.01e-01 |
| Transport of Mature Transcript to Cytoplasm | 63 | 3.22e-01 | 7.22e-02 | 8.68e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 16 | 6.18e-01 | 7.20e-02 | 9.54e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 16 | 6.18e-01 | 7.20e-02 | 9.54e-01 |
| RMTs methylate histone arginines | 30 | 4.95e-01 | -7.19e-02 | 9.11e-01 |
| Meiosis | 52 | 3.70e-01 | -7.18e-02 | 8.89e-01 |
| Transport of the SLBP independent Mature mRNA | 24 | 5.44e-01 | 7.15e-02 | 9.33e-01 |
| Toll-like Receptor Cascades | 131 | 1.59e-01 | 7.13e-02 | 8.26e-01 |
| Developmental Biology | 813 | 6.17e-04 | 7.11e-02 | 6.60e-02 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 60 | 3.41e-01 | -7.11e-02 | 8.68e-01 |
| Defective CFTR causes cystic fibrosis | 46 | 4.05e-01 | -7.10e-02 | 9.01e-01 |
| NR1H2 and NR1H3-mediated signaling | 44 | 4.16e-01 | -7.10e-02 | 9.01e-01 |
| Activation of Matrix Metalloproteinases | 29 | 5.09e-01 | -7.09e-02 | 9.19e-01 |
| Switching of origins to a post-replicative state | 75 | 2.91e-01 | -7.05e-02 | 8.56e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 16 | 6.26e-01 | 7.05e-02 | 9.57e-01 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 5.95e-01 | -7.04e-02 | 9.54e-01 |
| Platelet Aggregation (Plug Formation) | 37 | 4.59e-01 | -7.03e-02 | 9.01e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 14 | 6.49e-01 | -7.03e-02 | 9.57e-01 |
| Misspliced GSK3beta mutants stabilize beta-catenin | 14 | 6.49e-01 | 7.03e-02 | 9.57e-01 |
| S33 mutants of beta-catenin aren't phosphorylated | 14 | 6.49e-01 | 7.03e-02 | 9.57e-01 |
| S37 mutants of beta-catenin aren't phosphorylated | 14 | 6.49e-01 | 7.03e-02 | 9.57e-01 |
| S45 mutants of beta-catenin aren't phosphorylated | 14 | 6.49e-01 | 7.03e-02 | 9.57e-01 |
| T41 mutants of beta-catenin aren't phosphorylated | 14 | 6.49e-01 | 7.03e-02 | 9.57e-01 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 14 | 6.49e-01 | 7.03e-02 | 9.57e-01 |
| Carboxyterminal post-translational modifications of tubulin | 35 | 4.73e-01 | -7.01e-02 | 9.01e-01 |
| Intra-Golgi traffic | 36 | 4.67e-01 | 7.00e-02 | 9.01e-01 |
| Activation of BAD and translocation to mitochondria | 14 | 6.51e-01 | -6.98e-02 | 9.57e-01 |
| Signaling by RAF1 mutants | 39 | 4.52e-01 | -6.97e-02 | 9.01e-01 |
| Synthesis of DNA | 100 | 2.30e-01 | -6.95e-02 | 8.56e-01 |
| Interleukin-2 family signaling | 40 | 4.48e-01 | -6.93e-02 | 9.01e-01 |
| Pre-NOTCH Expression and Processing | 46 | 4.18e-01 | 6.91e-02 | 9.01e-01 |
| Mitochondrial translation termination | 64 | 3.40e-01 | -6.91e-02 | 8.68e-01 |
| Neurotransmitter release cycle | 43 | 4.34e-01 | -6.90e-02 | 9.01e-01 |
| TRAF3-dependent IRF activation pathway | 14 | 6.55e-01 | 6.90e-02 | 9.57e-01 |
| Phase I - Functionalization of compounds | 91 | 2.56e-01 | 6.90e-02 | 8.56e-01 |
| VEGFA-VEGFR2 Pathway | 91 | 2.57e-01 | 6.87e-02 | 8.56e-01 |
| RNA Polymerase I Promoter Escape | 22 | 5.79e-01 | -6.83e-02 | 9.46e-01 |
| Assembly and cell surface presentation of NMDA receptors | 24 | 5.64e-01 | -6.81e-02 | 9.43e-01 |
| Erythrocytes take up carbon dioxide and release oxygen | 10 | 7.10e-01 | 6.80e-02 | 9.68e-01 |
| O2/CO2 exchange in erythrocytes | 10 | 7.10e-01 | 6.80e-02 | 9.68e-01 |
| G1/S DNA Damage Checkpoints | 55 | 3.84e-01 | -6.80e-02 | 8.92e-01 |
| TNF signaling | 34 | 4.94e-01 | 6.79e-02 | 9.11e-01 |
| Resolution of Abasic Sites (AP sites) | 31 | 5.14e-01 | -6.78e-02 | 9.19e-01 |
| Ion homeostasis | 48 | 4.17e-01 | 6.77e-02 | 9.01e-01 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 20 | 6.01e-01 | -6.76e-02 | 9.54e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 47 | 4.24e-01 | 6.75e-02 | 9.01e-01 |
| Signaling by PTK6 | 47 | 4.24e-01 | 6.75e-02 | 9.01e-01 |
| Translesion synthesis by REV1 | 12 | 6.89e-01 | -6.67e-02 | 9.66e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 19 | 6.15e-01 | -6.66e-02 | 9.54e-01 |
| Signaling by Insulin receptor | 71 | 3.33e-01 | -6.64e-02 | 8.68e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 27 | 5.52e-01 | 6.61e-02 | 9.33e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 31 | 5.25e-01 | 6.60e-02 | 9.28e-01 |
| MAPK3 (ERK1) activation | 10 | 7.18e-01 | -6.60e-02 | 9.68e-01 |
| Oxidative Stress Induced Senescence | 58 | 3.86e-01 | 6.59e-02 | 8.92e-01 |
| Collagen formation | 81 | 3.06e-01 | 6.58e-02 | 8.57e-01 |
| Transcriptional regulation of white adipocyte differentiation | 74 | 3.29e-01 | 6.56e-02 | 8.68e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 19 | 6.21e-01 | -6.56e-02 | 9.54e-01 |
| Processive synthesis on the C-strand of the telomere | 14 | 6.71e-01 | -6.55e-02 | 9.59e-01 |
| Potassium Channels | 92 | 2.78e-01 | 6.55e-02 | 8.56e-01 |
| Nucleotide Excision Repair | 87 | 2.92e-01 | -6.54e-02 | 8.56e-01 |
| Metabolism | 1725 | 9.83e-06 | -6.50e-02 | 1.95e-03 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 61 | 3.81e-01 | -6.49e-02 | 8.92e-01 |
| Mitochondrial translation | 70 | 3.48e-01 | -6.49e-02 | 8.76e-01 |
| Axon guidance | 443 | 1.97e-02 | 6.49e-02 | 4.63e-01 |
| Regulation of signaling by NODAL | 10 | 7.23e-01 | 6.47e-02 | 9.68e-01 |
| Elevation of cytosolic Ca2+ levels | 14 | 6.76e-01 | -6.46e-02 | 9.59e-01 |
| Regulation of RUNX1 Expression and Activity | 16 | 6.55e-01 | 6.46e-02 | 9.57e-01 |
| Integrin cell surface interactions | 61 | 3.83e-01 | -6.46e-02 | 8.92e-01 |
| Interleukin-2 signaling | 11 | 7.12e-01 | 6.43e-02 | 9.68e-01 |
| G2/M Checkpoints | 110 | 2.46e-01 | -6.41e-02 | 8.56e-01 |
| RA biosynthesis pathway | 19 | 6.29e-01 | 6.41e-02 | 9.57e-01 |
| TCF dependent signaling in response to WNT | 150 | 1.76e-01 | -6.40e-02 | 8.26e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 6.40e-01 | 6.37e-02 | 9.57e-01 |
| RAB geranylgeranylation | 54 | 4.19e-01 | -6.36e-02 | 9.01e-01 |
| Regulation of FZD by ubiquitination | 17 | 6.51e-01 | -6.33e-02 | 9.57e-01 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 47 | 4.53e-01 | 6.32e-02 | 9.01e-01 |
| Presynaptic function of Kainate receptors | 16 | 6.63e-01 | -6.30e-02 | 9.57e-01 |
| Transport of the SLBP Dependant Mature mRNA | 25 | 5.86e-01 | 6.29e-02 | 9.50e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 26 | 5.79e-01 | 6.29e-02 | 9.46e-01 |
| Export of Viral Ribonucleoproteins from Nucleus | 24 | 5.95e-01 | 6.27e-02 | 9.54e-01 |
| Interleukin-1 signaling | 82 | 3.27e-01 | -6.26e-02 | 8.68e-01 |
| FCERI mediated MAPK activation | 28 | 5.66e-01 | -6.26e-02 | 9.43e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 46 | 4.64e-01 | 6.25e-02 | 9.01e-01 |
| MHC class II antigen presentation | 95 | 2.93e-01 | 6.25e-02 | 8.56e-01 |
| Interleukin-4 and Interleukin-13 signaling | 103 | 2.74e-01 | -6.24e-02 | 8.56e-01 |
| Signaling by NTRK2 (TRKB) | 24 | 5.98e-01 | -6.23e-02 | 9.54e-01 |
| COPII-mediated vesicle transport | 56 | 4.21e-01 | 6.22e-02 | 9.01e-01 |
| Synthesis of PE | 10 | 7.34e-01 | 6.22e-02 | 9.68e-01 |
| Visual phototransduction | 87 | 3.23e-01 | -6.14e-02 | 8.68e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 18 | 6.53e-01 | -6.13e-02 | 9.57e-01 |
| Host Interactions of HIV factors | 102 | 2.87e-01 | -6.10e-02 | 8.56e-01 |
| SUMOylation of chromatin organization proteins | 44 | 4.84e-01 | 6.09e-02 | 9.08e-01 |
| Nervous system development | 466 | 2.51e-02 | 6.08e-02 | 5.29e-01 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 11 | 7.27e-01 | 6.07e-02 | 9.68e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 45 | 4.83e-01 | 6.05e-02 | 9.07e-01 |
| NoRC negatively regulates rRNA expression | 34 | 5.42e-01 | -6.05e-02 | 9.33e-01 |
| Death Receptor Signalling | 121 | 2.51e-01 | 6.04e-02 | 8.56e-01 |
| PI3K Cascade | 40 | 5.09e-01 | 6.03e-02 | 9.19e-01 |
| SLC-mediated transmembrane transport | 226 | 1.19e-01 | -6.03e-02 | 7.76e-01 |
| Signaling by MET | 63 | 4.09e-01 | -6.01e-02 | 9.01e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 18 | 6.59e-01 | 6.01e-02 | 9.57e-01 |
| Diseases associated with visual transduction | 11 | 7.30e-01 | -6.00e-02 | 9.68e-01 |
| Diseases of the neuronal system | 11 | 7.30e-01 | -6.00e-02 | 9.68e-01 |
| Retinoid cycle disease events | 11 | 7.30e-01 | -6.00e-02 | 9.68e-01 |
| Negative epigenetic regulation of rRNA expression | 37 | 5.30e-01 | -5.97e-02 | 9.28e-01 |
| RUNX2 regulates osteoblast differentiation | 24 | 6.13e-01 | 5.96e-02 | 9.54e-01 |
| Signal Transduction | 2343 | 3.95e-06 | 5.95e-02 | 1.10e-03 |
| RNA Polymerase II Pre-transcription Events | 63 | 4.16e-01 | -5.93e-02 | 9.01e-01 |
| Killing mechanisms | 10 | 7.46e-01 | -5.92e-02 | 9.68e-01 |
| WNT5:FZD7-mediated leishmania damping | 10 | 7.46e-01 | -5.92e-02 | 9.68e-01 |
| FGFR4 ligand binding and activation | 13 | 7.12e-01 | -5.92e-02 | 9.68e-01 |
| Infection with Mycobacterium tuberculosis | 24 | 6.16e-01 | -5.91e-02 | 9.54e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 11 | 7.34e-01 | 5.91e-02 | 9.68e-01 |
| Stimuli-sensing channels | 88 | 3.40e-01 | 5.89e-02 | 8.68e-01 |
| DNA Replication | 107 | 2.93e-01 | -5.89e-02 | 8.56e-01 |
| Syndecan interactions | 17 | 6.78e-01 | -5.81e-02 | 9.59e-01 |
| Negative regulation of the PI3K/AKT network | 104 | 3.07e-01 | 5.80e-02 | 8.57e-01 |
| FGFR2 mutant receptor activation | 26 | 6.10e-01 | 5.79e-02 | 9.54e-01 |
| Synthesis of PA | 30 | 5.84e-01 | -5.78e-02 | 9.49e-01 |
| RNA Polymerase I Transcription Initiation | 36 | 5.49e-01 | -5.78e-02 | 9.33e-01 |
| Uptake and actions of bacterial toxins | 29 | 5.91e-01 | 5.77e-02 | 9.54e-01 |
| MET activates RAP1 and RAC1 | 11 | 7.41e-01 | 5.76e-02 | 9.68e-01 |
| Interactions of Vpr with host cellular proteins | 26 | 6.13e-01 | 5.74e-02 | 9.54e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 7.42e-01 | 5.74e-02 | 9.68e-01 |
| EPHA-mediated growth cone collapse | 14 | 7.12e-01 | 5.71e-02 | 9.68e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 14 | 7.12e-01 | 5.69e-02 | 9.68e-01 |
| Deactivation of the beta-catenin transactivating complex | 32 | 5.79e-01 | 5.67e-02 | 9.46e-01 |
| Ovarian tumor domain proteases | 30 | 5.93e-01 | 5.65e-02 | 9.54e-01 |
| Signalling to RAS | 20 | 6.62e-01 | -5.64e-02 | 9.57e-01 |
| GPVI-mediated activation cascade | 29 | 6.00e-01 | 5.63e-02 | 9.54e-01 |
| Assembly of the pre-replicative complex | 54 | 4.76e-01 | -5.61e-02 | 9.01e-01 |
| Downstream signaling of activated FGFR1 | 30 | 5.95e-01 | 5.61e-02 | 9.54e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 27 | 6.14e-01 | -5.60e-02 | 9.54e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 17 | 6.89e-01 | 5.60e-02 | 9.66e-01 |
| Interleukin-35 Signalling | 12 | 7.37e-01 | -5.60e-02 | 9.68e-01 |
| Reversible hydration of carbon dioxide | 12 | 7.37e-01 | -5.59e-02 | 9.68e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 13 | 7.28e-01 | 5.57e-02 | 9.68e-01 |
| Cyclin D associated events in G1 | 40 | 5.44e-01 | 5.55e-02 | 9.33e-01 |
| G1 Phase | 40 | 5.44e-01 | 5.55e-02 | 9.33e-01 |
| EPH-Ephrin signaling | 84 | 3.80e-01 | 5.55e-02 | 8.92e-01 |
| Nuclear Envelope Breakdown | 41 | 5.39e-01 | 5.55e-02 | 9.33e-01 |
| RHO GTPases Activate ROCKs | 18 | 6.85e-01 | 5.53e-02 | 9.62e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 30 | 6.00e-01 | -5.53e-02 | 9.54e-01 |
| Disorders of transmembrane transporters | 145 | 2.52e-01 | -5.52e-02 | 8.56e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 110 | 3.18e-01 | 5.52e-02 | 8.68e-01 |
| FRS-mediated FGFR1 signaling | 22 | 6.55e-01 | -5.51e-02 | 9.57e-01 |
| Neutrophil degranulation | 395 | 6.17e-02 | -5.49e-02 | 7.32e-01 |
| EPH-ephrin mediated repulsion of cells | 43 | 5.35e-01 | 5.48e-02 | 9.28e-01 |
| Metabolism of RNA | 504 | 3.63e-02 | -5.47e-02 | 6.35e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 63 | 4.53e-01 | 5.46e-02 | 9.01e-01 |
| SUMOylation of DNA damage response and repair proteins | 56 | 4.81e-01 | 5.45e-02 | 9.04e-01 |
| VEGFR2 mediated cell proliferation | 19 | 6.81e-01 | -5.45e-02 | 9.59e-01 |
| Interferon Signaling | 148 | 2.54e-01 | 5.44e-02 | 8.56e-01 |
| DNA Replication Pre-Initiation | 68 | 4.38e-01 | -5.44e-02 | 9.01e-01 |
| S Phase | 139 | 2.69e-01 | -5.44e-02 | 8.56e-01 |
| Downstream TCR signaling | 76 | 4.13e-01 | -5.43e-02 | 9.01e-01 |
| Presynaptic depolarization and calcium channel opening | 12 | 7.45e-01 | 5.43e-02 | 9.68e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 27 | 6.28e-01 | 5.39e-02 | 9.57e-01 |
| Epigenetic regulation of gene expression | 72 | 4.31e-01 | -5.37e-02 | 9.01e-01 |
| Signaling by WNT | 235 | 1.57e-01 | -5.37e-02 | 8.22e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 49 | 5.16e-01 | 5.37e-02 | 9.19e-01 |
| Prolonged ERK activation events | 14 | 7.29e-01 | -5.35e-02 | 9.68e-01 |
| Synthesis of bile acids and bile salts | 28 | 6.24e-01 | 5.35e-02 | 9.57e-01 |
| Depolymerisation of the Nuclear Lamina | 14 | 7.30e-01 | -5.34e-02 | 9.68e-01 |
| Phase II - Conjugation of compounds | 87 | 3.90e-01 | 5.33e-02 | 8.97e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 26 | 6.39e-01 | -5.31e-02 | 9.57e-01 |
| Bile acid and bile salt metabolism | 36 | 5.82e-01 | 5.30e-02 | 9.48e-01 |
| Signaling by Leptin | 10 | 7.72e-01 | 5.30e-02 | 9.78e-01 |
| Transport of small molecules | 631 | 2.39e-02 | -5.30e-02 | 5.11e-01 |
| Constitutive Signaling by EGFRvIII | 15 | 7.24e-01 | -5.28e-02 | 9.68e-01 |
| Signaling by EGFRvIII in Cancer | 15 | 7.24e-01 | -5.28e-02 | 9.68e-01 |
| Processing of DNA double-strand break ends | 52 | 5.14e-01 | -5.24e-02 | 9.19e-01 |
| Chaperone Mediated Autophagy | 18 | 7.01e-01 | -5.24e-02 | 9.68e-01 |
| SUMO E3 ligases SUMOylate target proteins | 136 | 2.93e-01 | 5.23e-02 | 8.56e-01 |
| Regulation of TNFR1 signaling | 26 | 6.45e-01 | 5.22e-02 | 9.57e-01 |
| NCAM signaling for neurite out-growth | 54 | 5.09e-01 | -5.19e-02 | 9.19e-01 |
| Mitotic Anaphase | 191 | 2.19e-01 | -5.17e-02 | 8.56e-01 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | 10 | 7.77e-01 | 5.17e-02 | 9.78e-01 |
| Opioid Signalling | 78 | 4.30e-01 | 5.17e-02 | 9.01e-01 |
| HCMV Early Events | 47 | 5.41e-01 | 5.16e-02 | 9.33e-01 |
| PI Metabolism | 79 | 4.30e-01 | 5.14e-02 | 9.01e-01 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 41 | 5.69e-01 | -5.14e-02 | 9.44e-01 |
| Interleukin-1 family signaling | 117 | 3.39e-01 | -5.12e-02 | 8.68e-01 |
| Metabolism of water-soluble vitamins and cofactors | 98 | 3.81e-01 | -5.12e-02 | 8.92e-01 |
| Fatty acid metabolism | 148 | 2.85e-01 | -5.10e-02 | 8.56e-01 |
| Generation of second messenger molecules | 26 | 6.53e-01 | -5.09e-02 | 9.57e-01 |
| Activation of ATR in response to replication stress | 30 | 6.31e-01 | -5.08e-02 | 9.57e-01 |
| Cargo trafficking to the periciliary membrane | 42 | 5.71e-01 | 5.06e-02 | 9.45e-01 |
| Potential therapeutics for SARS | 33 | 6.17e-01 | 5.04e-02 | 9.54e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 14 | 7.45e-01 | 5.03e-02 | 9.68e-01 |
| Telomere Extension By Telomerase | 19 | 7.06e-01 | -5.00e-02 | 9.68e-01 |
| Signaling by NTRK1 (TRKA) | 113 | 3.59e-01 | 5.00e-02 | 8.83e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 82 | 4.36e-01 | 4.98e-02 | 9.01e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 82 | 4.36e-01 | 4.98e-02 | 9.01e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 82 | 4.36e-01 | 4.98e-02 | 9.01e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 82 | 4.36e-01 | 4.98e-02 | 9.01e-01 |
| Rab regulation of trafficking | 108 | 3.73e-01 | -4.97e-02 | 8.90e-01 |
| Degradation of beta-catenin by the destruction complex | 71 | 4.73e-01 | -4.93e-02 | 9.01e-01 |
| Regulation of innate immune responses to cytosolic DNA | 11 | 7.78e-01 | 4.91e-02 | 9.78e-01 |
| G beta:gamma signalling through CDC42 | 15 | 7.42e-01 | -4.91e-02 | 9.68e-01 |
| Interleukin-12 signaling | 38 | 6.01e-01 | -4.91e-02 | 9.54e-01 |
| Citric acid cycle (TCA cycle) | 18 | 7.21e-01 | -4.86e-02 | 9.68e-01 |
| ECM proteoglycans | 53 | 5.41e-01 | -4.85e-02 | 9.33e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 82 | 4.49e-01 | 4.84e-02 | 9.01e-01 |
| Neuronal System | 355 | 1.20e-01 | 4.81e-02 | 7.76e-01 |
| Repression of WNT target genes | 12 | 7.73e-01 | -4.81e-02 | 9.78e-01 |
| Cellular Senescence | 115 | 3.74e-01 | 4.81e-02 | 8.90e-01 |
| FCERI mediated Ca+2 mobilization | 27 | 6.68e-01 | 4.77e-02 | 9.57e-01 |
| Biological oxidations | 182 | 2.68e-01 | 4.77e-02 | 8.56e-01 |
| Mitotic Metaphase and Anaphase | 192 | 2.56e-01 | -4.76e-02 | 8.56e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 161 | 3.00e-01 | 4.74e-02 | 8.56e-01 |
| Mitotic Prometaphase | 156 | 3.09e-01 | 4.73e-02 | 8.57e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 28 | 6.65e-01 | 4.73e-02 | 9.57e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 37 | 6.22e-01 | -4.69e-02 | 9.54e-01 |
| O-linked glycosylation of mucins | 53 | 5.55e-01 | -4.69e-02 | 9.33e-01 |
| Amino acids regulate mTORC1 | 47 | 5.80e-01 | -4.66e-02 | 9.46e-01 |
| Neddylation | 192 | 2.67e-01 | -4.65e-02 | 8.56e-01 |
| Regulation of RAS by GAPs | 56 | 5.49e-01 | -4.63e-02 | 9.33e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 101 | 4.22e-01 | -4.63e-02 | 9.01e-01 |
| HSF1 activation | 21 | 7.14e-01 | -4.62e-02 | 9.68e-01 |
| Tie2 Signaling | 17 | 7.44e-01 | -4.57e-02 | 9.68e-01 |
| L1CAM interactions | 95 | 4.42e-01 | 4.57e-02 | 9.01e-01 |
| PI-3K cascade:FGFR2 | 23 | 7.05e-01 | 4.56e-02 | 9.68e-01 |
| Downregulation of ERBB2 signaling | 23 | 7.05e-01 | 4.56e-02 | 9.68e-01 |
| SUMOylation of RNA binding proteins | 36 | 6.38e-01 | 4.54e-02 | 9.57e-01 |
| HIV Infection | 179 | 3.01e-01 | -4.49e-02 | 8.56e-01 |
| Common Pathway of Fibrin Clot Formation | 20 | 7.29e-01 | -4.48e-02 | 9.68e-01 |
| Formation of the cornified envelope | 42 | 6.16e-01 | 4.47e-02 | 9.54e-01 |
| HDR through Single Strand Annealing (SSA) | 31 | 6.67e-01 | -4.47e-02 | 9.57e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 12 | 7.90e-01 | 4.45e-02 | 9.82e-01 |
| Hedgehog 'off' state | 86 | 4.77e-01 | -4.44e-02 | 9.01e-01 |
| Platelet sensitization by LDL | 16 | 7.59e-01 | -4.44e-02 | 9.76e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | 20 | 7.31e-01 | -4.43e-02 | 9.68e-01 |
| Neurodegenerative Diseases | 20 | 7.31e-01 | -4.43e-02 | 9.68e-01 |
| Ephrin signaling | 19 | 7.38e-01 | 4.43e-02 | 9.68e-01 |
| TRAF6 mediated NF-kB activation | 20 | 7.33e-01 | 4.40e-02 | 9.68e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 12 | 7.94e-01 | 4.36e-02 | 9.82e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 18 | 7.50e-01 | -4.34e-02 | 9.70e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 7.44e-01 | 4.33e-02 | 9.68e-01 |
| Chemokine receptors bind chemokines | 47 | 6.08e-01 | -4.32e-02 | 9.54e-01 |
| Regulation of expression of SLITs and ROBOs | 109 | 4.36e-01 | -4.32e-02 | 9.01e-01 |
| Activation of GABAB receptors | 37 | 6.50e-01 | -4.32e-02 | 9.57e-01 |
| GABA B receptor activation | 37 | 6.50e-01 | -4.32e-02 | 9.57e-01 |
| Antiviral mechanism by IFN-stimulated genes | 58 | 5.71e-01 | -4.30e-02 | 9.45e-01 |
| Signaling by WNT in cancer | 30 | 6.84e-01 | 4.29e-02 | 9.62e-01 |
| Synaptic adhesion-like molecules | 21 | 7.34e-01 | -4.29e-02 | 9.68e-01 |
| DNA strand elongation | 26 | 7.06e-01 | -4.28e-02 | 9.68e-01 |
| Integration of energy metabolism | 100 | 4.60e-01 | -4.27e-02 | 9.01e-01 |
| Signaling by the B Cell Receptor (BCR) | 97 | 4.70e-01 | -4.25e-02 | 9.01e-01 |
| Signaling by NODAL | 18 | 7.55e-01 | 4.24e-02 | 9.73e-01 |
| APC/C-mediated degradation of cell cycle proteins | 74 | 5.28e-01 | -4.24e-02 | 9.28e-01 |
| Regulation of mitotic cell cycle | 74 | 5.28e-01 | -4.24e-02 | 9.28e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 87 | 4.97e-01 | 4.21e-02 | 9.11e-01 |
| Diseases of metabolism | 208 | 2.96e-01 | 4.21e-02 | 8.56e-01 |
| Metabolism of vitamins and cofactors | 155 | 3.68e-01 | -4.20e-02 | 8.89e-01 |
| ABC-family proteins mediated transport | 81 | 5.15e-01 | -4.18e-02 | 9.19e-01 |
| Ca2+ pathway | 55 | 5.92e-01 | -4.17e-02 | 9.54e-01 |
| Interleukin-20 family signaling | 24 | 7.25e-01 | -4.16e-02 | 9.68e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 19 | 7.54e-01 | -4.15e-02 | 9.73e-01 |
| Synthesis of PIPs at the plasma membrane | 52 | 6.04e-01 | 4.15e-02 | 9.54e-01 |
| Elastic fibre formation | 36 | 6.66e-01 | -4.15e-02 | 9.57e-01 |
| IGF1R signaling cascade | 48 | 6.19e-01 | 4.15e-02 | 9.54e-01 |
| FCGR3A-mediated phagocytosis | 61 | 5.76e-01 | 4.14e-02 | 9.46e-01 |
| Leishmania phagocytosis | 61 | 5.76e-01 | 4.14e-02 | 9.46e-01 |
| Parasite infection | 61 | 5.76e-01 | 4.14e-02 | 9.46e-01 |
| Chaperonin-mediated protein folding | 79 | 5.25e-01 | 4.14e-02 | 9.28e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 99 | 4.80e-01 | 4.11e-02 | 9.03e-01 |
| Adaptive Immune System | 603 | 8.60e-02 | 4.11e-02 | 7.62e-01 |
| Hedgehog 'on' state | 71 | 5.51e-01 | -4.09e-02 | 9.33e-01 |
| TNFR1-induced proapoptotic signaling | 13 | 7.98e-01 | 4.09e-02 | 9.82e-01 |
| SUMOylation of DNA methylation proteins | 15 | 7.84e-01 | 4.09e-02 | 9.82e-01 |
| Scavenging of heme from plasma | 11 | 8.15e-01 | -4.08e-02 | 9.90e-01 |
| Mitotic Prophase | 66 | 5.68e-01 | 4.07e-02 | 9.43e-01 |
| Transport to the Golgi and subsequent modification | 143 | 4.02e-01 | 4.07e-02 | 9.01e-01 |
| G1/S Transition | 110 | 4.62e-01 | -4.06e-02 | 9.01e-01 |
| FCGR3A-mediated IL10 synthesis | 40 | 6.58e-01 | -4.05e-02 | 9.57e-01 |
| Cardiac conduction | 126 | 4.36e-01 | 4.02e-02 | 9.01e-01 |
| Nitric oxide stimulates guanylate cyclase | 22 | 7.44e-01 | 4.02e-02 | 9.68e-01 |
| Methylation | 11 | 8.18e-01 | -4.02e-02 | 9.90e-01 |
| B-WICH complex positively regulates rRNA expression | 24 | 7.35e-01 | 3.99e-02 | 9.68e-01 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 14 | 7.97e-01 | 3.97e-02 | 9.82e-01 |
| HCMV Late Events | 41 | 6.62e-01 | -3.94e-02 | 9.57e-01 |
| Ion transport by P-type ATPases | 48 | 6.38e-01 | 3.93e-02 | 9.57e-01 |
| FRS-mediated FGFR2 signaling | 24 | 7.40e-01 | -3.92e-02 | 9.68e-01 |
| Intrinsic Pathway for Apoptosis | 44 | 6.54e-01 | -3.90e-02 | 9.57e-01 |
| Transcriptional Regulation by VENTX | 35 | 6.90e-01 | 3.90e-02 | 9.66e-01 |
| Diseases of programmed cell death | 21 | 7.58e-01 | -3.89e-02 | 9.75e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 24 | 7.43e-01 | 3.87e-02 | 9.68e-01 |
| Trafficking and processing of endosomal TLR | 11 | 8.24e-01 | -3.87e-02 | 9.90e-01 |
| p130Cas linkage to MAPK signaling for integrins | 15 | 7.95e-01 | -3.87e-02 | 9.82e-01 |
| Interleukin-6 signaling | 11 | 8.24e-01 | -3.86e-02 | 9.90e-01 |
| HIV Transcription Initiation | 38 | 6.81e-01 | -3.86e-02 | 9.59e-01 |
| RNA Polymerase II HIV Promoter Escape | 38 | 6.81e-01 | -3.86e-02 | 9.59e-01 |
| RNA Polymerase II Promoter Escape | 38 | 6.81e-01 | -3.86e-02 | 9.59e-01 |
| RNA Polymerase II Transcription Initiation | 38 | 6.81e-01 | -3.86e-02 | 9.59e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 38 | 6.81e-01 | -3.86e-02 | 9.59e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 38 | 6.81e-01 | -3.86e-02 | 9.59e-01 |
| Transcriptional Regulation by TP53 | 306 | 2.47e-01 | -3.86e-02 | 8.56e-01 |
| Class I MHC mediated antigen processing & presentation | 308 | 2.46e-01 | 3.86e-02 | 8.56e-01 |
| C-type lectin receptors (CLRs) | 115 | 4.77e-01 | -3.85e-02 | 9.01e-01 |
| PPARA activates gene expression | 106 | 4.99e-01 | 3.81e-02 | 9.12e-01 |
| Separation of Sister Chromatids | 139 | 4.41e-01 | -3.79e-02 | 9.01e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 27 | 7.33e-01 | -3.79e-02 | 9.68e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 23 | 7.55e-01 | 3.77e-02 | 9.73e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 19 | 7.76e-01 | -3.77e-02 | 9.78e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 19 | 7.76e-01 | -3.77e-02 | 9.78e-01 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 51 | 6.42e-01 | -3.76e-02 | 9.57e-01 |
| Asparagine N-linked glycosylation | 237 | 3.24e-01 | 3.72e-02 | 8.68e-01 |
| Cilium Assembly | 160 | 4.18e-01 | 3.71e-02 | 9.01e-01 |
| Activation of AMPK downstream of NMDARs | 10 | 8.39e-01 | 3.71e-02 | 9.91e-01 |
| Activation of HOX genes during differentiation | 45 | 6.68e-01 | -3.70e-02 | 9.57e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 45 | 6.68e-01 | -3.70e-02 | 9.57e-01 |
| PI-3K cascade:FGFR1 | 21 | 7.69e-01 | 3.70e-02 | 9.78e-01 |
| Activation of the phototransduction cascade | 11 | 8.32e-01 | -3.69e-02 | 9.90e-01 |
| Peptide ligand-binding receptors | 171 | 4.07e-01 | -3.68e-02 | 9.01e-01 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 15 | 8.05e-01 | 3.68e-02 | 9.86e-01 |
| Diseases of hemostasis | 15 | 8.05e-01 | 3.68e-02 | 9.86e-01 |
| PKA-mediated phosphorylation of CREB | 18 | 7.87e-01 | 3.67e-02 | 9.82e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 65 | 6.12e-01 | 3.64e-02 | 9.54e-01 |
| Downstream signal transduction | 29 | 7.35e-01 | 3.63e-02 | 9.68e-01 |
| eNOS activation | 10 | 8.42e-01 | 3.63e-02 | 9.91e-01 |
| Cytokine Signaling in Immune system | 733 | 9.71e-02 | -3.62e-02 | 7.65e-01 |
| Cell Cycle Checkpoints | 212 | 3.66e-01 | -3.61e-02 | 8.89e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 30 | 7.33e-01 | -3.60e-02 | 9.68e-01 |
| Interleukin-10 signaling | 39 | 6.98e-01 | -3.60e-02 | 9.68e-01 |
| Activation of the pre-replicative complex | 27 | 7.48e-01 | 3.57e-02 | 9.68e-01 |
| Smooth Muscle Contraction | 35 | 7.15e-01 | -3.57e-02 | 9.68e-01 |
| RHO GTPases Activate Formins | 98 | 5.43e-01 | 3.56e-02 | 9.33e-01 |
| PI3K/AKT Signaling in Cancer | 98 | 5.45e-01 | 3.54e-02 | 9.33e-01 |
| Thromboxane signalling through TP receptor | 18 | 7.95e-01 | -3.54e-02 | 9.82e-01 |
| RAF-independent MAPK1/3 activation | 23 | 7.69e-01 | -3.54e-02 | 9.78e-01 |
| ESR-mediated signaling | 148 | 4.60e-01 | 3.52e-02 | 9.01e-01 |
| Regulation of lipid metabolism by PPARalpha | 108 | 5.28e-01 | 3.52e-02 | 9.28e-01 |
| Signaling by NTRKs | 131 | 4.87e-01 | 3.52e-02 | 9.09e-01 |
| Regulation of TP53 Expression and Degradation | 32 | 7.30e-01 | 3.52e-02 | 9.68e-01 |
| IRS-related events triggered by IGF1R | 47 | 6.78e-01 | 3.50e-02 | 9.59e-01 |
| Transcriptional regulation of granulopoiesis | 30 | 7.40e-01 | -3.50e-02 | 9.68e-01 |
| DSCAM interactions | 11 | 8.42e-01 | 3.48e-02 | 9.91e-01 |
| Arachidonic acid metabolism | 50 | 6.74e-01 | -3.45e-02 | 9.59e-01 |
| Phospholipase C-mediated cascade; FGFR4 | 14 | 8.24e-01 | -3.43e-02 | 9.90e-01 |
| COPI-mediated anterograde transport | 74 | 6.12e-01 | -3.42e-02 | 9.54e-01 |
| Hyaluronan uptake and degradation | 11 | 8.45e-01 | 3.41e-02 | 9.91e-01 |
| Signaling by PDGFR in disease | 19 | 7.97e-01 | 3.41e-02 | 9.82e-01 |
| FOXO-mediated transcription | 59 | 6.51e-01 | 3.41e-02 | 9.57e-01 |
| Activation of NMDA receptors and postsynaptic events | 71 | 6.21e-01 | 3.40e-02 | 9.54e-01 |
| HDACs deacetylate histones | 26 | 7.66e-01 | -3.37e-02 | 9.78e-01 |
| Post NMDA receptor activation events | 58 | 6.58e-01 | 3.36e-02 | 9.57e-01 |
| SARS-CoV-1 Infection | 38 | 7.20e-01 | 3.36e-02 | 9.68e-01 |
| Hedgehog ligand biogenesis | 51 | 6.79e-01 | -3.35e-02 | 9.59e-01 |
| Metabolism of steroids | 130 | 5.12e-01 | -3.33e-02 | 9.19e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 81 | 6.05e-01 | -3.33e-02 | 9.54e-01 |
| Diseases associated with the TLR signaling cascade | 20 | 7.97e-01 | 3.33e-02 | 9.82e-01 |
| Diseases of Immune System | 20 | 7.97e-01 | 3.33e-02 | 9.82e-01 |
| mTORC1-mediated signalling | 20 | 7.97e-01 | -3.33e-02 | 9.82e-01 |
| PD-1 signaling | 15 | 8.25e-01 | -3.30e-02 | 9.90e-01 |
| MAPK family signaling cascades | 287 | 3.39e-01 | -3.29e-02 | 8.68e-01 |
| Molecules associated with elastic fibres | 28 | 7.64e-01 | 3.29e-02 | 9.78e-01 |
| Metabolism of lipids | 628 | 1.62e-01 | -3.28e-02 | 8.26e-01 |
| SARS-CoV Infections | 70 | 6.35e-01 | 3.28e-02 | 9.57e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 6.89e-01 | 3.28e-02 | 9.66e-01 |
| DAP12 signaling | 26 | 7.73e-01 | -3.27e-02 | 9.78e-01 |
| FRS-mediated FGFR3 signaling | 19 | 8.05e-01 | -3.26e-02 | 9.86e-01 |
| Glycogen metabolism | 23 | 7.87e-01 | 3.26e-02 | 9.82e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 7.35e-01 | 3.26e-02 | 9.68e-01 |
| TNFR1-induced NFkappaB signaling pathway | 24 | 7.85e-01 | 3.22e-02 | 9.82e-01 |
| Chromosome Maintenance | 67 | 6.50e-01 | -3.21e-02 | 9.57e-01 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 22 | 7.95e-01 | -3.20e-02 | 9.82e-01 |
| SUMOylation | 142 | 5.11e-01 | 3.20e-02 | 9.19e-01 |
| Amine ligand-binding receptors | 37 | 7.39e-01 | -3.17e-02 | 9.68e-01 |
| Platelet homeostasis | 78 | 6.29e-01 | -3.16e-02 | 9.57e-01 |
| Extension of Telomeres | 42 | 7.23e-01 | -3.16e-02 | 9.68e-01 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 23 | 7.94e-01 | -3.15e-02 | 9.82e-01 |
| Homologous DNA Pairing and Strand Exchange | 36 | 7.44e-01 | -3.15e-02 | 9.68e-01 |
| Detoxification of Reactive Oxygen Species | 29 | 7.69e-01 | -3.15e-02 | 9.78e-01 |
| SUMOylation of intracellular receptors | 28 | 7.74e-01 | -3.14e-02 | 9.78e-01 |
| Keratan sulfate/keratin metabolism | 28 | 7.74e-01 | 3.13e-02 | 9.78e-01 |
| Telomere Maintenance | 51 | 7.01e-01 | -3.11e-02 | 9.68e-01 |
| Gluconeogenesis | 29 | 7.72e-01 | -3.11e-02 | 9.78e-01 |
| MAPK1/MAPK3 signaling | 251 | 3.98e-01 | -3.10e-02 | 8.98e-01 |
| Downregulation of TGF-beta receptor signaling | 20 | 8.11e-01 | 3.10e-02 | 9.88e-01 |
| CLEC7A (Dectin-1) signaling | 83 | 6.26e-01 | -3.10e-02 | 9.57e-01 |
| Resolution of Sister Chromatid Cohesion | 87 | 6.21e-01 | 3.07e-02 | 9.54e-01 |
| RAF/MAP kinase cascade | 245 | 4.09e-01 | -3.07e-02 | 9.01e-01 |
| Gap junction trafficking and regulation | 26 | 7.88e-01 | 3.05e-02 | 9.82e-01 |
| DNA Double Strand Break Response | 36 | 7.52e-01 | -3.04e-02 | 9.72e-01 |
| NRIF signals cell death from the nucleus | 10 | 8.68e-01 | 3.04e-02 | 9.91e-01 |
| TCR signaling | 97 | 6.07e-01 | -3.03e-02 | 9.54e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 338 | 3.45e-01 | 3.00e-02 | 8.71e-01 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 8.70e-01 | -2.99e-02 | 9.91e-01 |
| Budding and maturation of HIV virion | 20 | 8.17e-01 | 2.99e-02 | 9.90e-01 |
| ERK/MAPK targets | 22 | 8.09e-01 | -2.98e-02 | 9.88e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 35 | 7.60e-01 | -2.98e-02 | 9.76e-01 |
| Interferon gamma signaling | 66 | 6.76e-01 | -2.98e-02 | 9.59e-01 |
| GRB2 events in EGFR signaling | 13 | 8.54e-01 | -2.95e-02 | 9.91e-01 |
| MyD88-independent TLR4 cascade | 85 | 6.38e-01 | 2.95e-02 | 9.57e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling | 85 | 6.38e-01 | 2.95e-02 | 9.57e-01 |
| VLDLR internalisation and degradation | 12 | 8.59e-01 | 2.95e-02 | 9.91e-01 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 14 | 8.48e-01 | 2.95e-02 | 9.91e-01 |
| Phospholipid metabolism | 183 | 4.95e-01 | -2.93e-02 | 9.11e-01 |
| Chromatin modifying enzymes | 172 | 5.15e-01 | 2.88e-02 | 9.19e-01 |
| Chromatin organization | 172 | 5.15e-01 | 2.88e-02 | 9.19e-01 |
| Synthesis of substrates in N-glycan biosythesis | 53 | 7.19e-01 | 2.86e-02 | 9.68e-01 |
| G alpha (12/13) signalling events | 72 | 6.77e-01 | 2.84e-02 | 9.59e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 19 | 8.31e-01 | -2.83e-02 | 9.90e-01 |
| Recycling of bile acids and salts | 15 | 8.50e-01 | -2.83e-02 | 9.91e-01 |
| MyD88 dependent cascade initiated on endosome | 79 | 6.67e-01 | 2.81e-02 | 9.57e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 79 | 6.67e-01 | 2.81e-02 | 9.57e-01 |
| NOD1/2 Signaling Pathway | 28 | 7.97e-01 | 2.80e-02 | 9.82e-01 |
| Abacavir transport and metabolism | 10 | 8.78e-01 | -2.80e-02 | 9.91e-01 |
| Fc epsilon receptor (FCERI) signaling | 116 | 6.08e-01 | -2.76e-02 | 9.54e-01 |
| PKA activation in glucagon signalling | 16 | 8.49e-01 | 2.76e-02 | 9.91e-01 |
| Processing of SMDT1 | 11 | 8.74e-01 | -2.76e-02 | 9.91e-01 |
| SHC-mediated cascade:FGFR1 | 21 | 8.27e-01 | -2.75e-02 | 9.90e-01 |
| HDR through Homologous Recombination (HRR) | 53 | 7.30e-01 | 2.74e-02 | 9.68e-01 |
| Retinoid metabolism and transport | 37 | 7.76e-01 | -2.70e-02 | 9.78e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 182 | 5.31e-01 | 2.70e-02 | 9.28e-01 |
| Metabolism of fat-soluble vitamins | 39 | 7.71e-01 | -2.69e-02 | 9.78e-01 |
| NCAM1 interactions | 34 | 7.88e-01 | -2.66e-02 | 9.82e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 36 | 7.84e-01 | -2.64e-02 | 9.82e-01 |
| Assembly Of The HIV Virion | 11 | 8.80e-01 | -2.63e-02 | 9.91e-01 |
| Gene expression (Transcription) | 1074 | 1.49e-01 | 2.63e-02 | 8.22e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 23 | 8.27e-01 | 2.63e-02 | 9.90e-01 |
| Regulation of TP53 Degradation | 31 | 8.00e-01 | 2.63e-02 | 9.83e-01 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 86 | 6.78e-01 | 2.60e-02 | 9.59e-01 |
| Platelet degranulation | 113 | 6.36e-01 | 2.58e-02 | 9.57e-01 |
| RNA Polymerase II Transcription | 965 | 1.78e-01 | 2.58e-02 | 8.29e-01 |
| Innate Immune System | 857 | 2.07e-01 | -2.56e-02 | 8.56e-01 |
| The phototransduction cascade | 30 | 8.09e-01 | -2.55e-02 | 9.88e-01 |
| Signaling by ERBB2 ECD mutants | 15 | 8.65e-01 | -2.54e-02 | 9.91e-01 |
| Neurotoxicity of clostridium toxins | 10 | 8.90e-01 | -2.53e-02 | 9.91e-01 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 10 | 8.90e-01 | -2.52e-02 | 9.91e-01 |
| Formation of Fibrin Clot (Clotting Cascade) | 36 | 7.94e-01 | 2.52e-02 | 9.82e-01 |
| Circadian Clock | 62 | 7.33e-01 | -2.51e-02 | 9.68e-01 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 65 | 7.28e-01 | -2.50e-02 | 9.68e-01 |
| Nonsense-Mediated Decay (NMD) | 65 | 7.28e-01 | -2.50e-02 | 9.68e-01 |
| Regulation of gene expression in beta cells | 17 | 8.59e-01 | -2.49e-02 | 9.91e-01 |
| Rap1 signalling | 15 | 8.69e-01 | -2.46e-02 | 9.91e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 260 | 5.01e-01 | 2.43e-02 | 9.14e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 18 | 8.59e-01 | -2.42e-02 | 9.91e-01 |
| Nucleosome assembly | 18 | 8.59e-01 | -2.42e-02 | 9.91e-01 |
| SUMOylation of SUMOylation proteins | 23 | 8.41e-01 | 2.42e-02 | 9.91e-01 |
| trans-Golgi Network Vesicle Budding | 60 | 7.47e-01 | -2.41e-02 | 9.68e-01 |
| SUMOylation of ubiquitinylation proteins | 28 | 8.27e-01 | 2.39e-02 | 9.90e-01 |
| Telomere C-strand synthesis initiation | 10 | 8.96e-01 | 2.39e-02 | 9.91e-01 |
| Regulation of TP53 Activity through Phosphorylation | 79 | 7.19e-01 | -2.34e-02 | 9.68e-01 |
| Extracellular matrix organization | 267 | 5.12e-01 | -2.34e-02 | 9.19e-01 |
| RHO GTPases activate PAKs | 21 | 8.54e-01 | 2.32e-02 | 9.91e-01 |
| DNA Damage Bypass | 35 | 8.12e-01 | -2.32e-02 | 9.89e-01 |
| Transcriptional Regulation by E2F6 | 30 | 8.26e-01 | -2.32e-02 | 9.90e-01 |
| Clathrin-mediated endocytosis | 122 | 6.60e-01 | 2.31e-02 | 9.57e-01 |
| Polo-like kinase mediated events | 14 | 8.81e-01 | -2.31e-02 | 9.91e-01 |
| MECP2 regulates neuronal receptors and channels | 16 | 8.73e-01 | 2.31e-02 | 9.91e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 23 | 8.49e-01 | 2.30e-02 | 9.91e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 68 | 7.47e-01 | -2.26e-02 | 9.68e-01 |
| TGF-beta receptor signaling activates SMADs | 23 | 8.51e-01 | 2.26e-02 | 9.91e-01 |
| RNA polymerase II transcribes snRNA genes | 59 | 7.65e-01 | -2.25e-02 | 9.78e-01 |
| Translation of structural proteins | 22 | 8.56e-01 | -2.23e-02 | 9.91e-01 |
| Signaling by FGFR1 in disease | 37 | 8.15e-01 | 2.22e-02 | 9.90e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 156 | 6.34e-01 | -2.21e-02 | 9.57e-01 |
| Leishmania parasite growth and survival | 156 | 6.34e-01 | -2.21e-02 | 9.57e-01 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 26 | 8.49e-01 | -2.15e-02 | 9.91e-01 |
| Glycosaminoglycan metabolism | 108 | 7.00e-01 | 2.15e-02 | 9.68e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 78 | 7.48e-01 | 2.11e-02 | 9.68e-01 |
| Generic Transcription Pathway | 868 | 2.98e-01 | 2.10e-02 | 8.56e-01 |
| RIP-mediated NFkB activation via ZBP1 | 15 | 8.88e-01 | -2.09e-02 | 9.91e-01 |
| Transcription of the HIV genome | 54 | 7.91e-01 | -2.09e-02 | 9.82e-01 |
| Metabolism of folate and pterines | 14 | 8.93e-01 | -2.08e-02 | 9.91e-01 |
| Leishmania infection | 232 | 5.86e-01 | 2.08e-02 | 9.50e-01 |
| Effects of PIP2 hydrolysis | 25 | 8.59e-01 | 2.06e-02 | 9.91e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 21 | 8.71e-01 | 2.05e-02 | 9.91e-01 |
| SLC transporter disorders | 85 | 7.44e-01 | -2.05e-02 | 9.68e-01 |
| Collagen degradation | 36 | 8.32e-01 | 2.04e-02 | 9.90e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 166 | 6.57e-01 | 2.00e-02 | 9.57e-01 |
| Metabolism of steroid hormones | 31 | 8.47e-01 | -2.00e-02 | 9.91e-01 |
| Translesion synthesis by POLI | 13 | 9.01e-01 | -1.99e-02 | 9.91e-01 |
| Extra-nuclear estrogen signaling | 69 | 7.75e-01 | -1.99e-02 | 9.78e-01 |
| Positive epigenetic regulation of rRNA expression | 36 | 8.39e-01 | 1.96e-02 | 9.91e-01 |
| Regulation of HSF1-mediated heat shock response | 58 | 7.96e-01 | 1.96e-02 | 9.82e-01 |
| GRB2 events in ERBB2 signaling | 16 | 8.92e-01 | 1.95e-02 | 9.91e-01 |
| Activation of G protein gated Potassium channels | 23 | 8.71e-01 | -1.95e-02 | 9.91e-01 |
| G protein gated Potassium channels | 23 | 8.71e-01 | -1.95e-02 | 9.91e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 23 | 8.71e-01 | -1.95e-02 | 9.91e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 37 | 8.38e-01 | -1.94e-02 | 9.91e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 17 | 8.91e-01 | 1.93e-02 | 9.91e-01 |
| IRS-mediated signalling | 44 | 8.25e-01 | 1.92e-02 | 9.90e-01 |
| G alpha (q) signalling events | 193 | 6.49e-01 | 1.91e-02 | 9.57e-01 |
| Transcriptional regulation by small RNAs | 33 | 8.51e-01 | -1.90e-02 | 9.91e-01 |
| UCH proteinases | 69 | 7.86e-01 | -1.89e-02 | 9.82e-01 |
| Cell-extracellular matrix interactions | 14 | 9.03e-01 | 1.89e-02 | 9.91e-01 |
| Miscellaneous transport and binding events | 22 | 8.78e-01 | -1.89e-02 | 9.91e-01 |
| Processing of Intronless Pre-mRNAs | 12 | 9.12e-01 | 1.84e-02 | 9.91e-01 |
| Signal amplification | 27 | 8.69e-01 | -1.83e-02 | 9.91e-01 |
| FLT3 Signaling | 258 | 6.13e-01 | -1.83e-02 | 9.54e-01 |
| Downstream signaling of activated FGFR3 | 24 | 8.78e-01 | 1.82e-02 | 9.91e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 44 | 8.35e-01 | 1.82e-02 | 9.91e-01 |
| Signaling by FGFR2 in disease | 36 | 8.51e-01 | -1.81e-02 | 9.91e-01 |
| Na+/Cl- dependent neurotransmitter transporters | 17 | 8.97e-01 | -1.81e-02 | 9.91e-01 |
| MAP kinase activation | 57 | 8.14e-01 | 1.81e-02 | 9.90e-01 |
| Attenuation phase | 19 | 8.93e-01 | 1.79e-02 | 9.91e-01 |
| Plasma lipoprotein clearance | 32 | 8.61e-01 | 1.79e-02 | 9.91e-01 |
| SUMOylation of transcription factors | 16 | 9.02e-01 | -1.77e-02 | 9.91e-01 |
| Fatty acyl-CoA biosynthesis | 29 | 8.69e-01 | 1.77e-02 | 9.91e-01 |
| ER to Golgi Anterograde Transport | 116 | 7.43e-01 | 1.77e-02 | 9.68e-01 |
| Assembly of collagen fibrils and other multimeric structures | 53 | 8.25e-01 | -1.76e-02 | 9.90e-01 |
| Intrinsic Pathway of Fibrin Clot Formation | 21 | 8.90e-01 | -1.74e-02 | 9.91e-01 |
| Mitotic G1 phase and G1/S transition | 125 | 7.40e-01 | -1.72e-02 | 9.68e-01 |
| Triglyceride metabolism | 33 | 8.64e-01 | 1.72e-02 | 9.91e-01 |
| COPI-dependent Golgi-to-ER retrograde traffic | 73 | 8.00e-01 | -1.72e-02 | 9.83e-01 |
| MicroRNA (miRNA) biogenesis | 15 | 9.09e-01 | 1.71e-02 | 9.91e-01 |
| Interleukin-15 signaling | 13 | 9.15e-01 | -1.71e-02 | 9.91e-01 |
| GABA receptor activation | 51 | 8.33e-01 | 1.71e-02 | 9.90e-01 |
| Costimulation by the CD28 family | 59 | 8.21e-01 | 1.71e-02 | 9.90e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 25 | 8.83e-01 | -1.70e-02 | 9.91e-01 |
| Golgi Associated Vesicle Biogenesis | 48 | 8.39e-01 | -1.70e-02 | 9.91e-01 |
| Immune System | 1737 | 2.49e-01 | -1.69e-02 | 8.56e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 21 | 8.94e-01 | -1.67e-02 | 9.91e-01 |
| Cellular responses to external stimuli | 398 | 5.72e-01 | -1.66e-02 | 9.45e-01 |
| Translocation of ZAP-70 to Immunological synapse | 12 | 9.21e-01 | 1.65e-02 | 9.91e-01 |
| Interactions of Rev with host cellular proteins | 26 | 8.85e-01 | -1.64e-02 | 9.91e-01 |
| mRNA Splicing - Major Pathway | 134 | 7.44e-01 | 1.63e-02 | 9.68e-01 |
| Processive synthesis on the lagging strand | 12 | 9.22e-01 | -1.63e-02 | 9.91e-01 |
| Nucleobase catabolism | 32 | 8.74e-01 | -1.62e-02 | 9.91e-01 |
| Signaling by BRAF and RAF fusions | 59 | 8.29e-01 | -1.62e-02 | 9.90e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 15 | 9.14e-01 | -1.62e-02 | 9.91e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 31 | 8.77e-01 | -1.61e-02 | 9.91e-01 |
| Regulation of signaling by CBL | 18 | 9.06e-01 | 1.61e-02 | 9.91e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 16 | 9.11e-01 | -1.61e-02 | 9.91e-01 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 9.31e-01 | -1.59e-02 | 9.91e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 33 | 8.75e-01 | -1.58e-02 | 9.91e-01 |
| Diseases of mitotic cell cycle | 33 | 8.75e-01 | -1.58e-02 | 9.91e-01 |
| Glycolysis | 59 | 8.34e-01 | -1.58e-02 | 9.91e-01 |
| Glycogen synthesis | 12 | 9.25e-01 | 1.58e-02 | 9.91e-01 |
| AMER1 mutants destabilize the destruction complex | 13 | 9.22e-01 | 1.58e-02 | 9.91e-01 |
| APC truncation mutants have impaired AXIN binding | 13 | 9.22e-01 | 1.58e-02 | 9.91e-01 |
| AXIN missense mutants destabilize the destruction complex | 13 | 9.22e-01 | 1.58e-02 | 9.91e-01 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | 13 | 9.22e-01 | 1.58e-02 | 9.91e-01 |
| Truncations of AMER1 destabilize the destruction complex | 13 | 9.22e-01 | 1.58e-02 | 9.91e-01 |
| truncated APC mutants destabilize the destruction complex | 13 | 9.22e-01 | 1.58e-02 | 9.91e-01 |
| Signal regulatory protein family interactions | 13 | 9.22e-01 | -1.58e-02 | 9.91e-01 |
| Rho GTPase cycle | 130 | 7.60e-01 | 1.55e-02 | 9.76e-01 |
| Free fatty acids regulate insulin secretion | 11 | 9.30e-01 | -1.52e-02 | 9.91e-01 |
| SUMOylation of DNA replication proteins | 34 | 8.78e-01 | 1.52e-02 | 9.91e-01 |
| Protein folding | 85 | 8.09e-01 | 1.52e-02 | 9.88e-01 |
| GPCR ligand binding | 399 | 6.07e-01 | -1.50e-02 | 9.54e-01 |
| PKA activation | 17 | 9.16e-01 | 1.48e-02 | 9.91e-01 |
| Rev-mediated nuclear export of HIV RNA | 25 | 8.99e-01 | 1.47e-02 | 9.91e-01 |
| SUMOylation of transcription cofactors | 36 | 8.79e-01 | -1.47e-02 | 9.91e-01 |
| Negative regulation of FGFR4 signaling | 27 | 8.95e-01 | 1.47e-02 | 9.91e-01 |
| EML4 and NUDC in mitotic spindle formation | 79 | 8.24e-01 | 1.45e-02 | 9.90e-01 |
| Homology Directed Repair | 85 | 8.19e-01 | -1.44e-02 | 9.90e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 75 | 8.33e-01 | 1.41e-02 | 9.90e-01 |
| Amplification of signal from the kinetochores | 75 | 8.33e-01 | 1.41e-02 | 9.90e-01 |
| PIP3 activates AKT signaling | 240 | 7.08e-01 | 1.41e-02 | 9.68e-01 |
| Transcriptional regulation by RUNX3 | 82 | 8.26e-01 | 1.40e-02 | 9.90e-01 |
| Deadenylation-dependent mRNA decay | 44 | 8.74e-01 | 1.38e-02 | 9.91e-01 |
| SHC-mediated cascade:FGFR2 | 23 | 9.12e-01 | -1.33e-02 | 9.91e-01 |
| Disease | 1225 | 4.40e-01 | 1.32e-02 | 9.01e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 33 | 8.95e-01 | -1.32e-02 | 9.91e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 81 | 8.40e-01 | 1.30e-02 | 9.91e-01 |
| cGMP effects | 16 | 9.30e-01 | 1.27e-02 | 9.91e-01 |
| Gap junction trafficking | 24 | 9.17e-01 | 1.23e-02 | 9.91e-01 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 11 | 9.44e-01 | -1.22e-02 | 9.94e-01 |
| Antigen processing-Cross presentation | 77 | 8.55e-01 | -1.20e-02 | 9.91e-01 |
| Signaling by FGFR2 IIIa TM | 12 | 9.43e-01 | 1.18e-02 | 9.94e-01 |
| G2/M Transition | 152 | 8.05e-01 | -1.16e-02 | 9.86e-01 |
| ER-Phagosome pathway | 62 | 8.75e-01 | 1.16e-02 | 9.91e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 20 | 9.29e-01 | 1.15e-02 | 9.91e-01 |
| Response to elevated platelet cytosolic Ca2+ | 117 | 8.32e-01 | 1.14e-02 | 9.90e-01 |
| CaM pathway | 30 | 9.15e-01 | -1.12e-02 | 9.91e-01 |
| Calmodulin induced events | 30 | 9.15e-01 | -1.12e-02 | 9.91e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 31 | 9.14e-01 | 1.12e-02 | 9.91e-01 |
| Protein ubiquitination | 43 | 8.99e-01 | -1.12e-02 | 9.91e-01 |
| Basigin interactions | 24 | 9.25e-01 | -1.12e-02 | 9.91e-01 |
| Nuclear import of Rev protein | 24 | 9.25e-01 | -1.11e-02 | 9.91e-01 |
| Signaling by FGFR in disease | 55 | 8.87e-01 | 1.11e-02 | 9.91e-01 |
| Activation of BH3-only proteins | 28 | 9.21e-01 | 1.09e-02 | 9.91e-01 |
| G alpha (i) signalling events | 347 | 7.29e-01 | 1.09e-02 | 9.68e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 75 | 8.71e-01 | -1.08e-02 | 9.91e-01 |
| Activation of kainate receptors upon glutamate binding | 25 | 9.25e-01 | -1.08e-02 | 9.91e-01 |
| HIV Life Cycle | 110 | 8.50e-01 | 1.04e-02 | 9.91e-01 |
| Intracellular signaling by second messengers | 275 | 7.68e-01 | 1.04e-02 | 9.78e-01 |
| Pyrimidine catabolism | 11 | 9.53e-01 | -1.02e-02 | 9.96e-01 |
| PTEN Regulation | 123 | 8.47e-01 | -1.01e-02 | 9.91e-01 |
| Regulation of TP53 Activity | 141 | 8.37e-01 | -1.01e-02 | 9.91e-01 |
| Signaling by ROBO receptors | 149 | 8.33e-01 | 1.00e-02 | 9.90e-01 |
| Long-term potentiation | 22 | 9.35e-01 | -1.00e-02 | 9.91e-01 |
| DAP12 interactions | 32 | 9.22e-01 | -9.96e-03 | 9.91e-01 |
| DNA Damage Recognition in GG-NER | 28 | 9.29e-01 | 9.76e-03 | 9.91e-01 |
| Infectious disease | 595 | 6.91e-01 | -9.59e-03 | 9.66e-01 |
| Metabolism of cofactors | 19 | 9.44e-01 | -9.28e-03 | 9.94e-01 |
| HATs acetylate histones | 64 | 8.99e-01 | -9.22e-03 | 9.91e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 30 | 9.30e-01 | 9.21e-03 | 9.91e-01 |
| Nonhomologous End-Joining (NHEJ) | 29 | 9.34e-01 | 8.85e-03 | 9.91e-01 |
| HSF1-dependent transactivation | 28 | 9.36e-01 | -8.83e-03 | 9.91e-01 |
| Cellular responses to stress | 391 | 7.65e-01 | -8.82e-03 | 9.78e-01 |
| Signaling by Hedgehog | 118 | 8.71e-01 | 8.68e-03 | 9.91e-01 |
| Membrane Trafficking | 530 | 7.38e-01 | 8.54e-03 | 9.68e-01 |
| Signaling by Erythropoietin | 24 | 9.43e-01 | 8.42e-03 | 9.94e-01 |
| Transcriptional regulation by RUNX2 | 104 | 8.82e-01 | 8.42e-03 | 9.91e-01 |
| DNA Double-Strand Break Repair | 109 | 8.80e-01 | 8.34e-03 | 9.91e-01 |
| Metabolism of non-coding RNA | 39 | 9.30e-01 | -8.12e-03 | 9.91e-01 |
| snRNP Assembly | 39 | 9.30e-01 | -8.12e-03 | 9.91e-01 |
| Signaling by ERBB2 | 43 | 9.27e-01 | -8.10e-03 | 9.91e-01 |
| Fanconi Anemia Pathway | 24 | 9.45e-01 | -8.07e-03 | 9.94e-01 |
| CTLA4 inhibitory signaling | 21 | 9.49e-01 | -8.04e-03 | 9.96e-01 |
| Mitotic Spindle Checkpoint | 90 | 8.96e-01 | -7.99e-03 | 9.91e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 35 | 9.36e-01 | -7.90e-03 | 9.91e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 19 | 9.53e-01 | -7.81e-03 | 9.96e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 48 | 9.26e-01 | 7.76e-03 | 9.91e-01 |
| Golgi-to-ER retrograde transport | 104 | 8.93e-01 | 7.66e-03 | 9.91e-01 |
| Frs2-mediated activation | 12 | 9.64e-01 | 7.62e-03 | 9.98e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 80 | 9.07e-01 | -7.53e-03 | 9.91e-01 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 9.64e-01 | 7.44e-03 | 9.98e-01 |
| Keratan sulfate biosynthesis | 24 | 9.51e-01 | 7.31e-03 | 9.96e-01 |
| TP53 Regulates Metabolic Genes | 73 | 9.16e-01 | 7.13e-03 | 9.91e-01 |
| Vesicle-mediated transport | 565 | 7.75e-01 | 7.06e-03 | 9.78e-01 |
| ISG15 antiviral mechanism | 52 | 9.31e-01 | -6.99e-03 | 9.91e-01 |
| Mitotic G2-G2/M phases | 154 | 8.83e-01 | -6.91e-03 | 9.91e-01 |
| Transcriptional regulation by RUNX1 | 161 | 8.83e-01 | -6.74e-03 | 9.91e-01 |
| IRF3-mediated induction of type I IFN | 11 | 9.70e-01 | 6.65e-03 | 9.99e-01 |
| Platelet activation, signaling and aggregation | 232 | 8.65e-01 | -6.50e-03 | 9.91e-01 |
| LGI-ADAM interactions | 13 | 9.68e-01 | -6.41e-03 | 9.99e-01 |
| DNA Repair | 226 | 8.73e-01 | -6.18e-03 | 9.91e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 25 | 9.58e-01 | -6.07e-03 | 9.96e-01 |
| Oncogenic MAPK signaling | 74 | 9.30e-01 | -5.94e-03 | 9.91e-01 |
| Metabolism of proteins | 1576 | 6.99e-01 | -5.93e-03 | 9.68e-01 |
| HCMV Infection | 65 | 9.36e-01 | -5.79e-03 | 9.91e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 27 | 9.58e-01 | 5.79e-03 | 9.96e-01 |
| Regulation of RUNX2 expression and activity | 60 | 9.39e-01 | 5.73e-03 | 9.93e-01 |
| NS1 Mediated Effects on Host Pathways | 28 | 9.59e-01 | 5.65e-03 | 9.96e-01 |
| Signaling by Nuclear Receptors | 215 | 8.87e-01 | -5.61e-03 | 9.91e-01 |
| mRNA Splicing | 142 | 9.09e-01 | 5.55e-03 | 9.91e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 30 | 9.58e-01 | 5.53e-03 | 9.96e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 29 | 9.60e-01 | 5.38e-03 | 9.96e-01 |
| Organelle biogenesis and maintenance | 227 | 8.90e-01 | -5.33e-03 | 9.91e-01 |
| Post-translational protein modification | 1143 | 7.68e-01 | 5.22e-03 | 9.78e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 24 | 9.65e-01 | 5.12e-03 | 9.98e-01 |
| SHC1 events in ERBB4 signaling | 14 | 9.76e-01 | -4.69e-03 | 1.00e+00 |
| Inwardly rectifying K+ channels | 29 | 9.65e-01 | -4.65e-03 | 9.98e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 12 | 9.78e-01 | 4.56e-03 | 1.00e+00 |
| Interleukin-37 signaling | 19 | 9.73e-01 | -4.48e-03 | 1.00e+00 |
| ADORA2B mediated anti-inflammatory cytokines production | 120 | 9.35e-01 | 4.29e-03 | 9.91e-01 |
| Downstream signaling of activated FGFR2 | 29 | 9.70e-01 | 4.02e-03 | 9.99e-01 |
| Ion channel transport | 155 | 9.34e-01 | 3.88e-03 | 9.91e-01 |
| Interleukin-17 signaling | 64 | 9.57e-01 | 3.86e-03 | 9.96e-01 |
| Metal ion SLC transporters | 21 | 9.76e-01 | 3.83e-03 | 1.00e+00 |
| Cytosolic sensors of pathogen-associated DNA | 50 | 9.64e-01 | -3.68e-03 | 9.98e-01 |
| MyD88 cascade initiated on plasma membrane | 71 | 9.58e-01 | 3.58e-03 | 9.96e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 71 | 9.58e-01 | 3.58e-03 | 9.96e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 71 | 9.58e-01 | 3.58e-03 | 9.96e-01 |
| Glucose metabolism | 77 | 9.59e-01 | -3.42e-03 | 9.96e-01 |
| DAG and IP3 signaling | 36 | 9.72e-01 | -3.36e-03 | 1.00e+00 |
| M Phase | 292 | 9.22e-01 | 3.33e-03 | 9.91e-01 |
| Amyloid fiber formation | 43 | 9.71e-01 | 3.25e-03 | 9.99e-01 |
| SHC1 events in ERBB2 signaling | 22 | 9.79e-01 | 3.23e-03 | 1.00e+00 |
| Zinc transporters | 14 | 9.84e-01 | -3.18e-03 | 1.00e+00 |
| Signaling by FGFR4 | 36 | 9.74e-01 | -3.14e-03 | 1.00e+00 |
| Cell Cycle | 522 | 9.03e-01 | 3.14e-03 | 9.91e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 16 | 9.83e-01 | 2.99e-03 | 1.00e+00 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 16 | 9.83e-01 | 2.99e-03 | 1.00e+00 |
| SHC1 events in EGFR signaling | 14 | 9.85e-01 | -2.90e-03 | 1.00e+00 |
| Transmission across Chemical Synapses | 222 | 9.41e-01 | 2.89e-03 | 9.94e-01 |
| RHO GTPase Effectors | 218 | 9.42e-01 | -2.88e-03 | 9.94e-01 |
| Cellular response to heat stress | 74 | 9.66e-01 | 2.86e-03 | 9.98e-01 |
| Muscle contraction | 188 | 9.54e-01 | -2.42e-03 | 9.96e-01 |
| Signaling by NOTCH | 154 | 9.60e-01 | -2.33e-03 | 9.96e-01 |
| Viral Messenger RNA Synthesis | 29 | 9.84e-01 | 2.21e-03 | 1.00e+00 |
| Lysosome Vesicle Biogenesis | 29 | 9.84e-01 | -2.16e-03 | 1.00e+00 |
| Signaling by Rho GTPases | 339 | 9.47e-01 | 2.12e-03 | 9.95e-01 |
| Metabolism of carbohydrates | 251 | 9.54e-01 | -2.12e-03 | 9.96e-01 |
| tRNA processing | 85 | 9.75e-01 | -1.99e-03 | 1.00e+00 |
| Glutamate Neurotransmitter Release Cycle | 22 | 9.88e-01 | 1.87e-03 | 1.00e+00 |
| Hemostasis | 534 | 9.44e-01 | -1.80e-03 | 9.94e-01 |
| Synthesis of PIPs at the Golgi membrane | 17 | 9.90e-01 | -1.76e-03 | 1.00e+00 |
| Signaling by FGFR3 in disease | 22 | 9.89e-01 | -1.76e-03 | 1.00e+00 |
| Signaling by FGFR3 point mutants in cancer | 22 | 9.89e-01 | -1.76e-03 | 1.00e+00 |
| Platelet calcium homeostasis | 26 | 9.88e-01 | 1.67e-03 | 1.00e+00 |
| Defects in vitamin and cofactor metabolism | 15 | 9.92e-01 | -1.53e-03 | 1.00e+00 |
| Sialic acid metabolism | 28 | 9.89e-01 | 1.46e-03 | 1.00e+00 |
| Regulation of MECP2 expression and activity | 25 | 9.91e-01 | -1.27e-03 | 1.00e+00 |
| Regulation of insulin secretion | 70 | 9.86e-01 | 1.22e-03 | 1.00e+00 |
| STING mediated induction of host immune responses | 13 | 9.95e-01 | 1.04e-03 | 1.00e+00 |
| Programmed Cell Death | 149 | 9.83e-01 | -9.87e-04 | 1.00e+00 |
| Unblocking of NMDA receptors, glutamate binding and activation | 20 | 9.94e-01 | -9.41e-04 | 1.00e+00 |
| Apoptosis | 146 | 9.87e-01 | 8.09e-04 | 1.00e+00 |
| Physiological factors | 12 | 9.96e-01 | 7.84e-04 | 1.00e+00 |
| SHC-mediated cascade:FGFR3 | 18 | 9.95e-01 | 7.77e-04 | 1.00e+00 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 31 | 9.95e-01 | 6.85e-04 | 1.00e+00 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 29 | 9.95e-01 | -6.58e-04 | 1.00e+00 |
| Synthesis of IP2, IP, and Ins in the cytosol | 14 | 9.97e-01 | 5.83e-04 | 1.00e+00 |
| Insulin receptor signalling cascade | 50 | 9.95e-01 | -5.51e-04 | 1.00e+00 |
| G-protein activation | 23 | 9.96e-01 | 5.33e-04 | 1.00e+00 |
| Late Phase of HIV Life Cycle | 101 | 9.94e-01 | 4.04e-04 | 1.00e+00 |
| Ca-dependent events | 32 | 9.98e-01 | 2.48e-04 | 1.00e+00 |
| Class A/1 (Rhodopsin-like receptors) | 284 | 9.95e-01 | 2.00e-04 | 1.00e+00 |
| Chondroitin sulfate biosynthesis | 20 | 9.99e-01 | 1.49e-04 | 1.00e+00 |
| Fatty acids | 11 | 1.00e+00 | 5.62e-05 | 1.00e+00 |
| Cell Cycle, Mitotic | 417 | 9.99e-01 | -2.21e-05 | 1.00e+00 |
Detailed Gene set reports
Regulation of IFNA signaling
| 972 | |
|---|---|
| set | Regulation of IFNA signaling |
| setSize | 25 |
| pANOVA | 3.24e-06 |
| s.dist | 0.538 |
| p.adjustANOVA | 0.0011 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IFNA1 | 8460.0 |
| IFNA10 | 8460.0 |
| IFNA14 | 8460.0 |
| IFNA16 | 8460.0 |
| IFNA17 | 8460.0 |
| IFNA2 | 8460.0 |
| IFNA21 | 8460.0 |
| IFNA4 | 8460.0 |
| IFNA5 | 8460.0 |
| IFNA6 | 8460.0 |
| IFNA7 | 8460.0 |
| IFNA8 | 8460.0 |
| SOCS1 | 7807.0 |
| STAT1 | 6730.0 |
| IFNAR1 | 6050.0 |
| JAK1 | 6042.0 |
| PTPN1 | 4997.0 |
| USP18 | 3647.5 |
| PTPN6 | 2437.0 |
| PTPN11 | 1646.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IFNA1 | 8460.0 |
| IFNA10 | 8460.0 |
| IFNA14 | 8460.0 |
| IFNA16 | 8460.0 |
| IFNA17 | 8460.0 |
| IFNA2 | 8460.0 |
| IFNA21 | 8460.0 |
| IFNA4 | 8460.0 |
| IFNA5 | 8460.0 |
| IFNA6 | 8460.0 |
| IFNA7 | 8460.0 |
| IFNA8 | 8460.0 |
| SOCS1 | 7807.0 |
| STAT1 | 6730.0 |
| IFNAR1 | 6050.0 |
| JAK1 | 6042.0 |
| PTPN1 | 4997.0 |
| USP18 | 3647.5 |
| PTPN6 | 2437.0 |
| PTPN11 | 1646.0 |
| IFNB1 | 1036.0 |
| TYK2 | -624.0 |
| SOCS3 | -5529.0 |
| STAT2 | -6061.0 |
| IFNAR2 | -6490.0 |
Presynaptic nicotinic acetylcholine receptors
| 873 | |
|---|---|
| set | Presynaptic nicotinic acetylcholine receptors |
| setSize | 12 |
| pANOVA | 0.00241 |
| s.dist | -0.506 |
| p.adjustANOVA | 0.18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHRNA1 | -7356 |
| CHRNA6 | -6869 |
| CHRNA2 | -6339 |
| CHRNE | -6183 |
| CHRND | -6135 |
| CHRNB3 | -5878 |
| CHRNG | -5355 |
| CHRNA3 | -4870 |
| CHRNB4 | -2978 |
| CHRNA4 | 1760 |
| CHRNA5 | 3458 |
| CHRNB2 | 4716 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHRNA1 | -7356 |
| CHRNA6 | -6869 |
| CHRNA2 | -6339 |
| CHRNE | -6183 |
| CHRND | -6135 |
| CHRNB3 | -5878 |
| CHRNG | -5355 |
| CHRNA3 | -4870 |
| CHRNB4 | -2978 |
| CHRNA4 | 1760 |
| CHRNA5 | 3458 |
| CHRNB2 | 4716 |
TRAF6 mediated IRF7 activation
| 1237 | |
|---|---|
| set | TRAF6 mediated IRF7 activation |
| setSize | 28 |
| pANOVA | 5.74e-06 |
| s.dist | 0.495 |
| p.adjustANOVA | 0.00133 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IFNA1 | 8460 |
| IFNA10 | 8460 |
| IFNA14 | 8460 |
| IFNA16 | 8460 |
| IFNA17 | 8460 |
| IFNA2 | 8460 |
| IFNA21 | 8460 |
| IFNA4 | 8460 |
| IFNA5 | 8460 |
| IFNA6 | 8460 |
| IFNA7 | 8460 |
| IFNA8 | 8460 |
| IFIH1 | 7184 |
| EP300 | 7062 |
| TANK | 6936 |
| SIKE1 | 6017 |
| CREBBP | 5288 |
| IRF7 | 5195 |
| TRAF6 | 4499 |
| MAVS | 1852 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IFNA1 | 8460 |
| IFNA10 | 8460 |
| IFNA14 | 8460 |
| IFNA16 | 8460 |
| IFNA17 | 8460 |
| IFNA2 | 8460 |
| IFNA21 | 8460 |
| IFNA4 | 8460 |
| IFNA5 | 8460 |
| IFNA6 | 8460 |
| IFNA7 | 8460 |
| IFNA8 | 8460 |
| IFIH1 | 7184 |
| EP300 | 7062 |
| TANK | 6936 |
| SIKE1 | 6017 |
| CREBBP | 5288 |
| IRF7 | 5195 |
| TRAF6 | 4499 |
| MAVS | 1852 |
| IFNB1 | 1036 |
| TRIM25 | 489 |
| IKBKE | -180 |
| RNF135 | -1483 |
| TRAF2 | -3152 |
| TBK1 | -3717 |
| DDX58 | -5046 |
| IRF3 | -5159 |
Synthesis of PIPs at the late endosome membrane
| 1196 | |
|---|---|
| set | Synthesis of PIPs at the late endosome membrane |
| setSize | 10 |
| pANOVA | 0.0104 |
| s.dist | 0.468 |
| p.adjustANOVA | 0.402 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MTMR7 | 8098 |
| MTMR9 | 8017 |
| MTMR2 | 7531 |
| MTM1 | 6139 |
| PIKFYVE | 5611 |
| PIK3C3 | 4685 |
| PIK3R4 | 4667 |
| MTMR4 | 4227 |
| PIK3C2A | -1421 |
| VAC14 | -3881 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MTMR7 | 8098 |
| MTMR9 | 8017 |
| MTMR2 | 7531 |
| MTM1 | 6139 |
| PIKFYVE | 5611 |
| PIK3C3 | 4685 |
| PIK3R4 | 4667 |
| MTMR4 | 4227 |
| PIK3C2A | -1421 |
| VAC14 | -3881 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane
| 1314 | |
|---|---|
| set | Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane |
| setSize | 11 |
| pANOVA | 0.00796 |
| s.dist | -0.462 |
| p.adjustANOVA | 0.346 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLC29A1 | -7409 |
| SLC25A5 | -7011 |
| SLC29A3 | -6621 |
| SLC28A3 | -6335 |
| SLC28A1 | -6258 |
| ARL2 | -5657 |
| SLC29A4 | -2053 |
| SLC25A4 | -1887 |
| SLC29A2 | -1010 |
| ARL2BP | 4213 |
| SLC28A2 | 5395 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SLC29A1 | -7409 |
| SLC25A5 | -7011 |
| SLC29A3 | -6621 |
| SLC28A3 | -6335 |
| SLC28A1 | -6258 |
| ARL2 | -5657 |
| SLC29A4 | -2053 |
| SLC25A4 | -1887 |
| SLC29A2 | -1010 |
| ARL2BP | 4213 |
| SLC28A2 | 5395 |
Mitophagy
| 684 | |
|---|---|
| set | Mitophagy |
| setSize | 20 |
| pANOVA | 0.000375 |
| s.dist | -0.459 |
| p.adjustANOVA | 0.0474 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TOMM7 | -7362.0 |
| SQSTM1 | -6673.0 |
| ULK1 | -6275.0 |
| MAP1LC3A | -5918.0 |
| FUNDC1 | -5036.0 |
| VDAC1 | -4779.0 |
| MFN2 | -4517.0 |
| TOMM40 | -4468.0 |
| ATG5 | -4451.0 |
| CSNK2A1 | -3850.0 |
| PGAM5 | -3801.0 |
| TOMM22 | -2762.0 |
| PINK1 | -2564.0 |
| CSNK2A2 | -2448.0 |
| MAP1LC3B | -2399.5 |
| SRC | -2273.0 |
| MFN1 | -1493.0 |
| TOMM5 | 155.0 |
| PARK2 | 1052.0 |
| UBA52 | 7367.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TOMM7 | -7362.0 |
| SQSTM1 | -6673.0 |
| ULK1 | -6275.0 |
| MAP1LC3A | -5918.0 |
| FUNDC1 | -5036.0 |
| VDAC1 | -4779.0 |
| MFN2 | -4517.0 |
| TOMM40 | -4468.0 |
| ATG5 | -4451.0 |
| CSNK2A1 | -3850.0 |
| PGAM5 | -3801.0 |
| TOMM22 | -2762.0 |
| PINK1 | -2564.0 |
| CSNK2A2 | -2448.0 |
| MAP1LC3B | -2399.5 |
| SRC | -2273.0 |
| MFN1 | -1493.0 |
| TOMM5 | 155.0 |
| PARK2 | 1052.0 |
| UBA52 | 7367.0 |
Constitutive Signaling by NOTCH1 HD Domain Mutants
| 214 | |
|---|---|
| set | Constitutive Signaling by NOTCH1 HD Domain Mutants |
| setSize | 11 |
| pANOVA | 0.0116 |
| s.dist | 0.44 |
| p.adjustANOVA | 0.403 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBA52 | 7367 |
| ADAM10 | 7355 |
| MIB1 | 7217 |
| NEURL1B | 6921 |
| ADAM17 | 6115 |
| NOTCH1 | 5769 |
| DLL1 | 5423 |
| JAG1 | 2863 |
| JAG2 | 1756 |
| DLL4 | -1758 |
| MIB2 | -3505 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| UBA52 | 7367 |
| ADAM10 | 7355 |
| MIB1 | 7217 |
| NEURL1B | 6921 |
| ADAM17 | 6115 |
| NOTCH1 | 5769 |
| DLL1 | 5423 |
| JAG1 | 2863 |
| JAG2 | 1756 |
| DLL4 | -1758 |
| MIB2 | -3505 |
Signaling by NOTCH1 HD Domain Mutants in Cancer
| 1132 | |
|---|---|
| set | Signaling by NOTCH1 HD Domain Mutants in Cancer |
| setSize | 11 |
| pANOVA | 0.0116 |
| s.dist | 0.44 |
| p.adjustANOVA | 0.403 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBA52 | 7367 |
| ADAM10 | 7355 |
| MIB1 | 7217 |
| NEURL1B | 6921 |
| ADAM17 | 6115 |
| NOTCH1 | 5769 |
| DLL1 | 5423 |
| JAG1 | 2863 |
| JAG2 | 1756 |
| DLL4 | -1758 |
| MIB2 | -3505 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| UBA52 | 7367 |
| ADAM10 | 7355 |
| MIB1 | 7217 |
| NEURL1B | 6921 |
| ADAM17 | 6115 |
| NOTCH1 | 5769 |
| DLL1 | 5423 |
| JAG1 | 2863 |
| JAG2 | 1756 |
| DLL4 | -1758 |
| MIB2 | -3505 |
Classical antibody-mediated complement activation
| 197 | |
|---|---|
| set | Classical antibody-mediated complement activation |
| setSize | 10 |
| pANOVA | 0.0163 |
| s.dist | -0.439 |
| p.adjustANOVA | 0.438 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| C1QA | -6933.0 |
| IGHG1 | -5437.5 |
| IGHG2 | -5437.5 |
| IGHG3 | -5437.5 |
| IGHG4 | -5437.5 |
| C1QC | -4474.0 |
| CRP | -4036.0 |
| C1R | -1889.0 |
| C1S | 2715.0 |
| C1QB | 6767.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| C1QA | -6933.0 |
| IGHG1 | -5437.5 |
| IGHG2 | -5437.5 |
| IGHG3 | -5437.5 |
| IGHG4 | -5437.5 |
| C1QC | -4474.0 |
| CRP | -4036.0 |
| C1R | -1889.0 |
| C1S | 2715.0 |
| C1QB | 6767.0 |
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
| 259 | |
|---|---|
| set | Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) |
| setSize | 13 |
| pANOVA | 0.00702 |
| s.dist | -0.432 |
| p.adjustANOVA | 0.346 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| C1GALT1C1 | -7313 |
| MUC1 | -7239 |
| MUC17 | -6488 |
| MUC13 | -6463 |
| MUC6 | -5779 |
| C1GALT1 | -5119 |
| MUC3A | -4072 |
| MUC4 | -1860 |
| MUC20 | -1401 |
| MUC2 | -652 |
| MUC15 | 617 |
| MUC5B | 955 |
| MUC19 | 7070 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| C1GALT1C1 | -7313 |
| MUC1 | -7239 |
| MUC17 | -6488 |
| MUC13 | -6463 |
| MUC6 | -5779 |
| C1GALT1 | -5119 |
| MUC3A | -4072 |
| MUC4 | -1860 |
| MUC20 | -1401 |
| MUC2 | -652 |
| MUC15 | 617 |
| MUC5B | 955 |
| MUC19 | 7070 |
Nucleotide-like (purinergic) receptors
| 770 | |
|---|---|
| set | Nucleotide-like (purinergic) receptors |
| setSize | 12 |
| pANOVA | 0.01 |
| s.dist | 0.429 |
| p.adjustANOVA | 0.397 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ADORA2A | 8075 |
| P2RY4 | 7244 |
| GPR17 | 5959 |
| P2RY12 | 5084 |
| P2RY13 | 4923 |
| P2RY1 | 4728 |
| ADORA2B | 4668 |
| ADORA1 | 4605 |
| P2RY10 | 3766 |
| P2RY14 | 2503 |
| P2RY6 | -1426 |
| P2RY2 | -1459 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ADORA2A | 8075 |
| P2RY4 | 7244 |
| GPR17 | 5959 |
| P2RY12 | 5084 |
| P2RY13 | 4923 |
| P2RY1 | 4728 |
| ADORA2B | 4668 |
| ADORA1 | 4605 |
| P2RY10 | 3766 |
| P2RY14 | 2503 |
| P2RY6 | -1426 |
| P2RY2 | -1459 |
CLEC7A (Dectin-1) induces NFAT activation
| 132 | |
|---|---|
| set | CLEC7A (Dectin-1) induces NFAT activation |
| setSize | 10 |
| pANOVA | 0.0195 |
| s.dist | 0.427 |
| p.adjustANOVA | 0.463 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CALM1 | 7920 |
| AHCYL1 | 7828 |
| PPP3CA | 7206 |
| PPP3CB | 5675 |
| NFATC2 | 5272 |
| ITPR1 | 3798 |
| NFATC3 | 3700 |
| NFATC1 | 3325 |
| ITPR3 | 93 |
| ITPR2 | -4489 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CALM1 | 7920 |
| AHCYL1 | 7828 |
| PPP3CA | 7206 |
| PPP3CB | 5675 |
| NFATC2 | 5272 |
| ITPR1 | 3798 |
| NFATC3 | 3700 |
| NFATC1 | 3325 |
| ITPR3 | 93 |
| ITPR2 | -4489 |
PINK1-PRKN Mediated Mitophagy
| 804 | |
|---|---|
| set | PINK1-PRKN Mediated Mitophagy |
| setSize | 14 |
| pANOVA | 0.00709 |
| s.dist | -0.416 |
| p.adjustANOVA | 0.346 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TOMM7 | -7362.0 |
| SQSTM1 | -6673.0 |
| MAP1LC3A | -5918.0 |
| VDAC1 | -4779.0 |
| MFN2 | -4517.0 |
| TOMM40 | -4468.0 |
| ATG5 | -4451.0 |
| TOMM22 | -2762.0 |
| PINK1 | -2564.0 |
| MAP1LC3B | -2399.5 |
| MFN1 | -1493.0 |
| TOMM5 | 155.0 |
| PARK2 | 1052.0 |
| UBA52 | 7367.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TOMM7 | -7362.0 |
| SQSTM1 | -6673.0 |
| MAP1LC3A | -5918.0 |
| VDAC1 | -4779.0 |
| MFN2 | -4517.0 |
| TOMM40 | -4468.0 |
| ATG5 | -4451.0 |
| TOMM22 | -2762.0 |
| PINK1 | -2564.0 |
| MAP1LC3B | -2399.5 |
| MFN1 | -1493.0 |
| TOMM5 | 155.0 |
| PARK2 | 1052.0 |
| UBA52 | 7367.0 |
Glucuronidation
| 470 | |
|---|---|
| set | Glucuronidation |
| setSize | 17 |
| pANOVA | 0.00589 |
| s.dist | 0.386 |
| p.adjustANOVA | 0.327 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UGT2A1 | 8448.0 |
| UGP2 | 7762.0 |
| UGT1A10 | 7618.5 |
| UGT1A7 | 7618.5 |
| UGT1A8 | 7618.5 |
| UGT1A9 | 7618.5 |
| UGT2A3 | 6643.0 |
| UGT1A6 | 5522.0 |
| ABHD10 | 4992.0 |
| UGT1A3 | 2829.0 |
| UGT1A4 | 2829.0 |
| UGT1A5 | 2829.0 |
| UGT3A1 | 2132.5 |
| UGT3A2 | 2132.5 |
| UGT1A1 | -2429.0 |
| SLC35D1 | -5130.0 |
| UGDH | -6086.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| UGT2A1 | 8448.0 |
| UGP2 | 7762.0 |
| UGT1A10 | 7618.5 |
| UGT1A7 | 7618.5 |
| UGT1A8 | 7618.5 |
| UGT1A9 | 7618.5 |
| UGT2A3 | 6643.0 |
| UGT1A6 | 5522.0 |
| ABHD10 | 4992.0 |
| UGT1A3 | 2829.0 |
| UGT1A4 | 2829.0 |
| UGT1A5 | 2829.0 |
| UGT3A1 | 2132.5 |
| UGT3A2 | 2132.5 |
| UGT1A1 | -2429.0 |
| SLC35D1 | -5130.0 |
| UGDH | -6086.0 |
Platelet Adhesion to exposed collagen
| 846 | |
|---|---|
| set | Platelet Adhesion to exposed collagen |
| setSize | 13 |
| pANOVA | 0.016 |
| s.dist | 0.386 |
| p.adjustANOVA | 0.438 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LYN | 8336 |
| ITGA1 | 7804 |
| GP6 | 7235 |
| FYN | 6896 |
| GP1BB | 6435 |
| VWF | 4919 |
| GP1BA | 3984 |
| ITGB1 | 3382 |
| GP9 | 1566 |
| GP5 | 1415 |
| ITGA2 | 251 |
| ITGA10 | -343 |
| FCER1G | -3739 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LYN | 8336 |
| ITGA1 | 7804 |
| GP6 | 7235 |
| FYN | 6896 |
| GP1BB | 6435 |
| VWF | 4919 |
| GP1BA | 3984 |
| ITGB1 | 3382 |
| GP9 | 1566 |
| GP5 | 1415 |
| ITGA2 | 251 |
| ITGA10 | -343 |
| FCER1G | -3739 |
Acetylcholine binding and downstream events
| 30 | |
|---|---|
| set | Acetylcholine binding and downstream events |
| setSize | 14 |
| pANOVA | 0.0137 |
| s.dist | -0.381 |
| p.adjustANOVA | 0.419 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHRNA1 | -7356.0 |
| CHRNA6 | -6869.0 |
| CHRNA2 | -6339.0 |
| CHRNE | -6183.0 |
| CHRND | -6135.0 |
| CHRNB3 | -5878.0 |
| CHRNG | -5355.0 |
| CHRNA3 | -4870.0 |
| CHRNB4 | -2978.0 |
| CHRNA9 | -138.0 |
| CHRNA4 | 1760.0 |
| CHRNA5 | 3458.0 |
| CHRNB2 | 4716.0 |
| CHRNA7 | 7328.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHRNA1 | -7356.0 |
| CHRNA6 | -6869.0 |
| CHRNA2 | -6339.0 |
| CHRNE | -6183.0 |
| CHRND | -6135.0 |
| CHRNB3 | -5878.0 |
| CHRNG | -5355.0 |
| CHRNA3 | -4870.0 |
| CHRNB4 | -2978.0 |
| CHRNA9 | -138.0 |
| CHRNA4 | 1760.0 |
| CHRNA5 | 3458.0 |
| CHRNB2 | 4716.0 |
| CHRNA7 | 7328.5 |
Postsynaptic nicotinic acetylcholine receptors
| 863 | |
|---|---|
| set | Postsynaptic nicotinic acetylcholine receptors |
| setSize | 14 |
| pANOVA | 0.0137 |
| s.dist | -0.381 |
| p.adjustANOVA | 0.419 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHRNA1 | -7356.0 |
| CHRNA6 | -6869.0 |
| CHRNA2 | -6339.0 |
| CHRNE | -6183.0 |
| CHRND | -6135.0 |
| CHRNB3 | -5878.0 |
| CHRNG | -5355.0 |
| CHRNA3 | -4870.0 |
| CHRNB4 | -2978.0 |
| CHRNA9 | -138.0 |
| CHRNA4 | 1760.0 |
| CHRNA5 | 3458.0 |
| CHRNB2 | 4716.0 |
| CHRNA7 | 7328.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHRNA1 | -7356.0 |
| CHRNA6 | -6869.0 |
| CHRNA2 | -6339.0 |
| CHRNE | -6183.0 |
| CHRND | -6135.0 |
| CHRNB3 | -5878.0 |
| CHRNG | -5355.0 |
| CHRNA3 | -4870.0 |
| CHRNB4 | -2978.0 |
| CHRNA9 | -138.0 |
| CHRNA4 | 1760.0 |
| CHRNA5 | 3458.0 |
| CHRNB2 | 4716.0 |
| CHRNA7 | 7328.5 |
Organic anion transporters
| 781 | |
|---|---|
| set | Organic anion transporters |
| setSize | 10 |
| pANOVA | 0.0442 |
| s.dist | -0.367 |
| p.adjustANOVA | 0.661 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLC25A22 | -6786 |
| SLC5A5 | -6212 |
| SLC17A6 | -5696 |
| SLC17A1 | -5013 |
| SLC17A7 | -3125 |
| SLC5A8 | -1174 |
| SLC17A5 | -987 |
| SLC17A8 | 49 |
| SLC25A18 | 2463 |
| SLC25A10 | 2645 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SLC25A22 | -6786 |
| SLC5A5 | -6212 |
| SLC17A6 | -5696 |
| SLC17A1 | -5013 |
| SLC17A7 | -3125 |
| SLC5A8 | -1174 |
| SLC17A5 | -987 |
| SLC17A8 | 49 |
| SLC25A18 | 2463 |
| SLC25A10 | 2645 |
Surfactant metabolism
| 1183 | |
|---|---|
| set | Surfactant metabolism |
| setSize | 21 |
| pANOVA | 0.005 |
| s.dist | -0.354 |
| p.adjustANOVA | 0.302 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CKAP4 | -6976.0 |
| DMBT1 | -6714.0 |
| SFTPC | -6555.0 |
| NAPSA | -6430.0 |
| ABCA3 | -6371.0 |
| ZDHHC2 | -6082.0 |
| SLC34A2 | -5391.0 |
| SFTPA1 | -5189.5 |
| SFTPA2 | -5189.5 |
| CTSH | -4621.0 |
| CSF2RB | -4364.0 |
| SLC34A1 | -4030.0 |
| LMCD1 | -3944.0 |
| SFTPB | -3359.0 |
| P2RY2 | -1459.0 |
| TTF1 | 1506.0 |
| SFTPD | 3651.0 |
| ADRA2C | 4058.0 |
| ADORA2B | 4668.0 |
| ADRA2A | 7005.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CKAP4 | -6976.0 |
| DMBT1 | -6714.0 |
| SFTPC | -6555.0 |
| NAPSA | -6430.0 |
| ABCA3 | -6371.0 |
| ZDHHC2 | -6082.0 |
| SLC34A2 | -5391.0 |
| SFTPA1 | -5189.5 |
| SFTPA2 | -5189.5 |
| CTSH | -4621.0 |
| CSF2RB | -4364.0 |
| SLC34A1 | -4030.0 |
| LMCD1 | -3944.0 |
| SFTPB | -3359.0 |
| P2RY2 | -1459.0 |
| TTF1 | 1506.0 |
| SFTPD | 3651.0 |
| ADRA2C | 4058.0 |
| ADORA2B | 4668.0 |
| ADRA2A | 7005.0 |
| ADORA2A | 8075.0 |
Organic cation transport
| 782 | |
|---|---|
| set | Organic cation transport |
| setSize | 10 |
| pANOVA | 0.0533 |
| s.dist | 0.353 |
| p.adjustANOVA | 0.695 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLC22A4 | 7652 |
| SLC22A5 | 6635 |
| RSC1A1 | 6477 |
| SLC22A3 | 5624 |
| RUNX1 | 3772 |
| SLC22A18 | 3165 |
| SLC22A15 | 2393 |
| SLC22A1 | 1767 |
| SLC22A16 | 1011 |
| SLC22A2 | -4111 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SLC22A4 | 7652 |
| SLC22A5 | 6635 |
| RSC1A1 | 6477 |
| SLC22A3 | 5624 |
| RUNX1 | 3772 |
| SLC22A18 | 3165 |
| SLC22A15 | 2393 |
| SLC22A1 | 1767 |
| SLC22A16 | 1011 |
| SLC22A2 | -4111 |
CREB1 phosphorylation through the activation of Adenylate Cyclase
| 139 | |
|---|---|
| set | CREB1 phosphorylation through the activation of Adenylate Cyclase |
| setSize | 10 |
| pANOVA | 0.054 |
| s.dist | 0.352 |
| p.adjustANOVA | 0.695 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CALM1 | 7920 |
| PRKAR2A | 6553 |
| PRKAR2B | 4069 |
| PRKAR1A | 4036 |
| CREB1 | 3889 |
| PRKACA | 2875 |
| ADCY1 | 2641 |
| ADCY8 | 1178 |
| PRKAR1B | 1113 |
| PRKACB | 27 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CALM1 | 7920 |
| PRKAR2A | 6553 |
| PRKAR2B | 4069 |
| PRKAR1A | 4036 |
| CREB1 | 3889 |
| PRKACA | 2875 |
| ADCY1 | 2641 |
| ADCY8 | 1178 |
| PRKAR1B | 1113 |
| PRKACB | 27 |
Activation of the TFAP2 (AP-2) family of transcription factors
| 53 | |
|---|---|
| set | Activation of the TFAP2 (AP-2) family of transcription factors |
| setSize | 11 |
| pANOVA | 0.0435 |
| s.dist | 0.352 |
| p.adjustANOVA | 0.661 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CITED1 | 8184 |
| YEATS4 | 7716 |
| EP300 | 7062 |
| CITED2 | 6629 |
| TFAP2A | 6325 |
| WWOX | 5323 |
| CREBBP | 5288 |
| TFAP2B | 2842 |
| CITED4 | 40 |
| TFAP2C | -4785 |
| TFAP2E | -6922 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CITED1 | 8184 |
| YEATS4 | 7716 |
| EP300 | 7062 |
| CITED2 | 6629 |
| TFAP2A | 6325 |
| WWOX | 5323 |
| CREBBP | 5288 |
| TFAP2B | 2842 |
| CITED4 | 40 |
| TFAP2C | -4785 |
| TFAP2E | -6922 |
Regulation of TLR by endogenous ligand
| 985 | |
|---|---|
| set | Regulation of TLR by endogenous ligand |
| setSize | 15 |
| pANOVA | 0.0189 |
| s.dist | 0.35 |
| p.adjustANOVA | 0.463 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FGA | 7144 |
| FGB | 6785 |
| S100A9 | 6561 |
| TLR6 | 6476 |
| APOB | 5490 |
| HMGB1 | 5336 |
| TLR2 | 5315 |
| LBP | 3908 |
| TLR1 | 2901 |
| TLR4 | 2473 |
| LY96 | 1627 |
| S100A8 | 583 |
| CD14 | 234 |
| CD36 | -369 |
| FGG | -3229 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FGA | 7144 |
| FGB | 6785 |
| S100A9 | 6561 |
| TLR6 | 6476 |
| APOB | 5490 |
| HMGB1 | 5336 |
| TLR2 | 5315 |
| LBP | 3908 |
| TLR1 | 2901 |
| TLR4 | 2473 |
| LY96 | 1627 |
| S100A8 | 583 |
| CD14 | 234 |
| CD36 | -369 |
| FGG | -3229 |
Creation of C4 and C2 activators
| 223 | |
|---|---|
| set | Creation of C4 and C2 activators |
| setSize | 17 |
| pANOVA | 0.0125 |
| s.dist | -0.35 |
| p.adjustANOVA | 0.419 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| C1QA | -6933.0 |
| MBL2 | -5945.0 |
| COLEC10 | -5698.0 |
| IGHG1 | -5437.5 |
| IGHG2 | -5437.5 |
| IGHG3 | -5437.5 |
| IGHG4 | -5437.5 |
| C1QC | -4474.0 |
| CRP | -4036.0 |
| FCN1 | -3245.5 |
| FCN2 | -3245.5 |
| C1R | -1889.0 |
| MASP1 | 312.0 |
| C1S | 2715.0 |
| COLEC11 | 4138.0 |
| MASP2 | 5217.0 |
| C1QB | 6767.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| C1QA | -6933.0 |
| MBL2 | -5945.0 |
| COLEC10 | -5698.0 |
| IGHG1 | -5437.5 |
| IGHG2 | -5437.5 |
| IGHG3 | -5437.5 |
| IGHG4 | -5437.5 |
| C1QC | -4474.0 |
| CRP | -4036.0 |
| FCN1 | -3245.5 |
| FCN2 | -3245.5 |
| C1R | -1889.0 |
| MASP1 | 312.0 |
| C1S | 2715.0 |
| COLEC11 | 4138.0 |
| MASP2 | 5217.0 |
| C1QB | 6767.0 |
Synthesis of pyrophosphates in the cytosol
| 1204 | |
|---|---|
| set | Synthesis of pyrophosphates in the cytosol |
| setSize | 10 |
| pANOVA | 0.0557 |
| s.dist | -0.349 |
| p.adjustANOVA | 0.709 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IP6K3 | -6483.0 |
| NUDT3 | -4631.0 |
| IP6K1 | -4490.0 |
| NUDT10 | -4258.5 |
| NUDT11 | -4258.5 |
| NUDT4 | -3386.0 |
| PPIP5K1 | -2132.0 |
| IPPK | -2094.0 |
| ITPK1 | 1801.0 |
| PPIP5K2 | 7551.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IP6K3 | -6483.0 |
| NUDT3 | -4631.0 |
| IP6K1 | -4490.0 |
| NUDT10 | -4258.5 |
| NUDT11 | -4258.5 |
| NUDT4 | -3386.0 |
| PPIP5K1 | -2132.0 |
| IPPK | -2094.0 |
| ITPK1 | 1801.0 |
| PPIP5K2 | 7551.0 |
Transport of vitamins, nucleosides, and related molecules
| 1319 | |
|---|---|
| set | Transport of vitamins, nucleosides, and related molecules |
| setSize | 37 |
| pANOVA | 0.000286 |
| s.dist | -0.345 |
| p.adjustANOVA | 0.0442 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLC29A1 | -7409 |
| SLC35A3 | -7091 |
| SLC25A5 | -7011 |
| SLC27A4 | -6975 |
| SLC27A6 | -6846 |
| SLC29A3 | -6621 |
| SLC5A6 | -6563 |
| SLC35D2 | -6350 |
| SLC28A3 | -6335 |
| SLC28A1 | -6258 |
| SLC35C1 | -5812 |
| ARL2 | -5657 |
| SLC35B4 | -5479 |
| SLC35D1 | -5130 |
| APOD | -4740 |
| SLCO1A2 | -4362 |
| SLC16A2 | -4315 |
| SLC35A2 | -3831 |
| SLCO2B1 | -3536 |
| LCN9 | -3233 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SLC29A1 | -7409 |
| SLC35A3 | -7091 |
| SLC25A5 | -7011 |
| SLC27A4 | -6975 |
| SLC27A6 | -6846 |
| SLC29A3 | -6621 |
| SLC5A6 | -6563 |
| SLC35D2 | -6350 |
| SLC28A3 | -6335 |
| SLC28A1 | -6258 |
| SLC35C1 | -5812 |
| ARL2 | -5657 |
| SLC35B4 | -5479 |
| SLC35D1 | -5130 |
| APOD | -4740 |
| SLCO1A2 | -4362 |
| SLC16A2 | -4315 |
| SLC35A2 | -3831 |
| SLCO2B1 | -3536 |
| LCN9 | -3233 |
| SLCO4A1 | -2819 |
| SLC29A4 | -2053 |
| SLC25A4 | -1887 |
| SLC27A1 | -1590 |
| SLC35B2 | -1297 |
| SLC29A2 | -1010 |
| LCN12 | -957 |
| AVP | -386 |
| ALB | 606 |
| SLC35A1 | 1115 |
| ARL2BP | 4213 |
| SLCO2A1 | 4666 |
| SLCO3A1 | 5164 |
| SLC28A2 | 5395 |
| SLCO1C1 | 7212 |
| SLCO1B1 | 7989 |
| SLCO1B3 | 7989 |
Glutathione synthesis and recycling
| 475 | |
|---|---|
| set | Glutathione synthesis and recycling |
| setSize | 12 |
| pANOVA | 0.0463 |
| s.dist | -0.332 |
| p.adjustANOVA | 0.678 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GGT6 | -6834 |
| GGCT | -6444 |
| CHAC1 | -5117 |
| GCLC | -2888 |
| GGT5 | -2390 |
| GGT1 | -2327 |
| GGT7 | -1938 |
| OPLAH | -1648 |
| CHAC2 | -171 |
| GCLM | 434 |
| GSS | 818 |
| CNDP2 | 3322 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GGT6 | -6834 |
| GGCT | -6444 |
| CHAC1 | -5117 |
| GCLC | -2888 |
| GGT5 | -2390 |
| GGT1 | -2327 |
| GGT7 | -1938 |
| OPLAH | -1648 |
| CHAC2 | -171 |
| GCLM | 434 |
| GSS | 818 |
| CNDP2 | 3322 |
Lewis blood group biosynthesis
| 616 | |
|---|---|
| set | Lewis blood group biosynthesis |
| setSize | 12 |
| pANOVA | 0.0476 |
| s.dist | 0.33 |
| p.adjustANOVA | 0.682 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FUT9 | 6933 |
| B3GALT5 | 6747 |
| FUT4 | 5517 |
| ST3GAL6 | 5235 |
| B4GALNT2 | 4787 |
| B3GALT1 | 4705 |
| ST3GAL3 | 3807 |
| FUT11 | 3181 |
| B3GALT4 | 1720 |
| FUT7 | 1514 |
| FUT10 | -1683 |
| ST6GALNAC6 | -3401 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FUT9 | 6933 |
| B3GALT5 | 6747 |
| FUT4 | 5517 |
| ST3GAL6 | 5235 |
| B4GALNT2 | 4787 |
| B3GALT1 | 4705 |
| ST3GAL3 | 3807 |
| FUT11 | 3181 |
| B3GALT4 | 1720 |
| FUT7 | 1514 |
| FUT10 | -1683 |
| ST6GALNAC6 | -3401 |
CRMPs in Sema3A signaling
| 140 | |
|---|---|
| set | CRMPs in Sema3A signaling |
| setSize | 15 |
| pANOVA | 0.0277 |
| s.dist | 0.328 |
| p.adjustANOVA | 0.55 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLXNA2 | 8385 |
| DPYSL3 | 7164 |
| FYN | 6896 |
| DPYSL2 | 5831 |
| PLXNA3 | 5493 |
| GSK3B | 5317 |
| CDK5 | 4865 |
| CDK5R1 | 4201 |
| PLXNA4 | 3530 |
| CRMP1 | 2864 |
| SEMA3A | 1539 |
| DPYSL4 | 492 |
| PLXNA1 | 143 |
| FES | -3007 |
| DPYSL5 | -5127 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PLXNA2 | 8385 |
| DPYSL3 | 7164 |
| FYN | 6896 |
| DPYSL2 | 5831 |
| PLXNA3 | 5493 |
| GSK3B | 5317 |
| CDK5 | 4865 |
| CDK5R1 | 4201 |
| PLXNA4 | 3530 |
| CRMP1 | 2864 |
| SEMA3A | 1539 |
| DPYSL4 | 492 |
| PLXNA1 | 143 |
| FES | -3007 |
| DPYSL5 | -5127 |
Regulation of localization of FOXO transcription factors
| 1007 | |
|---|---|
| set | Regulation of localization of FOXO transcription factors |
| setSize | 12 |
| pANOVA | 0.0535 |
| s.dist | -0.322 |
| p.adjustANOVA | 0.695 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| YWHAG | -7373 |
| YWHAB | -6213 |
| AKT2 | -5305 |
| FOXO1 | -5158 |
| AKT1 | -5082 |
| FOXO6 | -2537 |
| YWHAZ | -2511 |
| SFN | -846 |
| YWHAQ | 793 |
| AKT3 | 1565 |
| FOXO4 | 3308 |
| FOXO3 | 5172 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| YWHAG | -7373 |
| YWHAB | -6213 |
| AKT2 | -5305 |
| FOXO1 | -5158 |
| AKT1 | -5082 |
| FOXO6 | -2537 |
| YWHAZ | -2511 |
| SFN | -846 |
| YWHAQ | 793 |
| AKT3 | 1565 |
| FOXO4 | 3308 |
| FOXO3 | 5172 |
Degradation of cysteine and homocysteine
| 275 | |
|---|---|
| set | Degradation of cysteine and homocysteine |
| setSize | 11 |
| pANOVA | 0.0707 |
| s.dist | -0.315 |
| p.adjustANOVA | 0.75 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TXN2 | -6537.0 |
| CSAD | -6314.0 |
| SQRDL | -5426.5 |
| CDO1 | -5141.0 |
| GADL1 | -4793.0 |
| SUOX | -4292.0 |
| CTH | -3956.0 |
| GOT2 | -25.0 |
| SLC25A10 | 2645.0 |
| ADO | 4317.0 |
| MPST | 7994.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TXN2 | -6537.0 |
| CSAD | -6314.0 |
| SQRDL | -5426.5 |
| CDO1 | -5141.0 |
| GADL1 | -4793.0 |
| SUOX | -4292.0 |
| CTH | -3956.0 |
| GOT2 | -25.0 |
| SLC25A10 | 2645.0 |
| ADO | 4317.0 |
| MPST | 7994.0 |
Receptor-type tyrosine-protein phosphatases
| 955 | |
|---|---|
| set | Receptor-type tyrosine-protein phosphatases |
| setSize | 19 |
| pANOVA | 0.0176 |
| s.dist | 0.315 |
| p.adjustANOVA | 0.462 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLITRK6 | 8178 |
| PTPRD | 7405 |
| SLITRK2 | 6673 |
| SLITRK3 | 5786 |
| IL1RAPL2 | 5453 |
| PPFIBP1 | 4563 |
| PTPRF | 4362 |
| PPFIA1 | 4271 |
| PTPRS | 4006 |
| SLITRK1 | 3998 |
| LRRC4B | 3997 |
| IL1RAPL1 | 3515 |
| SLITRK4 | 2198 |
| SLITRK5 | 1176 |
| IL1RAP | 755 |
| NTRK3 | 469 |
| PPFIA4 | -511 |
| PPFIBP2 | -2056 |
| PPFIA3 | -4829 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SLITRK6 | 8178 |
| PTPRD | 7405 |
| SLITRK2 | 6673 |
| SLITRK3 | 5786 |
| IL1RAPL2 | 5453 |
| PPFIBP1 | 4563 |
| PTPRF | 4362 |
| PPFIA1 | 4271 |
| PTPRS | 4006 |
| SLITRK1 | 3998 |
| LRRC4B | 3997 |
| IL1RAPL1 | 3515 |
| SLITRK4 | 2198 |
| SLITRK5 | 1176 |
| IL1RAP | 755 |
| NTRK3 | 469 |
| PPFIA4 | -511 |
| PPFIBP2 | -2056 |
| PPFIA3 | -4829 |
KSRP (KHSRP) binds and destabilizes mRNA
| 597 | |
|---|---|
| set | KSRP (KHSRP) binds and destabilizes mRNA |
| setSize | 14 |
| pANOVA | 0.0424 |
| s.dist | -0.313 |
| p.adjustANOVA | 0.661 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DIS3 | -6375 |
| MAPK14 | -6365 |
| EXOSC3 | -6263 |
| AKT1 | -5082 |
| KHSRP | -4736 |
| MAPK11 | -4165 |
| EXOSC2 | -4043 |
| YWHAZ | -2511 |
| EXOSC7 | -40 |
| EXOSC9 | 1709 |
| PARN | 1842 |
| DCP2 | 2579 |
| EXOSC5 | 2873 |
| EXOSC8 | 3339 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DIS3 | -6375 |
| MAPK14 | -6365 |
| EXOSC3 | -6263 |
| AKT1 | -5082 |
| KHSRP | -4736 |
| MAPK11 | -4165 |
| EXOSC2 | -4043 |
| YWHAZ | -2511 |
| EXOSC7 | -40 |
| EXOSC9 | 1709 |
| PARN | 1842 |
| DCP2 | 2579 |
| EXOSC5 | 2873 |
| EXOSC8 | 3339 |
Defective B3GALTL causes Peters-plus syndrome (PpS)
| 256 | |
|---|---|
| set | Defective B3GALTL causes Peters-plus syndrome (PpS) |
| setSize | 33 |
| pANOVA | 0.00184 |
| s.dist | 0.313 |
| p.adjustANOVA | 0.151 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ADAMTSL1 | 8318 |
| ADAMTS1 | 8229 |
| ADAMTS14 | 7981 |
| ADAMTSL3 | 7930 |
| THBS1 | 7165 |
| THSD7A | 7069 |
| THSD1 | 6852 |
| ADAMTS8 | 6745 |
| THBS2 | 6628 |
| CFP | 6622 |
| ADAMTS9 | 6589 |
| ADAMTS15 | 6346 |
| ADAMTS3 | 5396 |
| ADAMTS7 | 4860 |
| ADAMTS12 | 4824 |
| ADAMTS19 | 4693 |
| THSD7B | 4255 |
| ADAMTSL4 | 2424 |
| THSD4 | 2153 |
| SEMA5B | 2018 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ADAMTSL1 | 8318.0 |
| ADAMTS1 | 8229.0 |
| ADAMTS14 | 7981.0 |
| ADAMTSL3 | 7930.0 |
| THBS1 | 7165.0 |
| THSD7A | 7069.0 |
| THSD1 | 6852.0 |
| ADAMTS8 | 6745.0 |
| THBS2 | 6628.0 |
| CFP | 6622.0 |
| ADAMTS9 | 6589.0 |
| ADAMTS15 | 6346.0 |
| ADAMTS3 | 5396.0 |
| ADAMTS7 | 4860.0 |
| ADAMTS12 | 4824.0 |
| ADAMTS19 | 4693.0 |
| THSD7B | 4255.0 |
| ADAMTSL4 | 2424.0 |
| THSD4 | 2153.0 |
| SEMA5B | 2018.0 |
| ADAMTS10 | 1643.0 |
| ADAMTS4 | 1241.0 |
| ADAMTS13 | 977.0 |
| ADAMTS20 | 426.0 |
| ADAMTS2 | 271.0 |
| ADAMTSL2 | -289.5 |
| ADAMTS5 | -483.0 |
| ADAMTSL5 | -515.0 |
| ADAMTS17 | -1179.0 |
| SBSPON | -2916.0 |
| SPON2 | -3655.0 |
| ADAMTS16 | -4047.0 |
| ADAMTS18 | -5793.0 |
Cleavage of the damaged pyrimidine
| 199 | |
|---|---|
| set | Cleavage of the damaged pyrimidine |
| setSize | 13 |
| pANOVA | 0.0534 |
| s.dist | -0.309 |
| p.adjustANOVA | 0.695 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TINF2 | -6993 |
| UNG | -6787 |
| H2AFX | -6405 |
| NEIL2 | -5837 |
| TERF2 | -5415 |
| OGG1 | -3771 |
| SMUG1 | -3737 |
| TDG | -2169 |
| POT1 | -74 |
| NEIL3 | 826 |
| NEIL1 | 1605 |
| TERF1 | 5641 |
| MBD4 | 8236 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TINF2 | -6993 |
| UNG | -6787 |
| H2AFX | -6405 |
| NEIL2 | -5837 |
| TERF2 | -5415 |
| OGG1 | -3771 |
| SMUG1 | -3737 |
| TDG | -2169 |
| POT1 | -74 |
| NEIL3 | 826 |
| NEIL1 | 1605 |
| TERF1 | 5641 |
| MBD4 | 8236 |
Depyrimidination
| 279 | |
|---|---|
| set | Depyrimidination |
| setSize | 13 |
| pANOVA | 0.0534 |
| s.dist | -0.309 |
| p.adjustANOVA | 0.695 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TINF2 | -6993 |
| UNG | -6787 |
| H2AFX | -6405 |
| NEIL2 | -5837 |
| TERF2 | -5415 |
| OGG1 | -3771 |
| SMUG1 | -3737 |
| TDG | -2169 |
| POT1 | -74 |
| NEIL3 | 826 |
| NEIL1 | 1605 |
| TERF1 | 5641 |
| MBD4 | 8236 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TINF2 | -6993 |
| UNG | -6787 |
| H2AFX | -6405 |
| NEIL2 | -5837 |
| TERF2 | -5415 |
| OGG1 | -3771 |
| SMUG1 | -3737 |
| TDG | -2169 |
| POT1 | -74 |
| NEIL3 | 826 |
| NEIL1 | 1605 |
| TERF1 | 5641 |
| MBD4 | 8236 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine
| 956 | |
|---|---|
| set | Recognition and association of DNA glycosylase with site containing an affected pyrimidine |
| setSize | 13 |
| pANOVA | 0.0534 |
| s.dist | -0.309 |
| p.adjustANOVA | 0.695 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TINF2 | -6993 |
| UNG | -6787 |
| H2AFX | -6405 |
| NEIL2 | -5837 |
| TERF2 | -5415 |
| OGG1 | -3771 |
| SMUG1 | -3737 |
| TDG | -2169 |
| POT1 | -74 |
| NEIL3 | 826 |
| NEIL1 | 1605 |
| TERF1 | 5641 |
| MBD4 | 8236 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TINF2 | -6993 |
| UNG | -6787 |
| H2AFX | -6405 |
| NEIL2 | -5837 |
| TERF2 | -5415 |
| OGG1 | -3771 |
| SMUG1 | -3737 |
| TDG | -2169 |
| POT1 | -74 |
| NEIL3 | 826 |
| NEIL1 | 1605 |
| TERF1 | 5641 |
| MBD4 | 8236 |
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
| 264 | |
|---|---|
| set | Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) |
| setSize | 12 |
| pANOVA | 0.0637 |
| s.dist | -0.309 |
| p.adjustANOVA | 0.738 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MUC1 | -7239 |
| MUC17 | -6488 |
| MUC13 | -6463 |
| MUC6 | -5779 |
| MUC3A | -4072 |
| MUC4 | -1860 |
| MUC20 | -1401 |
| MUC2 | -652 |
| MUC15 | 617 |
| MUC5B | 955 |
| GALNT3 | 2365 |
| MUC19 | 7070 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MUC1 | -7239 |
| MUC17 | -6488 |
| MUC13 | -6463 |
| MUC6 | -5779 |
| MUC3A | -4072 |
| MUC4 | -1860 |
| MUC20 | -1401 |
| MUC2 | -652 |
| MUC15 | 617 |
| MUC5B | 955 |
| GALNT3 | 2365 |
| MUC19 | 7070 |
Regulation of commissural axon pathfinding by SLIT and ROBO
| 998 | |
|---|---|
| set | Regulation of commissural axon pathfinding by SLIT and ROBO |
| setSize | 10 |
| pANOVA | 0.0931 |
| s.dist | 0.307 |
| p.adjustANOVA | 0.765 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ROBO2 | 7970 |
| SLIT2 | 6963 |
| NELL2 | 6407 |
| ROBO1 | 4580 |
| ROBO3 | 4463 |
| SLIT3 | 3855 |
| DCC | 3040 |
| NTN1 | 1685 |
| SRC | -2273 |
| SLIT1 | -6047 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ROBO2 | 7970 |
| SLIT2 | 6963 |
| NELL2 | 6407 |
| ROBO1 | 4580 |
| ROBO3 | 4463 |
| SLIT3 | 3855 |
| DCC | 3040 |
| NTN1 | 1685 |
| SRC | -2273 |
| SLIT1 | -6047 |
Defective GALNT12 causes colorectal cancer 1 (CRCS1)
| 263 | |
|---|---|
| set | Defective GALNT12 causes colorectal cancer 1 (CRCS1) |
| setSize | 12 |
| pANOVA | 0.0698 |
| s.dist | -0.302 |
| p.adjustANOVA | 0.75 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MUC1 | -7239 |
| MUC17 | -6488 |
| MUC13 | -6463 |
| MUC6 | -5779 |
| MUC3A | -4072 |
| MUC4 | -1860 |
| MUC20 | -1401 |
| MUC2 | -652 |
| MUC15 | 617 |
| MUC5B | 955 |
| GALNT12 | 3032 |
| MUC19 | 7070 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MUC1 | -7239 |
| MUC17 | -6488 |
| MUC13 | -6463 |
| MUC6 | -5779 |
| MUC3A | -4072 |
| MUC4 | -1860 |
| MUC20 | -1401 |
| MUC2 | -652 |
| MUC15 | 617 |
| MUC5B | 955 |
| GALNT12 | 3032 |
| MUC19 | 7070 |
O-glycosylation of TSR domain-containing proteins
| 771 | |
|---|---|
| set | O-glycosylation of TSR domain-containing proteins |
| setSize | 34 |
| pANOVA | 0.00246 |
| s.dist | 0.3 |
| p.adjustANOVA | 0.18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ADAMTSL1 | 8318 |
| ADAMTS1 | 8229 |
| ADAMTS14 | 7981 |
| ADAMTSL3 | 7930 |
| THBS1 | 7165 |
| THSD7A | 7069 |
| THSD1 | 6852 |
| ADAMTS8 | 6745 |
| THBS2 | 6628 |
| CFP | 6622 |
| ADAMTS9 | 6589 |
| ADAMTS15 | 6346 |
| ADAMTS3 | 5396 |
| ADAMTS7 | 4860 |
| ADAMTS12 | 4824 |
| ADAMTS19 | 4693 |
| THSD7B | 4255 |
| ADAMTSL4 | 2424 |
| THSD4 | 2153 |
| SEMA5B | 2018 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ADAMTSL1 | 8318.0 |
| ADAMTS1 | 8229.0 |
| ADAMTS14 | 7981.0 |
| ADAMTSL3 | 7930.0 |
| THBS1 | 7165.0 |
| THSD7A | 7069.0 |
| THSD1 | 6852.0 |
| ADAMTS8 | 6745.0 |
| THBS2 | 6628.0 |
| CFP | 6622.0 |
| ADAMTS9 | 6589.0 |
| ADAMTS15 | 6346.0 |
| ADAMTS3 | 5396.0 |
| ADAMTS7 | 4860.0 |
| ADAMTS12 | 4824.0 |
| ADAMTS19 | 4693.0 |
| THSD7B | 4255.0 |
| ADAMTSL4 | 2424.0 |
| THSD4 | 2153.0 |
| SEMA5B | 2018.0 |
| ADAMTS10 | 1643.0 |
| ADAMTS4 | 1241.0 |
| ADAMTS13 | 977.0 |
| ADAMTS20 | 426.0 |
| ADAMTS2 | 271.0 |
| ADAMTSL2 | -289.5 |
| ADAMTS5 | -483.0 |
| ADAMTSL5 | -515.0 |
| POFUT2 | -518.0 |
| ADAMTS17 | -1179.0 |
| SBSPON | -2916.0 |
| SPON2 | -3655.0 |
| ADAMTS16 | -4047.0 |
| ADAMTS18 | -5793.0 |
Initial triggering of complement
| 546 | |
|---|---|
| set | Initial triggering of complement |
| setSize | 24 |
| pANOVA | 0.0116 |
| s.dist | -0.298 |
| p.adjustANOVA | 0.403 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CFB | -7499.0 |
| C1QA | -6933.0 |
| MBL2 | -5945.0 |
| COLEC10 | -5698.0 |
| IGHG1 | -5437.5 |
| IGHG2 | -5437.5 |
| IGHG3 | -5437.5 |
| IGHG4 | -5437.5 |
| GZMM | -4945.0 |
| C1QC | -4474.0 |
| CRP | -4036.0 |
| FCN1 | -3245.5 |
| FCN2 | -3245.5 |
| CFD | -3213.0 |
| C1R | -1889.0 |
| C2 | -98.0 |
| MASP1 | 312.0 |
| C1S | 2715.0 |
| C4A | 3008.5 |
| C4B | 3008.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CFB | -7499.0 |
| C1QA | -6933.0 |
| MBL2 | -5945.0 |
| COLEC10 | -5698.0 |
| IGHG1 | -5437.5 |
| IGHG2 | -5437.5 |
| IGHG3 | -5437.5 |
| IGHG4 | -5437.5 |
| GZMM | -4945.0 |
| C1QC | -4474.0 |
| CRP | -4036.0 |
| FCN1 | -3245.5 |
| FCN2 | -3245.5 |
| CFD | -3213.0 |
| C1R | -1889.0 |
| C2 | -98.0 |
| MASP1 | 312.0 |
| C1S | 2715.0 |
| C4A | 3008.5 |
| C4B | 3008.5 |
| COLEC11 | 4138.0 |
| C3 | 4186.0 |
| MASP2 | 5217.0 |
| C1QB | 6767.0 |
DCC mediated attractive signaling
| 237 | |
|---|---|
| set | DCC mediated attractive signaling |
| setSize | 14 |
| pANOVA | 0.054 |
| s.dist | 0.298 |
| p.adjustANOVA | 0.695 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TRIO | 7832 |
| NCK1 | 7247 |
| WASL | 7182 |
| FYN | 6896 |
| ABLIM3 | 5594 |
| CDC42 | 5262 |
| DCC | 3040 |
| PTK2 | 2619 |
| ABLIM1 | 1755 |
| NTN1 | 1685 |
| DOCK1 | 616 |
| ABLIM2 | -2266 |
| SRC | -2273 |
| RAC1 | -3333 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TRIO | 7832 |
| NCK1 | 7247 |
| WASL | 7182 |
| FYN | 6896 |
| ABLIM3 | 5594 |
| CDC42 | 5262 |
| DCC | 3040 |
| PTK2 | 2619 |
| ABLIM1 | 1755 |
| NTN1 | 1685 |
| DOCK1 | 616 |
| ABLIM2 | -2266 |
| SRC | -2273 |
| RAC1 | -3333 |
Retrograde neurotrophin signalling
| 1034 | |
|---|---|
| set | Retrograde neurotrophin signalling |
| setSize | 14 |
| pANOVA | 0.0572 |
| s.dist | 0.294 |
| p.adjustANOVA | 0.709 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AP2B1 | 8028 |
| DNM3 | 7320 |
| NTRK1 | 6991 |
| SH3GL2 | 5812 |
| CLTC | 5306 |
| NGF | 5145 |
| DNM2 | 4416 |
| AP2M1 | 3545 |
| AP2A1 | 1877 |
| DNM1 | 1780 |
| DNAL4 | 1633 |
| AP2A2 | 879 |
| CLTA | -4322 |
| AP2S1 | -6992 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AP2B1 | 8028 |
| DNM3 | 7320 |
| NTRK1 | 6991 |
| SH3GL2 | 5812 |
| CLTC | 5306 |
| NGF | 5145 |
| DNM2 | 4416 |
| AP2M1 | 3545 |
| AP2A1 | 1877 |
| DNM1 | 1780 |
| DNAL4 | 1633 |
| AP2A2 | 879 |
| CLTA | -4322 |
| AP2S1 | -6992 |
Adherens junctions interactions
| 65 | |
|---|---|
| set | Adherens junctions interactions |
| setSize | 24 |
| pANOVA | 0.0139 |
| s.dist | 0.29 |
| p.adjustANOVA | 0.419 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDH6 | 7926 |
| CDH11 | 7542 |
| CDH3 | 7376 |
| CTNND1 | 7346 |
| ANG | 7197 |
| CDH7 | 6982 |
| CDH5 | 6976 |
| CTNNB1 | 6880 |
| CDH10 | 5920 |
| CADM1 | 5898 |
| CDH8 | 5036 |
| CDH4 | 4937 |
| CADM2 | 4383 |
| CDH9 | 1864 |
| CDH12 | 1311 |
| JUP | 297 |
| CDH15 | 165 |
| CDH18 | -186 |
| CTNNA1 | -503 |
| CDH13 | -1137 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDH6 | 7926 |
| CDH11 | 7542 |
| CDH3 | 7376 |
| CTNND1 | 7346 |
| ANG | 7197 |
| CDH7 | 6982 |
| CDH5 | 6976 |
| CTNNB1 | 6880 |
| CDH10 | 5920 |
| CADM1 | 5898 |
| CDH8 | 5036 |
| CDH4 | 4937 |
| CADM2 | 4383 |
| CDH9 | 1864 |
| CDH12 | 1311 |
| JUP | 297 |
| CDH15 | 165 |
| CDH18 | -186 |
| CTNNA1 | -503 |
| CDH13 | -1137 |
| CDH1 | -2783 |
| CDH2 | -3183 |
| CDH17 | -3476 |
| CADM3 | -6457 |
RNA Polymerase III Chain Elongation
| 935 | |
|---|---|
| set | RNA Polymerase III Chain Elongation |
| setSize | 13 |
| pANOVA | 0.0702 |
| s.dist | -0.29 |
| p.adjustANOVA | 0.75 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| POLR3GL | -7361 |
| POLR3H | -6751 |
| POLR3A | -4432 |
| CRCP | -4417 |
| POLR2K | -3757 |
| POLR3E | -1612 |
| POLR3C | -484 |
| POLR2E | -287 |
| POLR3G | -79 |
| POLR3K | 520 |
| POLR3F | 1650 |
| POLR3D | 2056 |
| POLR1C | 2110 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| POLR3GL | -7361 |
| POLR3H | -6751 |
| POLR3A | -4432 |
| CRCP | -4417 |
| POLR2K | -3757 |
| POLR3E | -1612 |
| POLR3C | -484 |
| POLR2E | -287 |
| POLR3G | -79 |
| POLR3K | 520 |
| POLR3F | 1650 |
| POLR3D | 2056 |
| POLR1C | 2110 |
Activated NTRK2 signals through FRS2 and FRS3
| 32 | |
|---|---|
| set | Activated NTRK2 signals through FRS2 and FRS3 |
| setSize | 10 |
| pANOVA | 0.113 |
| s.dist | -0.289 |
| p.adjustANOVA | 0.776 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | -6538 |
| SOS1 | -5434 |
| NTRK2 | -5232 |
| HRAS | -4398 |
| NRAS | -2879 |
| FRS2 | -2820 |
| PTPN11 | 1646 |
| KRAS | 2413 |
| NTF4 | 2544 |
| BDNF | 3182 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | -6538 |
| SOS1 | -5434 |
| NTRK2 | -5232 |
| HRAS | -4398 |
| NRAS | -2879 |
| FRS2 | -2820 |
| PTPN11 | 1646 |
| KRAS | 2413 |
| NTF4 | 2544 |
| BDNF | 3182 |
Olfactory Signaling Pathway
| 775 | |
|---|---|
| set | Olfactory Signaling Pathway |
| setSize | 276 |
| pANOVA | 7.06e-16 |
| s.dist | 0.283 |
| p.adjustANOVA | 9.81e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| OR5P2 | 8672.0 |
| OR4C15 | 8670.0 |
| OR2AG1 | 8668.5 |
| OR2AG2 | 8668.5 |
| OR8K5 | 8640.0 |
| OR1E1 | 8638.5 |
| OR1E2 | 8638.5 |
| OR8K3 | 8637.0 |
| OR7E24 | 8621.0 |
| OR4C16 | 8620.0 |
| OR14A2 | 8619.0 |
| OR9G1 | 8618.0 |
| OR52R1 | 8616.0 |
| OR5W2 | 8612.0 |
| OR5B3 | 8606.0 |
| OR7G2 | 8604.0 |
| OR10D3 | 8595.0 |
| OR52N2 | 8589.0 |
| OR8H1 | 8576.0 |
| OR8H2 | 8576.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| OR5P2 | 8672.0 |
| OR4C15 | 8670.0 |
| OR2AG1 | 8668.5 |
| OR2AG2 | 8668.5 |
| OR8K5 | 8640.0 |
| OR1E1 | 8638.5 |
| OR1E2 | 8638.5 |
| OR8K3 | 8637.0 |
| OR7E24 | 8621.0 |
| OR4C16 | 8620.0 |
| OR14A2 | 8619.0 |
| OR9G1 | 8618.0 |
| OR52R1 | 8616.0 |
| OR5W2 | 8612.0 |
| OR5B3 | 8606.0 |
| OR7G2 | 8604.0 |
| OR10D3 | 8595.0 |
| OR52N2 | 8589.0 |
| OR8H1 | 8576.0 |
| OR8H2 | 8576.0 |
| OR8H3 | 8576.0 |
| OR4L1 | 8538.0 |
| OR5T1 | 8530.5 |
| OR5T3 | 8530.5 |
| OR2F1 | 8524.5 |
| OR2F2 | 8524.5 |
| OR9K2 | 8522.0 |
| OR4B1 | 8520.0 |
| OR5T2 | 8501.0 |
| OR52A5 | 8494.0 |
| OR4N4 | 8487.0 |
| OR51G2 | 8472.0 |
| OR8D2 | 8469.0 |
| OR5AK2 | 8423.0 |
| OR10AG1 | 8400.0 |
| OR11H4 | 8393.0 |
| OR2AP1 | 8389.0 |
| OR8D1 | 8378.0 |
| OR4A16 | 8374.5 |
| OR4A5 | 8374.5 |
| OR7D4 | 8277.0 |
| OR8J1 | 8261.5 |
| OR8J3 | 8261.5 |
| OR6C1 | 8234.0 |
| OR6C3 | 8177.0 |
| OR51A7 | 8174.0 |
| OR5D14 | 8170.0 |
| OR6C70 | 8164.0 |
| OR8B2 | 8155.5 |
| OR8B3 | 8155.5 |
| OR6K3 | 8122.0 |
| OR13G1 | 8092.0 |
| OR5AS1 | 8083.0 |
| OR10V1 | 8031.0 |
| OR1S1 | 7971.5 |
| OR1S2 | 7971.5 |
| OR2A12 | 7934.0 |
| OR4K2 | 7890.0 |
| OR10C1 | 7810.0 |
| OR4D10 | 7778.0 |
| OR13A1 | 7755.0 |
| OR4M1 | 7741.5 |
| OR4M2 | 7741.5 |
| OR6C2 | 7714.0 |
| OR4P4 | 7687.0 |
| OR10P1 | 7660.0 |
| OR8B12 | 7637.0 |
| OR5K4 | 7629.0 |
| OR2A14 | 7471.0 |
| OR5P3 | 7458.0 |
| OR8K1 | 7444.0 |
| OR4K1 | 7406.0 |
| OR5AN1 | 7323.0 |
| OR8B4 | 7222.0 |
| OR5D18 | 7147.0 |
| OR3A1 | 7142.0 |
| GNGT1 | 7135.0 |
| OR5V1 | 7001.0 |
| OR1N1 | 6954.0 |
| OR5M1 | 6952.5 |
| OR5M10 | 6952.5 |
| OR13C8 | 6889.0 |
| OR6N1 | 6866.0 |
| OR2L2 | 6860.5 |
| OR2L3 | 6860.5 |
| OR2L5 | 6860.5 |
| OR2L8 | 6860.5 |
| OR5M11 | 6794.0 |
| OR52N5 | 6727.0 |
| OR52E2 | 6611.0 |
| OR1L8 | 6609.0 |
| OR12D2 | 6554.5 |
| OR6C6 | 6528.0 |
| OR9I1 | 6512.0 |
| OR6K2 | 6399.0 |
| OR2AJ1 | 6394.0 |
| OR10H3 | 6375.5 |
| OR10H4 | 6375.5 |
| OR2B11 | 6141.0 |
| OR6C75 | 5847.0 |
| OR4D11 | 5705.0 |
| OR4A47 | 5680.0 |
| OR6X1 | 5571.0 |
| OR56B1 | 5566.0 |
| OR8A1 | 5564.0 |
| OR4K15 | 5398.0 |
| OR2W3 | 5321.0 |
| OR2W1 | 5283.0 |
| OR4C12 | 5213.0 |
| OR6B2 | 5196.5 |
| OR6B3 | 5196.5 |
| OR6C68 | 5193.0 |
| OR5B21 | 5180.0 |
| OR1L4 | 5094.5 |
| OR1L6 | 5094.5 |
| OR14J1 | 5070.0 |
| OR52H1 | 5067.0 |
| OR52J3 | 5004.0 |
| OR52I1 | 4995.5 |
| OR52I2 | 4995.5 |
| OR51S1 | 4967.0 |
| OR4F15 | 4736.0 |
| OR2A1 | 4653.5 |
| OR2A2 | 4471.0 |
| OR4K5 | 4361.0 |
| OR1J1 | 4336.0 |
| RTP4 | 4328.0 |
| OR52W1 | 4217.0 |
| OR1C1 | 4184.0 |
| OR10J3 | 4072.5 |
| OR10J4 | 4072.5 |
| GNAL | 4047.0 |
| OR51F2 | 3990.0 |
| OR1M1 | 3888.0 |
| OR6F1 | 3676.0 |
| OR6C65 | 3646.0 |
| OR4Q3 | 3573.0 |
| OR9G4 | 3525.0 |
| OR4C5 | 3403.0 |
| OR10Q1 | 3350.0 |
| OR13D1 | 3320.0 |
| OR51F1 | 3199.0 |
| OR10A3 | 3183.5 |
| OR10A6 | 3183.5 |
| OR8U1 | 3078.0 |
| OR10G2 | 2974.0 |
| OR51I2 | 2855.0 |
| OR51I1 | 2598.0 |
| OR2C1 | 2594.0 |
| OR2J1 | 2585.5 |
| OR2J2 | 2585.5 |
| OR2A4 | 2572.5 |
| OR2A7 | 2572.5 |
| OR6P1 | 2559.0 |
| OR2AT4 | 2350.0 |
| OR4A15 | 2341.0 |
| OR4X2 | 2333.0 |
| OR8I2 | 2279.0 |
| RTP1 | 2226.0 |
| OR5J2 | 2197.0 |
| OR2V2 | 2170.0 |
| OR2K2 | 2140.0 |
| OR5I1 | 2069.0 |
| OR52B2 | 2007.0 |
| REEP4 | 1952.0 |
| OR51G1 | 1912.0 |
| OR10W1 | 1827.0 |
| OR10G4 | 1713.5 |
| OR10G7 | 1713.5 |
| OR10G8 | 1713.5 |
| OR10G9 | 1713.5 |
| OR2T1 | 1616.0 |
| OR5AP2 | 1511.0 |
| OR2T29 | 1469.0 |
| OR2T4 | 1469.0 |
| OR2T5 | 1469.0 |
| OR56A4 | 1179.0 |
| RTP3 | 1167.0 |
| OR6B1 | 914.0 |
| OR6K6 | 802.0 |
| OR5A1 | 750.0 |
| OR11H6 | 733.0 |
| OR4C11 | 723.0 |
| OR4N5 | 654.0 |
| OR5C1 | 536.0 |
| OR10S1 | 530.0 |
| OR6C76 | 461.0 |
| OR6S1 | 288.0 |
| OR5D16 | 181.0 |
| OR6C74 | 141.0 |
| REEP6 | 30.0 |
| OR52E4 | 0.0 |
| REEP2 | -211.0 |
| OR51Q1 | -377.0 |
| REEP1 | -622.0 |
| OR2A25 | -662.0 |
| OR8D4 | -713.0 |
| OR10J1 | -735.0 |
| OR10X1 | -839.0 |
| OR6Y1 | -923.0 |
| OR51T1 | -995.0 |
| OR11A1 | -1092.0 |
| OR4C3 | -1130.0 |
| OR51E1 | -1260.0 |
| OR2D3 | -1270.0 |
| OR5A2 | -1423.0 |
| OR2T2 | -1549.5 |
| OR2T35 | -1549.5 |
| OR13F1 | -1606.0 |
| OR4F17 | -1670.0 |
| OR4F4 | -1670.0 |
| OR4F5 | -1670.0 |
| OR12D3 | -1680.0 |
| OR5B2 | -1843.0 |
| OR52E6 | -1863.5 |
| OR52E8 | -1863.5 |
| OR51M1 | -1971.0 |
| OR9A4 | -1977.0 |
| OR10K2 | -1985.0 |
| OR10AD1 | -2067.0 |
| OR10H1 | -2194.0 |
| OR10H2 | -2194.0 |
| OR10H5 | -2194.0 |
| OR51D1 | -2211.0 |
| OR8B8 | -2219.0 |
| OR13J1 | -2265.0 |
| OR4D5 | -2267.0 |
| OR4E2 | -2290.0 |
| OR10A4 | -2303.0 |
| OR4D6 | -2435.0 |
| OR5L1 | -2598.5 |
| OR5L2 | -2598.5 |
| OR5M3 | -2678.0 |
| OR9Q1 | -2708.0 |
| OR1A1 | -2742.0 |
| OR10A2 | -3391.5 |
| OR10A5 | -3391.5 |
| OR7G3 | -3413.0 |
| OR5B12 | -3446.0 |
| OR2A5 | -3461.0 |
| OR5AR1 | -3488.0 |
| OR9Q2 | -3692.0 |
| REEP5 | -3800.0 |
| OR6N2 | -3858.0 |
| OR5AU1 | -3898.0 |
| OR52N4 | -3967.0 |
| OR7C2 | -3994.0 |
| OR11H7 | -3998.0 |
| OR13C3 | -4214.0 |
| RTP2 | -4216.0 |
| OR2T12 | -4265.0 |
| OR2T33 | -4265.0 |
| OR2T8 | -4265.0 |
| GNB1 | -4274.0 |
| OR1J4 | -4640.0 |
| OR1I1 | -4643.0 |
| OR2B6 | -4943.0 |
| OR52K2 | -4979.0 |
| OR11L1 | -5103.0 |
| OR6A2 | -5319.0 |
| OR51E2 | -5571.0 |
| OR5M8 | -5609.0 |
| OR4D2 | -5717.0 |
| OR52M1 | -5803.0 |
| OR10J5 | -6239.0 |
| OR4D1 | -6249.0 |
| OR2AK2 | -6454.0 |
| OR4S2 | -6466.0 |
| OR1F1 | -6496.0 |
| OR9A2 | -6589.0 |
| OR2D2 | -6945.0 |
| OR10G3 | -7057.0 |
| OR10Z1 | -7106.0 |
| OR52L1 | -7129.0 |
| OR2T6 | -7309.0 |
| OR52D1 | -7412.0 |
Signaling by FGFR4 in disease
| 1119 | |
|---|---|
| set | Signaling by FGFR4 in disease |
| setSize | 11 |
| pANOVA | 0.107 |
| s.dist | -0.281 |
| p.adjustANOVA | 0.765 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FGFR4 | -6966 |
| GRB2 | -6538 |
| SOS1 | -5434 |
| HRAS | -4398 |
| PIK3CA | -4223 |
| NRAS | -2879 |
| FRS2 | -2820 |
| GAB1 | 2072 |
| KRAS | 2413 |
| PLCG1 | 2920 |
| PIK3R1 | 7331 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FGFR4 | -6966 |
| GRB2 | -6538 |
| SOS1 | -5434 |
| HRAS | -4398 |
| PIK3CA | -4223 |
| NRAS | -2879 |
| FRS2 | -2820 |
| GAB1 | 2072 |
| KRAS | 2413 |
| PLCG1 | 2920 |
| PIK3R1 | 7331 |
Pyruvate metabolism
| 895 | |
|---|---|
| set | Pyruvate metabolism |
| setSize | 25 |
| pANOVA | 0.0164 |
| s.dist | -0.277 |
| p.adjustANOVA | 0.438 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PDHB | -7365 |
| LDHC | -6142 |
| DLAT | -5658 |
| MPC2 | -5583 |
| BSG | -5532 |
| PPARD | -5088 |
| VDAC1 | -4779 |
| PDPR | -4734 |
| PDP2 | -4529 |
| DLD | -4316 |
| MPC1 | -4082 |
| RXRA | -3410 |
| ME1 | -2615 |
| LDHA | -1009 |
| PDK1 | -205 |
| LDHB | -89 |
| SLC16A1 | -37 |
| SLC16A3 | 177 |
| PDK2 | 258 |
| HAGH | 860 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PDHB | -7365 |
| LDHC | -6142 |
| DLAT | -5658 |
| MPC2 | -5583 |
| BSG | -5532 |
| PPARD | -5088 |
| VDAC1 | -4779 |
| PDPR | -4734 |
| PDP2 | -4529 |
| DLD | -4316 |
| MPC1 | -4082 |
| RXRA | -3410 |
| ME1 | -2615 |
| LDHA | -1009 |
| PDK1 | -205 |
| LDHB | -89 |
| SLC16A1 | -37 |
| SLC16A3 | 177 |
| PDK2 | 258 |
| HAGH | 860 |
| PDHA1 | 2020 |
| PDK3 | 2957 |
| PDK4 | 4409 |
| GLO1 | 6146 |
| PDHA2 | 7002 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.0.2 (2020-06-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 18.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.7.1
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.7.1
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] stats4 parallel stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.1.0 GGally_2.0.0
## [3] beeswarm_0.2.3 gtools_3.8.2
## [5] echarts4r_0.3.2 mitch_1.0.6
## [7] fgsea_1.14.0 gplots_3.0.3
## [9] DESeq2_1.28.1 SummarizedExperiment_1.18.1
## [11] DelayedArray_0.14.0 matrixStats_0.56.0
## [13] Biobase_2.48.0 GenomicRanges_1.40.0
## [15] GenomeInfoDb_1.24.2 IRanges_2.22.2
## [17] S4Vectors_0.26.1 BiocGenerics_0.34.0
## [19] reshape2_1.4.4 forcats_0.5.0
## [21] stringr_1.4.0 dplyr_1.0.0
## [23] purrr_0.3.4 readr_1.3.1
## [25] tidyr_1.1.0 tibble_3.0.1
## [27] ggplot2_3.3.2 tidyverse_1.3.0
## [29] locfit_1.5-9.4 statmod_1.4.34
## [31] plyr_1.8.6
##
## loaded via a namespace (and not attached):
## [1] colorspace_1.4-1 ellipsis_0.3.1 rprojroot_1.3-2
## [4] XVector_0.28.0 fs_1.4.2 rstudioapi_0.11
## [7] farver_2.0.3 bit64_0.9-7 AnnotationDbi_1.50.1
## [10] fansi_0.4.1 lubridate_1.7.9 xml2_1.3.2
## [13] splines_4.0.2 geneplotter_1.66.0 knitr_1.29
## [16] jsonlite_1.7.0 broom_0.5.6 annotate_1.66.0
## [19] dbplyr_1.4.4 shiny_1.5.0 compiler_4.0.2
## [22] httr_1.4.1 backports_1.1.8 assertthat_0.2.1
## [25] Matrix_1.2-18 fastmap_1.0.1 cli_2.0.2
## [28] later_1.1.0.1 prettyunits_1.1.1 htmltools_0.5.0
## [31] tools_4.0.2 gtable_0.3.0 glue_1.4.1
## [34] GenomeInfoDbData_1.2.3 fastmatch_1.1-0 Rcpp_1.0.4.6
## [37] cellranger_1.1.0 vctrs_0.3.1 gdata_2.18.0
## [40] nlme_3.1-148 xfun_0.15 testthat_2.3.2
## [43] rvest_0.3.5 mime_0.9 lifecycle_0.2.0
## [46] XML_3.99-0.3 zlibbioc_1.34.0 MASS_7.3-51.6
## [49] scales_1.1.1 hms_0.5.3 promises_1.1.1
## [52] RColorBrewer_1.1-2 yaml_2.2.1 memoise_1.1.0
## [55] gridExtra_2.3 reshape_0.8.8 stringi_1.4.6
## [58] RSQLite_2.2.0 highr_0.8 genefilter_1.70.0
## [61] desc_1.2.0 caTools_1.18.0 BiocParallel_1.22.0
## [64] rlang_0.4.6 pkgconfig_2.0.3 bitops_1.0-6
## [67] evaluate_0.14 lattice_0.20-41 labeling_0.3
## [70] htmlwidgets_1.5.1 bit_1.1-15.2 tidyselect_1.1.0
## [73] magrittr_1.5 R6_2.4.1 generics_0.0.2
## [76] DBI_1.1.0 pillar_1.4.4 haven_2.3.1
## [79] withr_2.2.0 survival_3.2-3 RCurl_1.98-1.2
## [82] modelr_0.1.8 crayon_1.3.4 KernSmooth_2.23-17
## [85] rmarkdown_2.3 progress_1.2.2 grid_4.0.2
## [88] readxl_1.3.1 data.table_1.12.8 blob_1.2.1
## [91] reprex_0.3.0 digest_0.6.25 pbmcapply_1.5.0
## [94] xtable_1.8-4 httpuv_1.5.4 munsell_0.5.0END of report